Updated on 2024/02/01

写真a

 
FUJII Nobuharu
 
Organization
Okayama University Hospital Associate Professor
Position
Associate Professor
External link

Degree

  • - ( Okayama University )

Research Interests

  • Minor Histocompatibility Antigen

  • Fertility preservation

  • Bronchiolotis obliterans

Research Areas

  • Life Science / Hematology and medical oncology

Education

  • -   Department of Hematology, Oncology and Respiratory Medicine  

      More details

  • Kochi Medical School    

      More details

    Country: Japan

    researchmap

  • Okayama University   血液・腫瘍・呼吸器内科学(内科学第二)  

      More details

    Country: Japan

    researchmap

  • Kochi Medical School    

      More details

Research History

  • 岡山大学病院   部長(准教授)

    2023.4

      More details

  • 岡山大学病院   講師(副部長)

    2011.4

      More details

  • 岡山大学病院 血液・腫瘍内科   助教

    2010.4 - 2011.3

      More details

  • 岡山大学病院 血液・腫瘍内科   医員

    2009.9 - 2010.3

      More details

  • フレッドハッチンソン癌研究所

    2006.4 - 2009.8

      More details

  • 岡山大学医学部・歯学部附属病院助手

    2003.4 - 2006.3

      More details

  • Instrucor, Department of Medicine, Faculty of

    2003

      More details

  • 岡山大学医学部付属 病院 第二内科医員

    2002 - 2003

      More details

  • Medical Staff, Department of Medicine,

    2002 - 2003

      More details

  • Reseach Fellow, Department of Medicine,

    2000 - 2002

      More details

  • Okayama University   Medical School

    2000 - 2002

      More details

  • Faculty of Medicine, Okayama University,Japan

      More details

  • Medicine, Okayama University, Japan

      More details

  • Japan

      More details

  • Faculty of Medicine, , Okayama University,

      More details

▼display all

Professional Memberships

 

Papers

  • Evaluating the efficiency and safety of large-volume leukapheresis using the Spectra Optia continuous mononuclear cell collection protocol for peripheral blood stem cell collection from healthy donors: A retrospective study. International journal

    Yuichi Sumii, Keiko Fujii, Takumi Kondo, Tomohiro Urata, Maiko Kimura, Hideaki Fujiwara, Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Ken-Ichi Matsuoka, Fumio Otsuka, Yoshinobu Maeda, Nobuharu Fujii

    Transfusion   2023.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Large-volume leukapheresis (LVL) refers to processing of more than three volumes of blood in a single session for peripheral blood stem cell collection. Recently, continuous mononuclear cell collection (cMNC) protocol has been developed using the Spectra Optia system, which is a widely used apheresis device. LVL using the novel protocol has been investigated in patients. However, the efficiency and safety of LVL in healthy donors using this protocol has not been characterized. Therefore, this study aimed to evaluate the efficiency and tolerability of CD34+ collection of LVL with the cMNC protocol in healthy donors. STUDY DESIGN AND METHODS: We retrospectively collected data on LVL (>3 total blood volume) and normal-volume leukapheresis (NVL) performed in healthy donors between October 2019 and December 2021. All procedures were performed using the cMNC protocol. RESULTS: Although pre-apheresis CD34+ cell count was lesser in LVL (23.5 vs. 58.0/μL, p < .001), CD34+ collection efficiency was comparable between LVL and NVL (61.2% vs. 61.4%, p = .966). Platelet loss was significantly higher in LVL compared to NVL (38.0% vs. 29.4%, p < .001), with no correlation between attrition of platelet and processing blood volume. Moreover, the incidence of citrate toxicity during procedures was comparable between the two groups (31.6% vs. 21.4%, p = .322). All LVL procedures could be completed without any adverse events. CONCLUSION: Allogeneic LVL procedure using Spectra Optia cMNC protocol was well tolerated by the donors and resulted in efficient collection of CD34+ cells, which was comparable to that of NVL.

    DOI: 10.1111/trf.17563

    PubMed

    researchmap

  • 再発・難治性びまん性大細胞型B細胞性リンパ腫に対するtisagenlecleucel輸注後の早期再燃を予測する輸注前因子の検討

    北村 亘, 藤井 伸治, 鴨井 千尋, 浦田 知宏, 小林 宏紀, 山本 晃, 清家 圭介, 藤原 英晃, 淺田 騰, 遠西 大輔, 西森 久和, 藤井 敬子, 松岡 賢市, 前田 嘉信

    日本造血・免疫細胞療法学会雑誌   12 ( 4 )   259 - 267   2023.10

     More details

    Language:Japanese   Publisher:(一社)日本造血・免疫細胞療法学会  

    researchmap

  • Distribution and clinical impact of molecular subtypes with Dark Zone signature of DLBCL in a Japanese real-world study. International journal

    Tomohiro Urata, Yusuke Naoi, Aixiang Jiang, Merrill Boyle, Kazutaka Sunami, Toshi Imai, Yuichiro Nawa, Yasushi Hiramatsu, Kazuhiko Yamamoto, Soichiro Fujii, Isao Yoshida, Tomofumi Yano, Ryota Chijimatsu, Hiroyuki Murakami, Kazuhiro Ikeuchi, Hiroki Kobayashi, Katsuma Tani, Hideki Ujiie, Hirofumi Inoue, Shuta Tomida, Akira Yamamoto, Takumi Kondo, Hideaki Fujiwara, Noboru Asada, Hisakazu Nishimori, Keiko Fujii, Nobuharu Fujii, Ken-Ichi Matsuoka, Keisuke Sawada, Shuji Momose, Jun-Ichi Tamaru, Asami Nishikori, Yasuharu Sato, Tadashi Yoshino, Yoshinobu Maeda, David W Scott, Daisuke Ennishi

    Blood advances   2023.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    The distribution and clinical impact of cell-of-origin (COO) subtypes of diffuse large B-cell lymphoma (DLBCL) outside Western countries remain unknown. Recent literature also suggests that there is an additional COO subtype associated with the germinal center dark zone, that warrants wider validation to generalize clinical relevance. Here, we assembled a cohort of Japanese patients with untreated DLBCL and determined the refined COO subtypes, that include the dark zone signature (DZsig), using the NanoString DLBCL90 assay. To compare the distribution and clinical characteristics of the molecular subtypes, we used a dataset from the cohort of BC Cancer (BCC) (n = 804). Of the 1050 patients where DLBCL90 assay was successfully performed in our cohort, 35%, 45%, and 6% of patients were identified to be germinal center B-cell-like (GCB)-DLBCL, activated B-cell-like (ABC)-DLBCL, and DZsigpos-DLBCL, respectively, with the highest prevalence of ABC-DLBCL differing significantly from that of BCC (P < 0.001). GCB-DLBCL, ABC-DLBCL, and DZsigpos-DLBCL were associated with two-year overall survival rates of 88%, 75%, and 66%, respectively (P < 0.0001), with patients of the DZsigpos-DLBCL having the poorest prognosis. In contrast, GCB-DLBCL without DZsig showed excellent outcomes following rituximab-containing immunochemotherapy. DZsigpos-DLBCL was associated with the significant enrichment of tumors with CD10 expression, concurrent MYC/BCL2 expression, and depletion of microenvironmental components (all P < 0.05). These results provide evidence of the distinct distribution of clinically relevant molecular subtypes in Japanese DLBCL and that refined COO, as measured by the DLBCL90 assay, is a robust prognostic biomarker that is consistent across geographical areas.

    DOI: 10.1182/bloodadvances.2023010402

    PubMed

    researchmap

  • Feasibility of Flow Cytometry Analysis of Gastrointestinal Tract-Residing Lymphocytes in Hematopoietic Stem Cell Transplant Recipients.

    Masaya Iwamuro, Takumi Kondo, Daisuke Ennishi, Nobuharu Fujii, Ken-Ichi Matsuoka, Takahide Takahashi, Araki Hirabata, Takehiro Tanaka, Fumio Otsuka, Yoshinobu Maeda, Hiroyuki Okada

    Acta medica Okayama   77 ( 4 )   347 - 357   2023.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    The feasibility of lymphocyte isolation and flow cytometry using a single endoscopic biopsy specimen from the gastrointestinal tract of patients who have undergone hematopoietic stem cell transplantation has not been investigated. We acquired 51 endoscopic biopsy specimens from the gastrointestinal tract of 35 patients. We divided the flow cytometry samples into two groups: group A, successful lymphocyte isolation (n=24), and group B, incomplete isolation (n=27). We compared the backgrounds of the samples between the groups to reveal crucial elements in the successful isolation of lymphocytes residing in the gastrointestinal tract. Comparison between the groups revealed lymphocyte isolation success rates differed between biopsy sites. Isolation was most successful in samples from the duodenum (8/9, 88.9%), followed by the ileum (4/8, 50.0%), large intestine (4/11, 36.4%), and stomach (8/23, 34.8%). Tacrolimus was used more frequently in group B (92.6%) than in group A (62.5%) (p=0.015). Logistic regression analysis revealed that isolation from the duodenum or ileum was a significant factor for successful isolation, while tacrolimus use was not statistically significant. In conclusion, the duodenum and ileum are more suitable sites than the stomach and colorectum for acquiring samples for flow cytometry.

    DOI: 10.18926/AMO/65740

    PubMed

    researchmap

  • Negative Prognostic Impact of High-Dose or Long-Term Corticosteroid Use in Patients with Relapsed or Refractory B-Cell Lymphoma Who Received Tisagenlecleucel. International journal

    Toshiki Terao, Wataru Kitamura, Nobuharu Fujii, Noboru Asada, Chihiro Kamoi, Kanako Fujiwara, Kaho Kondo, Chisato Matsubara, Kenta Hayashino, Keisuke Seike, Hideaki Fujiwara, Daisuke Ennishi, Hisakazu Nishimori, Keiko Fujii, Ken-Ichi Matsuoka, Yoshinobu Maeda

    Transplantation and cellular therapy   29 ( 9 )   573.e1-573.e8   2023.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    The prognostic impact of corticosteroid therapy in patients receiving tisagenlecleucel (tisa-cel) treatment who are more likely to develop cytokine release syndrome (CRS) remains unclear. This study aimed to evaluate the clinical impact and lymphocyte kinetics of corticosteroid administration for CRS in 45 patients with relapsed and/or refractory B-cell lymphoma treated with tisa-cel. This was a retrospective evaluation of all consecutive patients diagnosed with relapsed and/or refractory diffuse large B-cell lymphoma, follicular lymphoma with histologic transformation to large B-cell lymphoma, or follicular lymphoma who received commercial-based tisa-cel treatment. The best overall response rate, complete response rate, median progression-free survival (PFS), and median overall survival (OS) were 72.7%, 45.5%, 6.6 months, and 15.3 months, respectively. CRS (predominantly grade 1/2) occurred in 40 patients (88.9%), and immune effector cell-associated neurotoxicity syndrome (ICANS) of all grades occurred in 3 patients (6.7%). No grade ≥3 ICANS occurred. Patients with high-dose (≥524 mg, methylprednisolone equivalent; n = 12) or long-term (≥8 days; n = 9) corticosteroid use had inferior PFS and OS to patients with low-dose or no corticosteroid use (both P < .05). The prognostic impact remained even in 23 patients with stable disease (SD) or progressive disease (PD) before tisa-cel infusion (P = .015). but not in patients with better disease status (P = .71). The timing of corticosteroid initiation did not have a prognostic impact. Multivariate analysis identified high-dose corticosteroid use and long-term corticosteroid use as independent prognostic factors for PFS and OS, respectively, after adjusting for elevated lactate dehydrogenase level before lymphodepletion chemotherapy and disease status (SD or PD). Lymphocyte kinetics analysis demonstrated that after methylprednisolone administration, the proportions of regulatory T cells (Tregs), CD4+ central memory T (TCM) cells, and natural killer (NK) cells were decreased, whereas the proportion of CD4+ effector memory T (TEM) cells was increased. Patients with a higher proportion of Tregs at day 7 had a lower incidence of CRS, but this did not affect prognosis, indicating that early elevation of Tregs may serve as a biomarker for CRS development. Furthermore, patients with higher numbers of CD4+ TCM cells and NK cells at various time points had significantly better PFS and OS, whereas the number of CD4+ TEM cells did not impact prognostic outcomes. This study suggests that high-dose or long-term corticosteroid use attenuates the efficacy of tisa-cel, especially in patients with SD or PD. Additionally, patients with high levels of CD4+ TCM cells and NK cells after tisa-cel infusion had longer PFS and OS.

    DOI: 10.1016/j.jtct.2023.06.018

    PubMed

    researchmap

  • Efficient granulocyte collection method using high concentrations of medium molecular weight hydroxyethyl starch

    Takumi Kondo, Keiko Fujii, Nobuharu Fujii, Yuichi Sumii, Tomohiro Urata, Maiko Kimura, Masayuki Matsuda, Shuntaro Ikegawa, Kana Washio, Hideaki Fujiwara, Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Ken‐ichi Matsuoka, Fumio Otsuka, Yoshinobu Maeda

    Transfusion   2023.6

     More details

    Publishing type:Research paper (scientific journal)   Publisher:Wiley  

    DOI: 10.1111/trf.17450

    researchmap

  • Clinical characteristics of late-onset interstitial pneumonia after allogeneic hematopoietic stem cell transplantation.

    Nobuharu Fujii, Makoto Onizuka, Takahiro Fukuda, Kazuhiro Ikegame, Toshiro Kawakita, Hirohisa Nakamae, Takeshi Kobayashi, Keisuke Kataoka, Masatsugu Tanaka, Tadakazu Kondo, Koji Kato, Atsushi Sato, Tatsuo Ichinohe, Yoshiko Atsuta, Masao Ogata, Ritsuro Suzuki, Hideki Nakasone

    International journal of hematology   2023.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Non-infectious pulmonary complications after allogeneic hematopoietic stem cell transplantation (HSCT) remain fatal. In particular, information regarding late-onset interstitial lung disease predominantly including organizing pneumonia and interstitial pneumonia (IP) is limited. A retrospective nationwide survey was conducted using data collected from the Japanese transplant outcome registry database from 2005 to 2010. This study focused on patients (n = 73) with IP diagnosed after day 90 post-HSCT. A total of 69 (94.5%) patients were treated with systemic steroids, and 34 (46.6%) experienced improvement. The presence of chronic graft-versus-host disease at the onset of IP was significantly associated with non-improvement of symptoms (odds ratio [OR] 0.35). At the time of last follow-up (median, 1471 days), 26 patients were alive. Of the 47 deaths, 32 (68%) were due to IP. The 3-year overall survival (OS) and non-relapse mortality (NRM) rates were 38.8% and 51.8%, respectively. In the multivariate analysis, the predictive factors for OS were comorbidities at IP onset (hazard ratio [HR]: 2.19) and performance status (PS) score of 2-4 (HR 2.77). Furthermore, cytomegalovirus reactivation requiring early intervention (HR 2.04), PS score of 2-4 (HR 2.63), and comorbidities at IP onset (HR 2.90) were also significantly associated with increased risk of NRM.

    DOI: 10.1007/s12185-023-03624-9

    PubMed

    researchmap

  • 臍帯血移植後にHTLV-1感染T細胞の多クローン性増殖を伴って発症した肺合併症に対し抗CCR4抗体が著効した1例

    松原 千哲, 松岡 賢市, 近藤 歌穂, 藤原 加奈子, 寺尾 俊紀, 植田 裕子, 松村 彰文, 守山 喬史, 村上 裕之, 近藤 匠, 清家 圭介, 藤原 英晃, 淺田 騰, 遠西 大輔, 西森 久和, 藤井 敬子, 藤井 伸治, 前田 嘉信

    臨床血液   64 ( 6 )   563 - 563   2023.6

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • Safety and efficacy of tisagenlecleucel in patients with relapsed or refractory B-cell lymphoma: the first real-world evidence in Japan.

    Hideki Goto, Toshio Kitawaki, Nobuharu Fujii, Koji Kato, Yasushi Onishi, Noriko Fukuhara, Takuji Yamauchi, Kazunori Toratani, Hiroki Kobayashi, Shota Yoshida, Masatoshi Shimo, Koichi Onodera, Hajime Senjo, Masahiro Onozawa, Kenji Hirata, Isao Yokota, Takanori Teshima

    International journal of clinical oncology   2023.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Tisagenlecleucel, an autologous CD19-directed T-cell immunotherapy, can induce a durable response in adult patients with relapsed/refractory (r/r) B-cell lymphoma. METHODS: To elucidate the outcome of chimeric antigen receptor (CAR) T-cell therapy in Japanese, we retrospectively analyzed the outcomes of 89 patients who received tisagenlecleucel for r/r diffuse large B-cell lymphoma (n = 71) or transformed follicular lymphoma (n = 18). RESULTS: With a median follow-up of 6.6-months, 65 (73.0%) patients achieved a clinical response. The overall survival (OS) and event-free survival (EFS) rates at 12 months were 67.0% and 46.3%, respectively. Overall, 80 patients (89.9%) had cytokine release syndrome (CRS), and 6 patients (6.7%) had a grade ≥ 3 event. ICANS occurred in 5 patients (5.6%); only 1 patient had grade 4 ICANS. Representative infectious events of any grade were cytomegalovirus viremia, bacteremia and sepsis. The most common other adverse events were ALT elevation, AST elevation, diarrhea, edema, and creatinine elevation. No treatment-related mortality was observed. A Sub-analysis showed that a high metabolic tumor volume (MTV; ≥ 80 ml) and stable disease /progressive disease before tisagenlecleucel infusion were both significantly associated with a poor EFS and OS in a multivariate analysis (P < 0.05). Notably, the combination of these 2 factors efficiently stratified the prognosis of these patients (HR 6.87 [95% CI 2.4-19.65; P < 0.05] into a high-risk group). CONCLUSION: We report the first real-world data on tisagenlecleucel for r/r B-cell lymphoma in Japan. Tisagenlecleucel is feasible and effective, even in late line treatment. In addition, our results support a new algorithm for predicting the outcomes of tisagenlecleucel.

    DOI: 10.1007/s10147-023-02334-w

    PubMed

    researchmap

  • Bone marrow microenvironment disruption and sustained inflammation with prolonged haematologic toxicity after CAR T-cell therapy. International journal

    Wataru Kitamura, Noboru Asada, Yusuke Naoi, Masaya Abe, Hideaki Fujiwara, Daisuke Ennishi, Hisakazu Nishimori, Keiko Fujii, Nobuharu Fujii, Ken-Ichi Matsuoka, Tadashi Yoshino, Yoshinobu Maeda

    British journal of haematology   202 ( 2 )   294 - 307   2023.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Mechanisms of prolonged cytopenia (PC) after chimeric antigen receptor (CAR) T-cell therapy, an emerging therapy for relapsed or refractory diffuse large B-cell lymphoma, remain elusive. Haematopoiesis is tightly regulated by the bone marrow (BM) microenvironment, called the 'niche'. To investigate whether alterations in the BM niche cells are associated with PC, we analysed CD271+ stromal cells in BM biopsy specimens and the cytokine profiles of the BM and serum obtained before and on day 28 after CAR T-cell infusion. Imaging analyses of the BM biopsy specimens revealed that CD271+ niche cells were severely impaired after CAR T-cell infusion in patients with PC. Cytokine analyses after CAR T-cell infusion showed that CXC chemokine ligand 12 and stem cell factor, niche factors essential for haematopoietic recovery, were significantly decreased in the BM of patients with PC, suggesting reduced niche cell function. The levels of inflammation-related cytokines on day 28 after CAR T-cell infusion were consistently high in the BM of patients with PC. Thus, we demonstrate for the first time that BM niche disruption and sustained elevation of inflammation-related cytokines in the BM following CAR T-cell infusion are associated with subsequent PC.

    DOI: 10.1111/bjh.18747

    PubMed

    researchmap

  • Early initiation of low-dose gilteritinib maintenance improves posttransplant outcomes in patients with R/R FLT3mut AML. International journal

    Toshiki Terao, Ken-Ichi Matsuoka, Hiroko Ueda, Akifumi Matsumura, Chisato Matsubara, Kaho Kondo, Takumi Kondo, Hideaki Fujiwara, Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Keiko Fujii, Nobuharu Fujii, Yoshinobu Maeda

    Blood advances   7 ( 5 )   681 - 686   2022.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1182/bloodadvances.2022008991

    PubMed

    researchmap

  • Association between early corticosteroid administration and long-term survival in non-infectious pulmonary complications after allogeneic hematopoietic stem cell transplantation.

    Yui Kambara, Nobuharu Fujii, Yoshiaki Usui, Akira Yamamoto, Hisao Higo, Hideaki Fujiwara, Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Keiko Fujii, Ken-Ichi Matsuoka, Yoshinobu Maeda

    International journal of hematology   117 ( 4 )   578 - 589   2022.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Non-infectious pulmonary complications (NIPCs) after allogeneic hematopoietic stem cell transplantation (HSCT) are associated with poor outcomes. It is important to maximize the effectiveness of primary treatment because secondary treatment has not been established. We analyzed data from 393 patients who underwent allogeneic HSCT during a 10-year period. Thirty-seven were diagnosed with NIPCs, which consisted of idiopathic pneumonia syndrome, bronchiolitis obliterans, and interstitial lung disease including cryptogenic organizing pneumonia. Among these, 18 died (Dead group) while 19 remained alive (Alive group) during the study period. The median time between NIPC diagnosis and first administration of ≥ 1 mg/kg/day corticosteroids (prednisolone dose equivalent) was significantly longer in the Dead group than the Alive group, at 9 days versus 4 days (p = 0.01). We further divided these cases into those who received prednisolone within seven days and after 8 days. We found that the ≤ 7 days group were more likely to survive after their NIPC diagnosis compared to the ≥ 8 days group (p = 0.06). Our analysis showed that early initiation of corticosteroid therapy is associated with long-term survival in NIPCs.

    DOI: 10.1007/s12185-022-03517-3

    PubMed

    researchmap

  • A phase 2 study of axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma in Japan: 1-year follow-up and biomarker analysis.

    Koji Kato, Nobuharu Fujii, Shinichi Makita, Hideki Goto, Junya Kanda, Kazuyuki Shimada, Koichi Akashi, Koji Izutsu, Takanori Teshima, Natsuko Fukuda, Tokuhito Sumitani, Shota Nakamura, Hiroyuki Sumi, Shinji Shimizu, Yasuyuki Kakurai, Kenji Yoshikawa, Kensei Tobinai, Noriko Usui, Kiyohiko Hatake

    International journal of hematology   2022.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Axicabtagene ciloleucel (axi-cel) is an autologous, CD19-targeting chimeric antigen receptor T‑cell therapy. We recently reported the 3-month follow-up results of a phase 2, multicenter, open‑label, single-arm study of axi-cel in Japanese patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) (JapicCTI-183914). Here, we present 1-year efficacy and safety data and biomarker analysis data regarding mechanisms of resistance to axi-cel. Primary and secondary endpoints included investigator-assessed objective response rate (ORR), serious adverse events, and treatment-emergent adverse events. Axi-cel pharmacokinetics were also examined. Biomarker analysis was performed by cytokine measurement, immunohistochemistry, RNA sequencing, and whole-exome sequencing. At a median follow-up of 13.4 months, ORR was 86.7% (13/15 patients), and the complete response (CR) rate improved to 53.3% (8/15 patients) due to response conversion. Seven patients experienced disease progression, and one achieved CR after re-treatment with axi-cel. No new safety concerns were detected. Plausible resistance mechanisms to axi-cel varied among patients but included CD19 downregulation, programmed death-ligand 1 upregulation, and increased macrophage and angiogenesis signatures. The 1-year efficacy and safety of axi-cel were confirmed in Japanese patients with R/R LBCL. Resistance to treatment may involve multiple factors, including target antigen loss and an unfavorable tumor environment.Clinical trial registration: Japan Clinical Trials Information; JapicCTI-183914.

    DOI: 10.1007/s12185-022-03494-7

    PubMed

    researchmap

  • Prevention of non-infectious pulmonary complications after intro-bone marrow stem cell transplantation in mice Reviewed International journal

    Yoshiko Yamasuji-Maeda, Hisakazu Nishimori, Keisuke Seike, Akira Yamamoto, Hideaki Fujiwara, Taiga Kuroi, Kyosuke Saeki, Haruko Fujinaga, Sachiyo Okamoto, Ken-Ichi Matsuoka, Nobuharu Fujii, Takehiro Tanaka, Masahiro Fujii, Katsumi Mominoki, Takuro Kanekura, Yoshinobu Maeda

    PloS one   17 ( 9 )   e0273749   2022.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Non-infectious pulmonary complications including idiopathic pneumonia syndrome (IPS) and bronchiolitis obliterans syndrome (BOS), which are clinical and diagnostic manifestations of lung chronic graft-versus-host disease (GVHD), cause significant mortality after allogeneic stem cell transplantation (SCT). Increasing evidence suggests that alloantigen reactions in lung tissue play a central role in the pathogenesis of IPS and BOS; however, the mechanism is not fully understood. Several clinical and experimental studies have reported that intra-bone marrow (IBM)-SCT provides high rates of engraftment and is associated with a low incidence of acute GVHD. In the present study, allogeneic SCT was conducted in mouse models of IPS and BOS, to compare intravenous (IV)-SCT with IBM-SCT. Allogeneic IBM-SCT improved the clinical and pathological outcomes of pulmonary complications compared to those of IV-SCT. The mechanisms underlying the reductions in pulmonary complications in IBM-SCT mice were explored. The infiltrating lung cells were mainly CD11b+ myeloid and CD3+ T cells, in the same proportions as in transplanted donor cells. In an in vivo bioluminescence imaging, a higher proportion of injected donor cells was detected in the lung during the early phase (1 h after IV-SCT) than after IBM-SCT (16.7 ± 1.1 vs. 3.1 ± 0.7 × 105 photons/s/animal, IV-SCT vs. IBM-SCT, P = 1.90 × 10-10). In the late phase (5 days) after SCT, there were also significantly more donor cells in the lung after IV-SCT than after IBM-SCT or allogeneic-SCT (508.5 ± 66.1 vs. 160.1 ± 61.9 × 106 photons/s/animal, IV-SCT vs. IBM-SCT, P = 0.001), suggesting that the allogeneic reaction induces sustained donor cell infiltration in the lung during the late phase. These results demonstrated that IBM-SCT is capable of reducing injected donor cells in the lung; IBM-SCT decreases donor cell infiltration. IBM-SCT therefore represents a promising transplantation strategy for reducing pulmonary complications, by suppressing the first step in the pathophysiology of chronic GVHD.

    DOI: 10.1371/journal.pone.0273749

    PubMed

    researchmap

  • 造血幹細胞移植後患者に対する就労支援と就学支援体制(実態調査)

    鴨井 千尋, 西森 久和, 鷲尾 佳奈, 藤井 伸治, 前田 嘉信

    日本造血・免疫細胞療法学会雑誌   11 ( 4 )   199 - 205   2022.10

     More details

    Language:Japanese   Publisher:(一社)日本造血・免疫細胞療法学会  

    造血幹細胞移植患者に対する就労支援と就学支援の2021年現在の実践状況を明らかにするため,中国地方の血液内科と小児血液腫瘍科の25施設31名の医師にアンケートを送付し,18施設,23名(74%)から回答を得た。就労支援の窓口は12施設(67%)が開設していたが,相談件数は半数以上が年間0件であった。自施設の就労支援体制について十分であると評価したのはわずか3名(14%)であった。就学支援の経験がある血液内科医は17名中3名(18%)と少なかった。7名(41%)がオンライン授業の経験があると回答した。自施設の高校生・大学生の就学支援体制について全ての施設が十分でないと回答した。これらの結果により,就労・就学支援体制は施設により差があり,改善の余地があることが明らかになった。多職種,他機関との協力関係を構築し,AYA世代を含む全ての患者を支援する体制の必要性が示唆された。(著者抄録)

    researchmap

    Other Link: https://search.jamas.or.jp/default/link?pub_year=2022&ichushi_jid=J07578&link_issn=&doc_id=20221028330002&doc_link_id=1390293788341809920&url=https%3A%2F%2Fcir.nii.ac.jp%2Fcrid%2F1390293788341809920&type=CiNii&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00003_2.gif

  • CD19 immunostaining of a stored paraffin-embedded vitrectomy cell block of intraocular lymphoma contributing to chimera antigen receptor T-cell therapy.

    Toshihiko Matsuo, Takehiro Tanaka, Nobuharu Fujii, Kentaro Fujii, Eisei Kondo

    Journal of clinical and experimental hematopathology : JCEH   62 ( 3 )   187 - 189   2022.9

     More details

  • Successful haematopoietic progenitor cell collection by plerixafor in combination with reduced dose granulocyte colony-stimulating factor for severe hypoxemia provoked by high-dose granulocyte colony-stimulating factor administration. International journal

    Yui Kambara, Noboru Asada, Kaori Kondo, Yuichi Sumii, Yuki Fujiwara, Keisuke Seike, Yasuhisa Sando, Kyosuke Saeki, Hisakazu Nishimori, Keiko Fujii, Nobuharu Fujii, Ken-Ichi Matsuoka, Yoshinobu Maeda

    Transfusion medicine (Oxford, England)   2022.9

     More details

    Language:English  

    DOI: 10.1111/tme.12916

    PubMed

    researchmap

  • Red blood cell depletion in small‐volume bone marrow processing using manipulation with third‐party red blood cells: A comparison of the performance of the <scp>COBE</scp> spectra and the spectra Optia systems

    Yuichi Sumii, Nobuharu Fujii, Keiko Fujii, Takumi Kondo, Tomohiro Urata, Maiko Kimura, Kana Washio, Hideaki Fujiwara, Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Ken‐ichi Matsuoka, Fumio Otsuka, Yoshinobu Maeda

    Transfusion   2022.8

     More details

    Publishing type:Research paper (scientific journal)   Publisher:Wiley  

    DOI: 10.1111/trf.17039

    researchmap

    Other Link: https://onlinelibrary.wiley.com/doi/full-xml/10.1111/trf.17039

  • Effect of Cryopreservation in Unrelated Bone Marrow and Peripheral Blood Stem Cell Transplantation in the Era of the COVID-19 Pandemic: An Update from the Japan Marrow Donor Program. International journal

    Yoshinobu Kanda, Noriko Doki, Minoru Kojima, Shinichi Kako, Masami Inoue, Naoyuki Uchida, Yasushi Onishi, Reiko Kamata, Mika Kotaki, Ryoji Kobayashi, Junji Tanaka, Takahiro Fukuda, Nobuharu Fujii, Koichi Miyamura, Shin-Ichiro Mori, Yasuo Mori, Yasuo Morishima, Hiromasa Yabe, Yoshiko Atsuta, Yoshihisa Kodera

    Transplantation and cellular therapy   28 ( 10 )   677.e1-677.e6   2022.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    During the COVID-19 pandemic, donor grafts are frequently cryopreserved to ensure that a graft is available before starting a conditioning regimen. However, there have been conflicting reports on the effect of cryopreservation on transplantation outcomes. Also, the impact of cryopreservation may differ in bone marrow (BM) transplantation (BMT) and peripheral blood stem cell (PBSC) transplantation (PBSCT). In this retrospective study, we analyzed the clinical data of both cryopreserved unrelated BMTs (n = 235) and PBSCTs (n = 118) and compared these with data from a large control cohort without cryopreservation including 4133 BMTs and 720 PBSCTs. Among the patients with cryopreserved grafts, 10 BMT recipients (4.3%) and 3 PBSCT recipients (2.5%) did not achieve neutrophil engraftment after transplantation, including 4 of the former and all 3 of the latter who died early before engraftment. In a multivariate analysis, cryopreservation was not associated with neutrophil engraftment in BMT but significantly delayed neutrophil engraftment in PBSCT (hazard ratio [HR], .82; 95% confidence interval [CI], .69 to .97; P = .023). There was an interaction with borderline significance between cryopreservation and the stem cell source (P = .067). Platelet engraftment was delayed by cryopreservation after both BMT and PBSCT. Only 2 cryopreserved grafts (<1%) were unused during the study period. The cryopreservation of unrelated donor BM and PBSC grafts is associated with a slight delay in neutrophil and platelet engraftment but an acceptable rate of graft failure. PBSC grafts may be more sensitive to cryopreservation than BM grafts. Cryopreservation is a reasonable option during COVID-19 pandemic, provided that the apheresis and transplantation centers are adept at cryopreservation. © 2022 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.

    DOI: 10.1016/j.jtct.2022.06.022

    PubMed

    researchmap

  • Analysis of Immunity against Measles, Mumps, Rubella, and Varicella Zoster in Adult Recipients of Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Experience.

    Shohei Yoshida, Nobuharu Fujii, Chihiro Kamoi, Wataru Kitamura, Hideaki Fujiwara, Noboru Asada, Hisakazu Nishimori, Keiko Fujii, Ken-Ichi Matsuoka, Yoshinobu Maeda

    Acta medica Okayama   76 ( 3 )   247 - 253   2022.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Vaccine-preventable disease (VPD) infections are more severe in immunocompromised hosts. Vaccination against measles, mumps, rubella, and varicella zoster (VZV) (MMRV) is therefore recommended for hematopoietic stem cell transplantation (HCT) recipients. However, studies on adult HCT recipients with VPD infections are limited. At our institution, we have systematically conducted serological MMRV tests as a part of check-up examinations during long-term follow-up (LTFU) after HCT since 2015. This retrospective study aimed to evaluate changes in the serostatus between before and 2 years after allogeneic HCT. Among 161 patients, the pre-transplant seropositivity was 82.7% for measles, 86.8% for mumps, 84.2% for rubella, and 94.3% for VZV. Among 56 patients who underwent LTFU including serological MMRV tests at 2 years after HCT, the percentages maintaining seroprotective antibody levels for measles, mumps, rubella and VZV were 71.5% (40/56), 51.8% (29/56), 48.2% (27/56), and 60.7% (34/56), respectively. Vaccination was recommended for 22 patients, and 12 were vaccinated. Among the 12 vaccinated patients, rates of seroconversion were examined in 2-6 patients for each of the four viruses. They were 100% (3/3) for measles, 33.3% (1/3) for mumps, 50% (3/6) for rubella, and 0% (0/2) for VZV. Further studies are warranted to clarify the effect of vaccination in adult HCT recipients.

    DOI: 10.18926/AMO/63718

    PubMed

    researchmap

  • Comparison of cryoprotectants in hematopoietic cell infusion-related adverse events. International journal

    Kazuhiko Ikeda, Keiji Minakawa, Kenichi Yamahara, Minami Yamada-Fujiwara, Yoshiki Okuyama, Shin-Ichiro Fujiwara, Rie Yamazaki, Heiwa Kanamori, Tohru Iseki, Tokiko Nagamura-Inoue, Kazuaki Kameda, Kazuhiro Nagai, Nobuharu Fujii, Takashi Ashida, Asao Hirose, Tsutomu Takahashi, Hitoshi Ohto, Koki Ueda, Ryuji Tanosaki

    Transfusion   62 ( 6 )   1280 - 1288   2022.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: The standard cryoprotectant for human cellular products is dimethyl sulfoxide (DMSO), which is associated with hematopoietic cell infusion-related adverse events (HCI-AEs) in hematopoietic stem cell transplantation including peripheral blood stem cell (PBSC) transplantation (PBSCT). DMSO is often used with hydroxyethyl starch (HES), which reduces DMSO concentration while maintaining the postthaw cell recovery. The cryoprotectant medium CP-1 (Kyokuto Pharmaceutical Industrial) is widely used in Japan. After mixture of a product with CP-1, DMSO and HES concentrations are 5% and 6%, respectively. However, the safety profile of CP-1 in association with HCI-AEs has not been investigated. STUDY DESIGN AND METHODS: To compare CP-1 with other cryoprotectants, we conducted a subgroup analysis of PBSCT recipients in a prospective surveillance study for HCI-AEs. Moreover, we validated the toxicity of CP-1 in 90 rats following various dose administration. RESULTS: The PBSC products cryopreserved with CP-1 (CP-1 group) and those with other cryoprotectants, mainly 10% DMSO (non-CP-1 group), were infused into 418 and 58 recipients, respectively. The rate of ≥grade 2 HCI-AEs was higher in the CP-1 group, but that of overall or ≥grade 3 HCI-AEs was not significantly different, compared to the non-CP-1 group. Similarly, after propensity score matching, ≥grade 2 HCI-AEs were more frequent in the CP-1 group, but the ≥grade 3 HCI-AE rate did not differ significantly between the groups. No significant toxicity was detected regardless of the CP-1 dose in the 90 rats. CONCLUSIONS: Infusion of a CP-1-containing PBSC product is feasible with the respect of HCI-AEs.

    DOI: 10.1111/trf.16877

    PubMed

    researchmap

  • Successful neutrophil engraftment supported by granulocyte transfusion in adult allogeneic transplant patients with peri-transplant active infection

    Shuntaro Ikegawa, Nobuharu Fujii, Keiko Fujii, Maiko Kimura, Masayuki Matsuda, Takumi Kondo, Hideaki Fujiwara, Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Ken-ichi Matsuoka, Yoshinobu Maeda

    Transfusion and Apheresis Science   103453 - 103453   2022.5

     More details

    Publishing type:Research paper (scientific journal)   Publisher:Elsevier BV  

    DOI: 10.1016/j.transci.2022.103453

    researchmap

  • Low hematocrit reduces the efficiency of <scp>CD34</scp> + cell collection when using the Spectra Optia continuous mononuclear cell collection procedure

    Takumi Kondo, Nobuharu Fujii, Keiko Fujii, Yuichi Sumii, Tomohiro Urata, Maiko Kimura, Masayuki Matsuda, Shuntaro Ikegawa, Kana Washio, Hideaki Fujiwara, Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Ken‐ichi Matsuoka, Fumio Otsuka, Yoshinobu Maeda

    Transfusion   2022.3

     More details

    Publishing type:Research paper (scientific journal)   Publisher:Wiley  

    DOI: 10.1111/trf.16856

    researchmap

    Other Link: https://onlinelibrary.wiley.com/doi/full-xml/10.1111/trf.16856

  • Transformed diffuse large B-cell lymphoma from marginal zone lymphoma in the anterior mediastinum: A case report and review of the literature.

    Wataru Kitamura, Noboru Asada, Tetsuya Tabata, Rei Shibata, Tatsuya Nishi, Yuka Kato, Hiroki Takasuka, Hideaki Fujiwara, Daisuke Ennishi, Hisakazu Nishimori, Nobuharu Fujii, Ken-Ichi Matsuoka, Katsuyuki Kiura, Tadashi Yoshino, Yoshinobu Maeda

    Journal of clinical and experimental hematopathology : JCEH   62 ( 1 )   35 - 40   2022.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Marginal zone lymphoma (MZL) arising from the anterior mediastinum is rare. In the majority of reported cases, the tumor was incidentally discovered, reflecting its indolent clinical features. We present a 38-year-old woman who had no medical history, and presented with a bulky anterior mediastinal tumor complicated by life-threatening compression of the vasculature and bronchi. Biopsy specimens of the neoplasm suggested transformed diffuse large B-cell lymphoma (DLBCL) from MZL. To our best knowledge, this is the first case report of anterior mediastinum MZL associated with an aggressive clinical course and life-threatening complications likely due to transformation to DLBCL.

    DOI: 10.3960/jslrt.21010

    PubMed

    researchmap

  • Chronic active Epstein-Barr virus infection presenting as refractory chronic sinusitis.

    Wataru Kitamura, Hideaki Fujiwara, Akifumi Matsumura, Takaya Higaki, Rei Shibata, Tomohiro Toji, Soichiro Fujii, Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Keiko Fujii, Nobuharu Fujii, Ken-Ichi Matsuoka, Tadashi Yoshino, Yoshinobu Maeda

    International journal of hematology   2022.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    A 44-year-old Japanese man presented with fever and sore throat. He had a history of refractory chronic sinusitis that did not respond to several years of pharmacotherapy, and underwent endoscopic sinus surgery (ESS) 5 months prior to his presentation, but his symptoms persisted. A biopsy specimen was taken from the right nasal cavity, and extranodal natural killer/T-cell lymphoma, nasal type (ENKTL) was diagnosed. Two years after complete remission was achieved by chemoradiation therapy, he developed hemophagocytic lymphohistiocytosis (HLH) without recurrence of ENKTL. Epstein-Barr virus (EBV)-DNA copy number was relatively high and EBV-infected lymphocytes (CD8 + T cells) were detected in the peripheral blood. Pathological review of the biopsy specimens taken during ESS showed that CD8 + T cells with slightly atypia infiltrating the stroma were EBV positive. These findings suggested that the patient had underlying chronic active EBV infection (CAEBV) that caused the refractory chronic sinusitis, eventually developed into ENKTL, and also caused HLH. Clinicians should consider adult-onset CAEBV in the differential diagnosis of patients with refractory chronic sinusitis.

    DOI: 10.1007/s12185-022-03306-y

    PubMed

    researchmap

  • Possible prognostic impact of WT1 mRNA expression at day + 30 after haploidentical peripheral blood stem cell transplantation with posttransplant cyclophosphamide for patients with myeloid neoplasm: a multicenter study from the Okayama Hematological Study Group

    Wataru Kitamura, Nobuharu Fujii, Yuichiro Nawa, Keigo Fujishita, Hiroyuki Sugiura, Takanori Yoshioka, Yuki Fujiwara, Yoshiaki Usui, Keiko Fujii, Hideaki Fujiwara, Noboru Asada, Hisakazu Nishimori, Ken-ichi Matsuoka, Yoshinobu Maeda

    International Journal of Hematology   115 ( 4 )   515 - 524   2022.2

     More details

    Publishing type:Research paper (scientific journal)   Publisher:Springer Science and Business Media LLC  

    DOI: 10.1007/s12185-022-03290-3

    researchmap

    Other Link: https://link.springer.com/article/10.1007/s12185-022-03290-3/fulltext.html

  • Characterization of myeloid neoplasms following allogeneic hematopoietic cell transplantation

    Masatomo Kuno, Satoshi Yamasaki, Nobuharu Fujii, Yasushi Ishida, Takahiro Fukuda, Keisuke Kataoka, Naoyuki Uchida, Yuta Katayama, Maho Sato, Daishi Onai, Toshihiro Miyamoto, Shuichi Ota, Satoshi Yoshioka, Takahide Ara, Akira Hangaishi, Yoshiko Hashii, Makoto Onizuka, Tatsuo Ichinohe, Yoshiko Atsuta, Yoshihiro Inamoto

    American Journal of Hematology   97 ( 2 )   185 - 193   2022.2

     More details

    Publishing type:Research paper (scientific journal)   Publisher:Wiley  

    DOI: 10.1002/ajh.26401

    researchmap

    Other Link: https://onlinelibrary.wiley.com/doi/full-xml/10.1002/ajh.26401

  • Risk factors and prognosis of non-infectious pulmonary complications after allogeneic hematopoietic stem cell transplantation.

    Makoto Onizuka, Nobuharu Fujii, Hideki Nakasone, Masao Ogata, Yoshiko Atsuta, Ritsuro Suzuki, Naoyuki Uchida, Kazuteru Ohashi, Yukiyasu Ozawa, Tetsuya Eto, Kazuhiro Ikegame, Hirohisa Nakamae, Masami Inoue, Takahiro Fukuda

    International journal of hematology   115 ( 4 )   534 - 544   2022.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Non-infectious pulmonary complications (NIPCs) following allogeneic hematopoietic stem cell transplantation (HSCT) are relatively rare, but frequently fatal. This study investigated the pre-transplant risk factors for developing NIPCs using Japanese transplant registry database entries from 2001 to 2009. Among 13,573 eligible patients, 535 experienced NIPCs (3.9%). Multivariate analysis identified high recipient age (60 + years: HR 1.85, P = 0.003), HLA mismatch (HR 1.61, P < 0.001), female to male HSCT (HR 1.54, P < 0.001), and unrelated bone marrow transplantation (UR-BMT) (HR 3.88, P < 0.001) as significantly associated with an increased risk of NIPCs. In contrast, a non-total body irradiation (TBI) regimen with reduced intensity conditioning (RIC) were associated with a decreased risk of NIPCs compared with a cyclophosphamide (CY) + TBI regimen (busulfan + CY: HR 0.67, P = 0.009, other non-TBI: HR 0.46, P < 0.001), fludarabine-based RIC (HR 0.52, P < 0.001), and other RIC (HR 0.42, P = 0.003). The mortality rate was significantly worse for patients with NIPCs than those without (HR 1.54, 71 P < 0.001). This large-scale retrospective study suggests that both allo-reactions to donor cells and conditioning regimen toxicity contributed to NIPCs following HSCT.

    DOI: 10.1007/s12185-021-03282-9

    PubMed

    researchmap

  • Sequential Combination of FLAM and Venetoclax plus Azacitidine to Bridge to Cord Blood Transplantation in a Patient with Primary Induction Failure Acute Myeloid Leukemia. International journal

    Hiroyuki Murakami, Ken-Ichi Matsuoka, Takeru Asano, Takashi Moriyama, Akifumi Matsumura, Hideaki Fujiwara, Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Keiko Fujii, Nobuharu Fujii, Tomohiro Toji, Tadashi Yoshino, Yoshinobu Maeda

    Case reports in oncology   15 ( 3 )   974 - 979   2022

     More details

    Language:English  

    Venetoclax (VEN) is an oral B-cell lymphoma-2 (BCL-2) inhibitor that has been widely used to treat various hematological disorders. Recent studies have demonstrated that VEN in combination with fludarabine-enhanced high-dose cytarabine (FLA) is effective for treating relapsed or refractory acute myeloid leukemia (AML). In the combination therapy, salvage chemotherapy and VEN are basically concurrently administrated; however, further optimization may enable the treatment to apply to larger numbers of patients with various clinical backgrounds. Here, we describe a case of refractory AML treated with a sequential combination of the intensive chemotherapy (fludarabine, cytarabine, and mitoxantrone; FLAM) and VEN/AZA to bridge to an unrelated cord blood transplantation (uCBT). By continuously adding VEN/AZA after FLAM, the patient achieved morphologic leukemia free state with only minor toxicities. Blood cell counts did not recover until the time of transplantation because of the deep myelosuppression caused by the treatment sequence, but the infection risk was safely managed during this period. After engraftment, maintenance therapy with VEN/AZA was performed, and the patient has survived without disease recurrence for over 9 months after transplantation. Our case suggests that bridging therapy with VEN and AZA from the time of the last chemotherapy to allogeneic transplantation may provide an effective and tolerable treatment strategy for refractory AML. Further studies of larger numbers of cases are needed to validate the effectiveness of this treatment.

    DOI: 10.1159/000526697

    PubMed

    researchmap

  • A Case of Relapsed Primary Central Nervous System Lymphoma Treated with CD19-directed Chimeric Antigen Receptor T Cell Therapy.

    Ryo Mizuta, Yoshihiro Otani, Kentaro Fujii, Atsuhito Uneda, Joji Ishida, Takehiro Tanaka, Shuntaro Ikegawa, Nobuharu Fujii, Yoshinobu Maeda, Isao Date

    NMC case report journal   9   275 - 280   2022

     More details

    Language:English  

    Although high-dose methotrexate (HD-MTX) is the standard therapy for primary central nervous system lymphoma (PCNSL), the prognosis remains poor. Because 90% of PCNSL is diffuse large B-cell lymphoma (DLBCL), chimeric antigen receptor (CAR)-T cell therapy is expected to be beneficial. However, there are limited reports on CAR-T cell therapy for PCNSL because of the concern of neurotoxicity. Here, we report a case of relapsed PCNSL treated with anti-CD19 CAR-T cell therapy. A 40-year-old woman presenting with visual disturbance in her left eye was initially diagnosed with bilateral uveitis. Her histological diagnosis was DLBCL, and she was positive for CD19. Although she received chemotherapy including HD-MTX, the tumor relapsed in her right occipital lobe. She underwent remission induction therapy and then anti-CD19 CAR-T cell therapy. Cytokine release syndrome (CRS) grade 2 occurred, but there were no complications of CAR-T cell-related encephalopathy syndrome (CRES). She has achieved complete response for more than 1 year. Anti-CD19 CAR-T cell therapy is a revolutionary immunotherapy for treating relapsed or refractory (R/R) B lineage malignancies. Although there are concerns regarding CRS and CRES in central nervous system lymphoma, the use of anti-CD19 CAR-T cells to treat R/R PCNSL is safe and feasible.

    DOI: 10.2176/jns-nmc.2022-0134

    PubMed

    researchmap

  • Characterization of localized macrophages in bronchiolitis obliterans after allogeneic hematopoietic cell transplantation.

    Taiga Kuroi, Nobuharu Fujii, Koichi Ichimura, Keisuke Seike, Akira Yamamoto, Yui Kambara, Seiichiro Sugimoto, Shinji Otani, Kyosuke Saeki, Hideaki Fujiwara, Hisakazu Nishiomori, Takahiro Oto, Yoshinobu Maeda

    International journal of hematology   114 ( 6 )   701 - 708   2021.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Bronchiolitis obliterans syndrome (BOS) remains one of the most devastating manifestations of chronic graft-versus-host disease in hematopoietic cell transplantation (HCT). Recent findings of BOS after lung transplantation indicate that donor (lung)-derived lung-resident macrophages contribute to BOS, suggesting that differences in the origin of immune cells and localized antigen-presenting cells cause the onset of BOS. METHODS: We identified the phenotype and origin of infiltrating macrophages using immunohistochemistry and fluorescence in situ hybridization in eight sex-mismatched HCT recipients who underwent lung transplantation for BOS after HCT. RESULTS: Most of the infiltrating macrophages appeared to be derived from donor (hematopoietic) cells in patients who developed BOS following HCT. Macrophages observed in the early-stage region of BOS were positive for cluster of differentiation (CD)68 and inducible nitric oxide synthase (iNOS) and negative for CD163 and CD206, suggesting an M1 phenotype. In the late-stage region, macrophages were negative for CD68 and iNOS in all patients, but also positive for CD163 and CD206 in some patients. CONCLUSIONS: Donor-derived M1-macrophages may be involved in the pathogenesis of the early-stage region of BOS. In addition, some macrophages in the late-stage region showed M2 polarization that might be involved in fibrosis.

    DOI: 10.1007/s12185-021-03214-7

    PubMed

    researchmap

  • Nodal Peripheral T-cell Lymphoma with T Follicular Helper Phenotype Presenting as Chorea During Treatment: A Case Report and Literature Review.

    Wataru Kitamura, Daisuke Ennishi, Ryoya Yukawa, Ryo Sasaki, Chikamasa Yoshida, Hiroki Takasuka, Hideaki Fujiwara, Noboru Asada, Hisakazu Nishimori, Keiko Fujii, Nobuharu Fujii, Ken-Ichi Matsuoka, Koji Abe, Tadashi Yoshino, Yoshinobu Maeda

    Internal medicine (Tokyo, Japan)   60 ( 19 )   3155 - 3160   2021.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    A 72-year-old man presented with chorea while undergoing treatment for recurrence of nodal peripheral T-cell lymphoma with T follicular helper (TFH) phenotype. An examination by brain N-isopropyl-p-iodoamphetamine (123I-IMP)-single photon emission computed tomography (SPECT) revealed no abnormalities other than a decreased cerebral blood flow (CBF) in the left striatum. After four courses of salvage chemotherapy, his clinical symptoms and asymmetric cerebral perfusion improved, suggesting that the decreased CBF had caused chorea. The significance of brain SPECT has not been fully clarified in patients with chorea-associated malignant lymphoma, warranting further investigations. Brain SPECT is an alternative approach to identify abnormalities in such patients.

    DOI: 10.2169/internalmedicine.7180-21

    PubMed

    researchmap

  • Phase 2 study of axicabtagene ciloleucel in Japanese patients with relapsed or refractory large B-cell lymphoma Reviewed

    Koji Kato, Shinichi Makita, Hideki Goto, Junya Kanda, Nobuharu Fujii, Kazuyuki Shimada, Koichi Akashi, Koji Izutsu, Takanori Teshima, Natsuko Fukuda, Tokuhito Sumitani, Hiroyuki Sumi, Shinji Shimizu, Yasuyuki Kakurai, Kenji Yoshikawa, Kensei Tobinai, Noriko Usui, Kiyohiko Hatake

    International Journal of Clinical Oncology   27 ( 1 )   213 - 223   2021.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Springer Science and Business Media LLC  

    <title>Abstract</title><sec>
    <title>Background</title>
    Axicabtagene ciloleucel (axi-cel) is an autologous chimeric antigen receptor T-cell based anti-CD19 therapy. The ZUMA-1 study, multicenter, single-arm, registrational Phase 1/2 study of axi-cel demonstrated high objective response rate in patients with relapsed/refractory large B-cell lymphoma. Here, we present the results of the bridging study to evaluate the efficacy and safety of axi-cel in Japanese patients (JapicCTI-183914).


    </sec><sec>
    <title>Methods</title>
    This study was the phase 2, multicenter, open-label, single-arm trial. Following leukapheresis, axi-cel manufacturing and lymphodepleting chemotherapy, patients received a single infusion of axi-cel (2.0 × 106 cells/kg). Bridging therapy between leukapheresis and conditioning chemotherapy was not allowed. The primary endpoint was objective response rate.


    </sec><sec>
    <title>Results</title>
    Among 17 enrolled patients, 16 received axi-cel infusion. In the 15 efficacy evaluable patients, objective response rate was 86.7% (95% confidence interval: 59.5–98.3%); complete response/partial response were observed in 4 (26.7%)/9 (60.0%) patients, respectively. No dose-limiting toxicities were observed. Grade ≥ 3 treatment-emergent adverse events occurred in 16 (100%) patients—most commonly neutropenia (81.3%), lymphopenia (81.3%) and thrombocytopenia (62.5%). Cytokine release syndrome occurred in 13 (81.3%) patients (12 cases of grade 1 or 2 and 1 case of grade 4). No neurologic events occurred. Two patients died due to disease progression, but no treatment-related death was observed by the data-cutoff date (October 23, 2019).


    </sec><sec>
    <title>Conclusion</title>
    The efficacy and safety of axi-cel was confirmed in Japanese patients with relapsed/refractory large B-cell lymphoma who have otherwise limited treatment options.


    </sec><sec>
    <title>Trial registration</title>
    JapicCTI-183914.


    </sec>

    DOI: 10.1007/s10147-021-02033-4

    PubMed

    researchmap

    Other Link: https://link.springer.com/article/10.1007/s10147-021-02033-4/fulltext.html

  • Desquamative esophagitis followed by esophageal cancer in a stem cell transplant recipient. Reviewed International journal

    Masaya Iwamuro, Nobuharu Fujii, Shunsuke Tanabe, Hiroyuki Okada

    Gastrointestinal endoscopy   2021.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.gie.2021.09.019

    PubMed

    researchmap

  • Marginal Zone Lymphoma and Lung Adenocarcinoma with an EGFR Exon 19 E746-S752del Mutation in a Patient with IgG4-related Disease Reviewed

    Sachi Okawa, Kammei Rai, Nobuharu Fujii, Yuka Gion, Kiichiro Ninomiya, Yuka Kato, Akihiko Taniguchi, Toshio Kubo, Eiki Ichihara, Kadoaki Ohashi, Nobuaki Miyahara, Katsuyuki Hotta, Masahiro Tabata, Yoshinobu Maeda, Katsuyuki Kiura

    Internal Medicine   60 ( 17 )   2831 - 2837   2021.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Japanese Society of Internal Medicine  

    A 68-year-old man presented with a solid mass at the left renal pelvis and ureter with multiple systemic lymphadenopathies and a mass with a cavity in the right lower lobe of the lung. While a transbronchial lung biopsy revealed no malignancy, a biopsy of the renal pelvis showed marginal zone lymphoma with polyclonal IgG4-positive cells. The serum IgG4 level and presence of a bilateral orbital mass suggested Mikulicz disease. The lesions shrank following the administration of steroids. A rebiopsy confirmed lung adenocarcinoma, and its background showed IgG4-positive cells a year later. IgG4-related diseases require careful follow-up because they can be complicated by malignancy.

    DOI: 10.2169/internalmedicine.6470-20

    PubMed

    researchmap

  • Transformation to diffuse large B-cell lymphoma with germinal center B-cell like subtype and discordant light chain expression in a patient with Waldenström macroglobulinemia/lymphoplasmacytic lymphoma. Reviewed

    Hiroki Kobayashi, Noboru Asada, Yuria Egusa, Tomoka Ikeda, Misa Sakamoto, Masaya Abe, Daisuke Ennishi, Masahiro Sakata, Akinobu Takaki, Soichiro Kawahara, Yusuke Meguri, Hisakazu Nishimori, Nobuharu Fujii, Ken-Ichi Matsuoka, Yasuharu Sato, Tadashi Yoshino, Yoshinobu Maeda

    International journal of hematology   114 ( 3 )   401 - 407   2021.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Waldenström macroglobulinemia (WM)/lymphoplasmacytic lymphoma (LPL) is a rare indolent B-cell neoplasm, and a gain-of-function mutation in the myeloid differentiation primary response 88 (MYD88), L265P, is a commonly recurring mutation in patients with WM/LPL. Histological transformation of WM/LPL to an aggressive lymphoma such as diffuse large B-cell lymphoma (DLBCL) is rare, and transformed DLBCL has a worse prognosis than de novo DLBCL, partly because transformed DLBCL is mostly classified as non-germinal center B-cell-like (non-GCB) subtype. We herein describe a 75-year-old man with DLBCL with a history of WM/LPL. DLBCL in this patient showed the GCB subtype, and the light chain restriction of DLBCL was different from that of the antecedent WM/LPL, indicating that the two types of lymphoma cells had distinctive origins. However, DLBCL in this patient harbored the MYD88 L265P mutation, and polymerase chain reaction and Sanger sequencing of the DLBCL and WM/LPL for immunoglobulin heavy chain gene rearrangement suggested a clonal relationship between the two lymphomas. Since the outcome of transformed DLBCL is worse than for de novo DLBCL, it is important to evaluate the clonal relationship between primary WM/LPL and the corresponding transformed DLBCL, even if the DLBCL expresses a GCB subtype or discordant light chain restriction.

    DOI: 10.1007/s12185-021-03157-z

    PubMed

    researchmap

  • 中国地方・四国地方における造血器悪性腫瘍患者に対する妊孕性温存体制の実態調査

    鴨井 千尋, 藤井 伸治, 嶋田 明, 名和 由一郎, 前田 嘉信

    臨床血液   62 ( 9 )   1388 - 1392   2021.9

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    妊孕性温存治療に関する認識と2020年現在の実践状況を明らかにするため,中国地方と四国地方の造血器悪性腫瘍患者を治療する医師を対象に調査を行った。アンケートを血液内科と小児血液腫瘍科の46施設59診療科に送付し,52名(88.1%)から回答を得た。患者への説明について,40名(76.9%)が統一された手順はないと回答し,37名(71.2%)が主治医単独で行うと回答した。対象年齢は決まっていないという回答が多数を占めた。自施設内で妊孕性温存治療を完遂できる施設は限られている。多くは他施設との協力が可能であった。一方,自施設で妊孕性温存治療は不可能かつ連携施設も存在しないという診療科が5ヶ所存在することが明らかになった。がん治療の影響で不妊になり得る全ての患者に妊孕性温存治療に関する情報を提供すべきである。地域のネットワークを活用し,施設間連携を強化することの必要性が示唆された。(著者抄録)

    researchmap

    Other Link: https://search.jamas.or.jp/default/link?pub_year=2021&ichushi_jid=J01540&link_issn=&doc_id=20211006220005&doc_link_id=1390289631643198720&url=https%3A%2F%2Fcir.nii.ac.jp%2Fcrid%2F1390289631643198720&type=CiNii&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00003_3.gif

  • Effectiveness of supplemental oral calcium drink in preventing citrate-related adverse effects in peripheral blood progenitor cell collection. International journal

    Keiko Fujii, Nobuharu Fujii, Takumi Kondo, Toshiharu Mitsuhashi, Makoto Nakamura, Keisuke Seike, Yasuhisa Sando, Maiko Kimura, Masayuki Matsuda, Shuntaro Ikegawa, Hiroyuki Sugiura, Fumio Otsuka, Yoshinobu Maeda

    Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis   60 ( 4 )   103147 - 103147   2021.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:PERGAMON-ELSEVIER SCIENCE LTD  

    Peripheral blood progenitor cells (PBPCs) are a predominant graft source in allogeneic hematopoietic cell transplantation. Citrate-induced hypocalcemia remains the most frequent side effect of PBPC apheresis. Although the method for preventing severe adverse events is established, more efficient prophylaxis is required so that volunteer donors can donate PBPCs without pain and anxiety. We studied 80 healthy donors who underwent PBPC harvest between February 2014 and June 2020. Of these, 23 donors who underwent apheresis between February 2014 and December 2015 received only the standard prophylaxis of intravenous calcium gluconate. Oral calcium drinks were provided to 57 donors who underwent apheresis from January 2016 to June 2020 to supplement intravenous calcium gluconate prophylaxis. The ionized calcium (ICa) levels at multiple time intervals and the hypocalcemic symptoms were evaluated. Oral supplementation with a calcium drink maintained significantly higher ICa levels. Analysis using the inverse probability weighted regression adjustment method suggested that calcium drinks reduced the frequency of citrate-related reactions by 39.2 %. Administering a prophylactic oral calcium drink before apheresis with intravenous administration of calcium gluconate is promising to further reduce citrate-induced hypocalcemia in volunteer donors.

    DOI: 10.1016/j.transci.2021.103147

    Web of Science

    PubMed

    researchmap

  • Squamous Metaplasia of the Stomach Associated with Lymphoma Infiltration.

    Masaya Iwamuro, Nobuharu Fujii, Takehiro Tanaka, Hiromitsu Kanzaki, Seiji Kawano, Yoshiro Kawahara, Hiroyuki Okada

    Internal medicine (Tokyo, Japan)   60 ( 14 )   2229 - 2234   2021.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    We herein report a patient who presented with follicular lymphoma. Although the stomach was initially intact, mucosal redness and multiple erosions appeared in the gastric body owing to infiltration of the follicular lymphoma cells. Subsequently, a slightly depressed, white area lacking gastric mucosal structure was detected in the lesser curvature of the gastric cardia and body, where lymphoma cell infiltration was also pathologically observed beneath the stratified squamous epithelium. This case indicated that, although infrequent, prolonged mucosal injury owing to lymphoma infiltration can cause squamous metaplasia in the stomach.

    DOI: 10.2169/internalmedicine.6271-20

    PubMed

    researchmap

  • Effects of Gram-negative Rod Blood Stream Infection on Acute GVHD in Allogeneic Hematopoietic Stem Cell Transplantation: A Single-institute Analysis. Reviewed

    Masaaki Nishinohara, Hisakazu Nishimori, Hideaki Fujiwara, Noboru Asada, Daisuke Ennishi, Ken-Ichi Matsuoka, Keiko Fujii, Nobuharu Fujii, Yoshinobu Maeda

    Acta medica Okayama   75 ( 3 )   279 - 287   2021.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    A bloodstream infection (BSI) is the most common serious infectious complication of hematopoietic stem cell transplantation (HSCT). BSI promotes an inflammatory state, which exacerbates acute graft-versus-host disease (GVHD). We investigated whether a Gram-negative rod bloodstream infection (GNR-BSI), which develops early after allo-HSCT, affected the onset or exacerbated acute GVHD in 465 patients who underwent allo-HSCT from 1995 through 2015 at a single institution. Eighty-eight patients (19%) developed BSI during the study period. Among the cultures, 50 (57%) were Gram-positive cocci (GPC) and 31 (35%) were GNR. Of the 465 patients, 187 (40%) developed acute GVHD of grade II or higher within the first 100 days post-allogeneic HSCT: 124 (27%) had acute GVHD grade II, 47 (10%) had grade III, and 16 (3%) had grade IV. Multivariate analysis revealed that GNR-BSI was a significant risk factor for grade II-IV acute GVHD (grade II-IV: hazard ratio [HR] 1.75, 95% confidence interval [CI] 1.03-2.97; grade III-IV: HR 2.37, 95% CI 1.03-5.43). These results suggest that GNR-BSI may predict the onset and exacerbation of acute GVHD.

    DOI: 10.18926/AMO/62219

    PubMed

    researchmap

  • Cryopreservation of Unrelated Hematopoietic Stem Cells from a Blood and Marrow Donor Bank During the COVID-19 Pandemic: A Nationwide Survey by the Japan Marrow Donor Program. International journal

    Yoshinobu Kanda, Masami Inoue, Naoyuki Uchida, Yasushi Onishi, Reiko Kamata, Mika Kotaki, Ryoji Kobayashi, Junji Tanaka, Takahiro Fukuda, Nobuharu Fujii, Koichi Miyamura, Shin-Ichiro Mori, Yasuo Mori, Yasuo Morishima, Hiromasa Yabe, Yoshihisa Kodera

    Transplantation and cellular therapy   27 ( 8 )   664.e1-664.e6   2021.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    During the COVID-19 pandemic, donor hematopoietic stem cell grafts are frequently cryopreserved to ensure the availability of graft before starting a conditioning regimen. However, the safety of cryopreservation has been controversial in unrelated hematopoietic stem cell transplantation (HSCT), especially for bone marrow (BM) grafts. In addition, in unrelated HSCT, the effect of the time from harvest to cryopreservation of donor grafts required for the transportation of donor graft has not been fully clarified. In this study, we retrospectively analyzed the first 112 patients with available data who underwent cryopreserved unrelated blood and marrow transplantation through the Japan Marrow Donor Program during the COVID-19 pandemic. There were 112 patients, including 83 who received BM grafts and 29 who received peripheral blood stem cell (PBSC) grafts. The median time from stem cell harvest to cryopreservation was 9.9 hours (range, 2.6 to 44.0 hours), and the median time from cryopreservation to infusion was 231.2 hours. The incidence of neutrophil engraftment at day 28 after HSCT was 91.1%, and among 109 patients (excluding 3 patients with early death), all but 1 patient achieved neutrophil engraftment within 60 days after HSCT. The time to neutrophil engraftment and time to platelet engraftment were shorter in PBSC transplantation compared with BM transplantation (BMT), but the differences were not statistically significant (P = .064 and .18). Multivariate analysis among BM recipients revealed that a higher number of frozen nucleated cells and the absence of HLA mismatch were associated with faster neutrophil engraftment. The time to neutrophil engraftment after unrelated cryopreserved BMT was not different from that after unrelated BMT without cryopreservation. Our findings suggest that unrelated donor BM and PBSC grafts can be safely cryopreserved even after transit from the harvest center to the transplantation center. In the current COVID-19 pandemic, cryopreservation can be considered as an option while balancing the risks and benefits of the procedure.

    DOI: 10.1016/j.jtct.2021.04.022

    PubMed

    researchmap

  • Successful Treatment of Acute Promyelocytic Leukemia Complicated with Endometrial Cancer by Arsenic Trioxide.

    Hiroyuki Sugiura, Hisakazu Nishimori, Hirofumi Matsuoka, Keiichiro Nakamura, Keiko Fujii, Nobuharu Fujii, Ken-Ichi Matsuoka, Yoshinobu Maeda

    Acta medica Okayama   75 ( 2 )   219 - 224   2021.4

     More details

    Language:English  

    Acute promyelocytic leukemia (APL) is a hematological emergency that requires urgent intervention because of the high incidence of early hemorrhagic death. When patients with APL experience a synchronous solid organ tumor, the tumor's treatment must also be done properly. Differentiation-inducing therapy using arsenic trioxide (ATO) has less hematological toxicity compared to cytotoxic chemotherapy and might be preferable for untreated APL patients with a synchronous solid organ tumor. Here we describe the first successful case of untreated APL and synchronous endometrial cancer (in an adult Japanese woman) treated with ATO consolidation therapy and the subsequent surgery and chemotherapy for endometrial cancer.

    DOI: 10.18926/AMO/61904

    PubMed

    researchmap

  • Pretransplant nivolumab further enhanced Treg expansion after posttransplant cyclophosphamide; another aspect for immune tolerance by PTCy after nivolumab. International journal

    Shuntaro Ikegawa, Yusuke Meguri, Kentaro Mizuhara, Takuya Fukumi, Hiroki Kobayashi, Yuichi Sumii, Takumi Kondo, Yasuhisa Sando, Miki Iwamoto, Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Keiko Fujii, Nobuharu Fujii, Yuka Fujisawa, Toshi Imai, Yoshinobu Maeda, Ken-Ichi Matsuoka

    Leukemia   35 ( 3 )   929 - 931   2021.3

     More details

  • A multicenter phase II study of intrabone single-unit cord blood transplantation without antithymocyte globulin. International journal

    Tetsuya Nishida, Takeshi Kobayashi, Masashi Sawa, Shinichi Masuda, Yasuhiko Shibasaki, Tatsunori Goto, Noriko Fukuhara, Nobuharu Fujii, Kazuhiro Ikegame, Junichi Sugita, Takashi Ikeda, Yachiyo Kuwatsuka, Ritsuro Suzuki, Yuho Najima, Noriko Doki, Tomonori Kato, Yuichiro Inagaki, Yoshikazu Utsu, Nobuyuki Aotsuka, Masayoshi Masuko, Seitaro Terakura, Yasushi Onishi, Yoshinobu Maeda, Masaya Okada, Takanori Teshima, Makoto Murata

    Annals of hematology   100 ( 3 )   743 - 752   2021.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    To overcome the delayed or failed engraftment after unrelated cord blood transplantation (CBT), we conducted a multicenter phase II study of intrabone single-unit CBT without antithymocyte globulin (ATG) for adult patients with hematological malignancies (UMIN-CTR, UMIN000020997). Sixty-four patients received an intrabone injection of unwashed (n = 61) or washed (n = 3) cord blood after local anesthesia. All injection-related adverse events were mild and resolved spontaneously. Sixty-two patients were evaluable for the efficacy of intrabone CBT of serological HLA-A, -B, and -DR ≥ 4/6 matched cord blood with a median number of 2.57 × 107/kg cryopreserved total nucleated cells. The probability of survival with neutrophil engraftment on day 28 was 77.4% (95% confidence interval, 67.0-85.8%), which exceeded the threshold value. The cumulative incidences of neutrophils ≥ 0.5 × 109/L on day 60 was 80.6% (68.2-88.6%), with a median time to recovery of 21 days after transplantation. The cumulative incidences of platelets ≥ 20 × 109/L and platelets ≥ 50 × 109/L on day 100 were 75.8% (62.6-84.9%) and 72.6% (59.4-82.1%), respectively, with median time to platelets ≥ 20 × 109/L and platelets ≥ 50 × 109/L of 38 and 45 days after transplantation, respectively. The cumulative incidences of grade II-IV and III-IV acute graft-versus-host disease were 29.0% and 6.5%, respectively. All responded to steroid therapy, and secondary treatments were not required. The present study suggests the efficacy of intrabone single-unit CBT without ATG in terms of early engraftment and controllable acute graft-versus-host disease.

    DOI: 10.1007/s00277-020-04365-z

    PubMed

    researchmap

  • Total body irradiation-based haploidentical hematopoietic stem cell transplantation using posttransplant cyclophosphamide after administration of inotuzumab ozogamicin: A case report. Reviewed International journal

    Masaya Abe, Nobuharu Fujii, Kentaro Mizuhara, Tomohiro Urata, Yuichi Sumii, Yuki Fujiwara, Keisuke Seike, Yasuhisa Sando, Makoto Nakamura, Keiko Fujii, Kyosuke Saeki, Yusuke Meguri, Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Ken-Ichi Matsuoka, Yoshinobu Maeda

    Leukemia research reports   15   100241 - 100241   2021

     More details

    Language:English  

    Owing to the poor prognosis of relapsed or refractory acute lymphoblastic leukemia (ALL), hematopoietic stem cell transplantation (HSCT) followed by effective salvage therapy is required. Inotuzumab ozogamicin (INO) was developed for ALL refractory to standard chemotherapy. However, previous reports suggest that sinusoidal obstruction syndrome (SOS) risk increases in patients with HSCT receiving INO, especially with dual alkylating agents. We report a case of relapsed Philadelphia chromosome-negative B-ALL where the patient underwent haploidentical HSCT using fludarabine/total body irradiation conditioning and posttransplant cyclophosphamide. Successful engraftment was achieved without SOS development.

    DOI: 10.1016/j.lrr.2021.100241

    PubMed

    researchmap

  • Treatment outcomes of IgG4-producing marginal zone B-cell lymphoma: a retrospective case series. Reviewed

    Yuichi Sumii, Noboru Asada, Yasuharu Sato, Koh-Ichi Ohshima, Masanori Makita, Yusuke Yoshimoto, Yuka Sogabe, Kenji Imajo, Yusuke Meguri, Daisuke Ennishi, Hisakazu Nishimori, Nobuharu Fujii, Ken-Ichi Matsuoka, Tadashi Yoshino, Yoshinobu Maeda

    International journal of hematology   112 ( 6 )   780 - 786   2020.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    IgG4-producing marginal zone B-cell lymphomas (MZLs) have been recently proposed as a subtype of MZLs. Despite the abundant literature on pathophysiological features of this type of lymphoma, only a few retrospective studies pertaining to the treatment outcomes have been reported, and its prognosis remains unclear. We retrospectively analyzed seven patients with IgG4-producing MZLs diagnosed at our institute, with specific reference to treatment and outcomes. The median age was 69.0 years (55-79), and all were males. The median follow-up period was 66.6 months (8-121). All patients had localized disease; four patients had tumors of the ocular adnexa, whereas two had retroperitoneal tumors. Five patients were treated with irradiation (30 Gy/15 fr) (n = 4) or surgery (n = 1), resulting in tumor reduction. Two patients were treated by chemotherapy or irradiation. Among them, one commenced rituximab monotherapy, which led to an inadequate reduction of the tumor. Subsequent irradiation induced complete response (CR). The other patient experienced repeated relapses during follow-up and finally achieved CR by combination chemotherapy. Treatment was well tolerated in all cases, and none of the patients showed disease progression at the last follow-up visit. Our results indicate that the standard treatments for MZLs are generally appropriate for IgG4-producing MZL.

    DOI: 10.1007/s12185-020-02968-w

    PubMed

    researchmap

  • Allogeneic hematopoietic stem cell transplantation in a prior lung transplant recipient. Reviewed

    Yuki Fujiwara, Ken-Ichi Matsuoka, Miki Iwamoto, Yuichi Sumii, Masaya Abe, Kentaro Mizuhara, Tomohiro Urata, Kyosuke Saeki, Yusuke Meguri, Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Keiko Fujii, Nobuharu Fujii, Junichi Sugita, Hajime Kobayashi, Takahiro Oto, Yoshinobu Maeda

    International journal of hematology   112 ( 6 )   871 - 877   2020.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Hematological diseases after solid organ transplant (SOT) are an emerging issue as the number of long-term SOT survivors increases. Expertise in managing patients requiring allogeneic hematopoietic stem cell transplantation (HSCT) after SOT from independent donors is needed; however, clinical reports of HSCT after SOT are limited, and the feasibility and risk are not well understood. In particular, HSCT in prior lung transplant recipients is thought to be complicated as the lung is immunologically distinct and is constantly exposed to the surrounding environment. Herein, we describe a case of successful HSCT in a patient with myelodysplastic syndromes who had previously received a lung transplant from a deceased donor for bronchiolitis obliterans syndrome. Reports about cases of HSCT after lung transplant are quite rare; thus, we discuss the mechanisms of immune tolerance through the clinical course of our case. This case suggests that HSCT after SOT can be considered a therapeutic option in cases where the transplanted organ is functionally retained and the hematological disease is in remission.

    DOI: 10.1007/s12185-020-02967-x

    PubMed

    researchmap

  • Adult T-cell Leukemia-lymphoma with Primary Breast Involvement: A Case Report and Literature Review. Reviewed

    Hiroki Kobayashi, Noboru Asada, Takuro Igawa, Masaya Abe, Yusuke Meguri, Daisuke Ennishi, Hisakazu Nishimori, Nobuharu Fujii, Ken-Ichi Matsuoka, Tadashi Yoshino, Yoshinobu Maeda

    Internal medicine (Tokyo, Japan)   59 ( 21 )   2757 - 2761   2020.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Breast involvement of Adult T-cell leukemia-lymphoma (ATLL) is extremely rare, and the data on the characteristics are limited. We herein describe a 49-year-old woman who presented with skin involvement of ATLL. Positron emission tomography/computed tomography showed bilateral breast lesions. Although the patient once achieved a complete metabolic response, a relapse of her ATLL occurred. The patient received subsequent allogeneic hematopoietic stem cell transplantation (HSCT). To our knowledge, only four cases of ATLL with breast involvement have previously been reported, and the prognoses have generally been poor. Breast lesions of ATLL have aggressive features, and intensive systemic chemotherapy and HSCT are required to improve survival.

    DOI: 10.2169/internalmedicine.5077-20

    PubMed

    researchmap

  • Post-transplantation cyclophosphamide restores early B-cell lymphogenesis that suppresses subsequent chronic graft-versus-host disease. Reviewed International journal

    Miki Iwamoto, Shuntaro Ikegawa, Takumi Kondo, Yusuke Meguri, Makoto Nakamura, Yasuhisa Sando, Hiroyuki Sugiura, Yuichi Sumii, Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Keiko Fujii, Nobuharu Fujii, Misako Shibakura, Yoshinobu Maeda, Ken-Ichi Matsuoka

    Bone marrow transplantation   56 ( 4 )   956 - 959   2020.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1038/s41409-020-01100-0

    PubMed

    researchmap

  • Persistent hypogammaglobulinemia due to immunoglobulin class switch impairment by peri-transplant rituximab therapy. Reviewed

    Kentaro Mizuhara, Nobuharu Fujii, Yusuke Meguri, Takahide Takahashi, Michinori Aoe, Makoto Nakamura, Keisuke Seike, Yasuhisa Sando, Keiko Fujii, Masaya Abe, Yuichi Sumii, Tomohiro Urata, Yuki Fujiwara, Kyosuke Saeki, Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Ken-Ichi Matsuoka, Yoshinobu Maeda

    International journal of hematology   112 ( 3 )   422 - 426   2020.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Post-transplant lymphoproliferative disorder (PTLD) is one of the most serious complications of allogeneic hematopoietic stem cell transplantation (HSCT). Rituximab is effective for PTLD; however, rituximab can produce adverse effects, including hypogammaglobulinemia. Here, we present the case of an 18-year-old female with refractory cytopenia of childhood who developed persistent selective hypogammaglobulinemia with low immunoglobulin G (IgG) 2 and IgG4 levels and monoclonal protein after rituximab therapy against probable PTLD. Despite B-cell recovery, the serum IgG levels gradually declined, reaching < 300 mg/dL at 33 months after rituximab treatment. In addition, class-switched memory (CD27 + IgD -) B cells were limited in phenotypic analysis. These findings suggest that peri-HSCT rituximab may contribute to an abnormal B-cell repertoire induced by impaired immunoglobulin class switch.

    DOI: 10.1007/s12185-020-02886-x

    PubMed

    researchmap

  • Secondary Pulmonary Alveolar Proteinosis Associated with Primary Myelofibrosis and Ruxolitinib Treatment: An Autopsy Case. Reviewed

    Hiroyuki Sugiura, Hisakazu Nishimori, Kazuya Nishii, Tomohiro Toji, Keiko Fujii, Nobuharu Fujii, Ken-Ichi Matsuoka, Koh Nakata, Katsuyuki Kiura, Yoshinobu Maeda

    Internal medicine (Tokyo, Japan)   59 ( 16 )   2023 - 2028   2020.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Pulmonary alveolar proteinosis (PAP) is an uncommon lung disorder characterized by the excessive accumulation of surfactant-derived lipoproteins in the pulmonary alveoli and terminal bronchiole. Secondary PAP associated with primary myelofibrosis (PMF) is extremely rare, and to our knowledge, no autopsy case has been reported. We herein report an autopsy case of secondary PAP occurring in a patient with PMF who was treated with the Janus kinase 1/2 inhibitor ruxolitinib. We confirmed a diagnosis of PAP with complications based on the pathological findings at the autopsy. Notably, this case might suggest an association between ruxolitinib treatment and PAP occurrence.

    DOI: 10.2169/internalmedicine.4082-19

    PubMed

    researchmap

  • Prospective evaluation of alternative donor from unrelated donor and cord blood in adult acute leukemia and myelodysplastic syndrome

    Seitaro Terakura, Tetsuya Nishida, Masashi Sawa, Tomonori Kato, Kotaro Miyao, Yukiyasu Ozawa, Tatsunori Goto, Akio Kohno, Kazutaka Ozeki, Yasushi Onishi, Noriko Fukuhara, Nobuharu Fujii, Hisayuki Yokoyama, Masanobu Kasai, Hiroatsu Iida, Nobuhiro Kanemura, Tomoyuki Endo, Hiroatsu Ago, Makoto Onizuka, Satoshi Iyama, Yuichiro Nawa, Mika Nakamae, Yasuyuki Nagata, Shingo Kurahashi, Yasuo Tomiya, Atsumi Yanagisawa, Ritsuro Suzuki, Yachiyo Kuwatsuka, Yoshiko Atsuta, Koichi Miyamura, Makoto Murata

    Bone Marrow Transplantation   55 ( 7 )   1399 - 1409   2020.7

     More details

    Publishing type:Research paper (scientific journal)  

    A prospectively registered observational study was conducted to assess the significance of allogeneic hematopoietic stem cell transplantation from highly HLA-matched unrelated donors (UD) and cord blood (CB) on outcomes in adult acute leukemia (AL) and myelodysplastic syndrome (MDS). Between 2007 and 2015, 231 transplant-eligible patients were registered for a phase 2 study of alternative donor transplantation. After registration, a sufficient time period was given to find appropriate UD. Patients received CB transplantation (CBT) if an appropriate UD was unavailable. In total, 119 patients received CBT (106 AL and 13 MDS) and 91 patients received UD transplantation (UDT) (86 AL and 5 MDS). The median age was 39 years in both groups. The primary objective was overall survival (OS); secondary objectives included cumulative incidences of non-relapse mortality (NRM) and relapse, and disease-free survival. Diagnosis, disease status at transplantation, refined disease risk index, and hematopoietic cell transplant-specific comorbidity index did not differ between UDT and CBT. In multivariate analyses, graft source was not a significant risk factor for all objectives. In adjusted analyses, UDT and CBT showed similar OS, NRM, and relapse in this prospective study. CB can be a comparable alternative stem cell source to UD by achieving a timely transplant.

    DOI: 10.1038/s41409-020-0859-8

    Scopus

    PubMed

    researchmap

  • 原発性マクログロブリン血症から形質転換したGerminal Center B-cellタイプのびまん性大細胞型B細胞リンパ腫の症例

    小林 宏紀, 淺田 騰, 遠西 大輔, 阿部 将也, 池田 知佳, 坂本 美彩, 江草 侑厘安, 廻 勇輔, 西森 久和, 藤井 伸治, 松岡 賢市, 佐藤 康晴, 吉野 正, 前田 嘉信

    日本リンパ網内系学会会誌   60   82 - 82   2020.7

     More details

    Language:Japanese   Publisher:(一社)日本リンパ網内系学会  

    researchmap

  • 原発性マクログロブリン血症から形質転換したGerminal Center B-cellタイプのびまん性大細胞型B細胞リンパ腫の症例

    小林 宏紀, 淺田 騰, 遠西 大輔, 阿部 将也, 池田 知佳, 坂本 美彩, 江草 侑厘安, 廻 勇輔, 西森 久和, 藤井 伸治, 松岡 賢市, 佐藤 康晴, 吉野 正, 前田 嘉信

    日本リンパ網内系学会会誌   60   82 - 82   2020.7

     More details

    Language:Japanese   Publisher:(一社)日本リンパ網内系学会  

    researchmap

  • Efficacy of HLA virtual cross-matched platelet transfusions for platelet transfusion refractoriness in hematopoietic stem cell transplantation. Reviewed International journal

    Keisuke Seike, Nobuharu Fujii, Naomi Asano, Shigenori Ohkuma, Yasushi Hirata, Keiko Fujii, Yasuhisa Sando, Makoto Nakamura, Kazunori Naito, Kyosuke Saeki, Yusuke Meguri, Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Ken-Ichi Matsuoka, Kazuo Tsubaki, Fumio Otsuka, Yoshinobu Maeda

    Transfusion   60 ( 3 )   473 - 478   2020.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Cross-matched platelet (cross-matched PLT) transfusion is effective for immune-mediated platelet transfusion refractoriness (PTR), but is more costly and time-consuming for physical cross-match than using standard PLT units. Recent studies have reported the utility of human leucocyte antigens (HLA) virtual cross-matched PLT (HLA-matched PLT) that is defined as HLA-A/B matched or no antibody against donor-specific antigen. Here, we evaluated the effect of HLA-matched PLTs for PTR in post hematopoietic stem cell transplant (HSCT) recipients. STUDY DESIGN AND METHODS: Our study included a total of 241 PLTs in 16 patients who underwent HSCT at Okayama University Hospital between 2010 and 2017, receiving either HLA-matched or cross-matched PLTs. We calculated the 24-hour corrected count increments (CCI-24) to evaluate the effect of PLTs. A CCI-24 ≥ 4500 was considered to be a successful transfusion. RESULTS: We analyzed 139 cross-matched PLTs and 102 HLA-matched PLTs. In the immune-mediated PTR, the rate of successful transfusion was 60.5% for cross-matched PLT and 63.4% for HLA-matched PLT (p = 0.825). On the other hand, the median CCI-24 for cross-matched PLT transfusions and HLA-matched PLT transfusions were 1856 and 5824 (p < 0.001), with a success rate of 28.1 and 54.1% in cases with non-immune-mediated PTR, respectively (p = 0.001). CONCLUSION: The effectiveness of HLA-matched PLT is not inferior to cross-matched PLT. This result indicates that physical cross-match can be omitted in post HSCT PTR.

    DOI: 10.1111/trf.15664

    PubMed

    researchmap

  • Comparison of the clinical characteristics of TAFRO syndrome and idiopathic multicentric Castleman disease in general internal medicine: a 6‐year retrospective study Reviewed

    Yoshito Nishimura, Yoshihisa Hanayama, Nobuharu Fujii, Eisei Kondo, Fumio Otsuka

    Internal Medicine Journal   50 ( 2 )   184 - 191   2020.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Wiley  

    DOI: 10.1111/imj.14404

    researchmap

    Other Link: https://onlinelibrary.wiley.com/doi/full-xml/10.1111/imj.14404

  • 造血幹細胞運搬条件設定に関する取り組み

    浅野 尚美, 小郷 博昭, 池田 亮, 閘 結稀, 高木 尚江, 清家 圭介, 三道 康永, 中村 真, 藤井 敬子, 藤井 伸治, 大塚 文男

    日本輸血細胞治療学会誌   66 ( 1 )   78 - 78   2020.2

     More details

    Language:Japanese   Publisher:(一社)日本輸血・細胞治療学会  

    researchmap

  • Efficacy of HLA virtual cross-matched platelet transfusions for platelet transfusion refractoriness in hematopoietic stem cell transplantation Reviewed

    Seike K, Fujii N, Asano N, Ohkuma S, Hirata Y , Fujii K, Sando Y, Nakamura M, Naito K , Saeki K, Meguri Y, Asada N, Ennishi D, Nishimori H, Matsuoka K, Tsubaki K, Otsuka F , Maeda Y.

    Transfusion   60 ( 3 )   473 - 478   2020.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    researchmap

  • Chemotherapy Improved Pulmonary Arterial Hypertension in a Patient with Chronic-Active Epstein-Barr Virus Infection. Reviewed

    Satoshi Akagi, Takashi Miki, Yasuhisa Sando, Nobuharu Fujii, Toshihiro Sarashina, Kazufumi Nakamura, Hiroshi Ito

    International heart journal   61 ( 1 )   191 - 194   2020.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Chronic-active Epstein-Barr virus infection (CAEBV) is a rare disease that can lead to pulmonary arterial hypertension (PAH). However, the treatment for CAEBV-associated PAH has not been established. We discuss a case of improved pulmonary hypertension after chemotherapy in a patient with CAEBV-associated PAH. A 44-year old man was admitted to our hospital because of an abnormal electrocardiogram and liver dysfunction detected by annual medical examination. Echocardiography showed a dilated right ventricle and an estimated right ventricular systolic pressure of 92 mmHg. Right heart catheterization revealed a mean pulmonary arterial pressure of 45 mmHg and pulmonary vascular resistance of 9.8 Wood units. Laboratory examination showed granular lymphocytes and 91% natural killer cells in lymphocyte subsets in peripheral blood. We diagnosed the patient as having CAEBV-associated PAH. After two cycles of chemotherapy without PAH-specific drugs, echocardiography showed improvement in the dilated right ventricle and an estimated right ventricular systolic pressure of 59 mmHg. Right heart catheterization revealed a mean pulmonary arterial pressure of 27 mmHg and pulmonary vascular resistance of 2.4 Wood units. Chemotherapy may improve pulmonary hypertension in patients with CAEBV-associated PAH.

    DOI: 10.1536/ihj.19-419

    PubMed

    researchmap

  • Prospective Phase 2 Study of Umbilical Cord Blood Transplantation in Adult Acute Leukemia and Myelodysplastic Syndrome Reviewed

    Seitaro Terakura, Tetsuya Nishida, Masashi Sawa, Tomonori Kato, Kotaro Miyao, Yukiyasu Ozawa, Akio Kohno, Yasushi Onishi, Noriko Fukuhara, Masanobu Kasai, Nobuharu Fujii, Hisayuki Yokoyama, Hiroatsu Iida, Nobuhiro Kanemura, Atsushi Fujieda, Hiroatsu Ago, Yutaka Tsutsumi, Fumihiko Nakamura, Kazuhiro Yago, Yukiyoshi Moriuchi, Shuichi Ota, Haruhiko Ohashi, Atsumi Yanagisawa, Ritsuro Suzuki, Yachiyo Kuwatsuka, Yoshiko Atsuta, Koichi Miyamura, Makoto Murata

    Biology of Blood and Marrow Transplantation   26 ( 1 )   139 - 144   2020.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Almost comparable transplantation outcomes have been reported with HLA-matched unrelated donor transplantation (UDT) and cord blood transplantation (CBT). We conducted a prospective phase 2 study to assess the efficacy and safety of single-unit myeloablative CBT in adult leukemia and myelodysplastic syndrome. Because the day 180 survival of UDT was approximately 80%, we determined the alternative hypothesis of expected day 180 survival with a successful engraftment rate of 80% and set the null hypothesis of threshold rate at 65%. Sixty-two patients (median age, 37 years) were registered, including 28 with acute myelogenous leukemia, 25 with acute lymphoblastic leukemia, and 9 with myelodysplastic syndrome. Of 61 eligible patients, 52 were successfully engrafted and survived at day 180 (85%; 95% confidence interval, 74% to 93%). Single-unit CBT was judged to be effective because the null hypothesis was rejected (P <. 001). Furthermore, neutrophil engraftment was observed in 57 patients (92%); the incidences of grade II-IV acute and chronic graft-versus-host disease were 30% and 32%, respectively; and the cumulative incidences of nonrelapse mortality and relapse at 2 years were 18% and 13%, respectively. The present study showed favorable survival outcomes with single-unit CBT. Therefore, this method may be considered if a well-HLA-matched UDT cannot be obtained.

    DOI: 10.1016/j.bbmt.2019.09.021

    Scopus

    PubMed

    researchmap

  • Prospective Evaluation of Alternative Donor from Unrelated Volunteer Donor and Cord Blood in Adult Acute Leukemia and Myelodysplastic Syndrome: No Difference between Unrelated Donor and Cord Blood

    Seitaro Terakura, Tetsuya Nishida, Masashi Sawa, Tomonori Kato, Kotaro Miyao, Yukiyasu Ozawa, Tatsunori Goto, Akio Kohno, Kazutaka Ozeki, Yasushi Onishi, Noriko Fukuhara, Nobuharu Fujii, Hisayuki Yokoyama, Masanobu Kasai, Hiroatsu Iida, Nobuhiro Kanemura, Tomoyuki Endo, Hiroatsu Ago, Makoto Onizuka, Satoshi Iyama, Yuichiro Nawa, Mika Nakamae, Yasuyuki Nagata, Shingo Kurahashi, Yasuo Tomiya, Atsumi Yanagisawa, Ritsuro Suzuki, Yachiyo Kuwatsuka, Yoshiko Atsuta, Koichi Miyamura, Makoto Murata

    BLOOD   134   2019.11

     More details

    Language:English   Publisher:AMER SOC HEMATOLOGY  

    0

    DOI: 10.1182/blood-2019-124634

    Web of Science

    researchmap

  • Macrophage elimination in bone marrow by dexamethasone palmitate is associated with successful engraftment in patients with hemophagocytic syndrome. Reviewed

    Hiroyuki Sugiura, Ken-Ichi Matsuoka, Masayuki Matsuda, Shuntaro Ikegawa, Tomoko Inomata, Taiga Kuroi, Takeru Asano, Shohei Yoshida, Hisakazu Nishimori, Keiko Fujii, Nobuharu Fujii, Yoshinobu Maeda

    International journal of hematology   110 ( 2 )   260 - 262   2019.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s12185-019-02659-1

    PubMed

    researchmap

  • Plasma exchange eliminates residual mogamulizumab but does not warrant prompt recovery of peripheral Treg levels. International journal

    Hiroyuki Sugiura, Ken-Ichi Matsuoka, Yasuhisa Sando, Yusuke Meguri, Shuntaro Ikegawa, Makoto Nakamura, Miki Iwamoto, Takanori Yoshioka, Takeru Asano, Eisei Kondo, Keiko Fujii, Nobuharu Fujii, Yoshinobu Maeda

    Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis   58 ( 4 )   472 - 474   2019.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Mogamulizumab (Mog), a humanized anti-CCR4 antibody, provides an important treatment option for relapsed/refractory adult T cell leukemia/lymphoma. However, administration of Mog before allogenic hematopoietic stem cell transplantation has been reported to be a risk factor for severe acute graft-versus-host disease (GVHD). The etiological hypothesis is Mogamulizumab may eradicate CCR4-positive regulatory T cells (Tregs). Theoretically, Treg homeostasis and course of GVHD can be affected by plasma exchange (PE) with decreasing plasma Mog concentration. Here, we present a case of severe acute GVHD after pretransplantation Mog, in which PE was performed for liver failure. As a result, plasma Mog concentration was decreased but it did not lead to the prompt elevation of Treg levels in peripheral blood and clinical responses of GVHD were limited to partial remission. Our case suggests that recovery of donor-derived Treg in the acute phase after HSCT is multifactorial and the single procedure of PE-based Mog depletion does not necessarily warrant the quick restoration of Treg homeostasis.

    DOI: 10.1016/j.transci.2019.05.011

    PubMed

    researchmap

  • Plasma exchange eliminates residual mogamulizumab but does not warrant prompt recovery of peripheral Treg levels. Reviewed

    Sugiura H, Matsuoka K, Sando Y, Meguri Y, Ikegawa S, Nakamura M, Iwamoto M, Yoshioka T, Asano T, Kondo E, Fujii K, Fujii N, Maeda Y.

    Transfusion and Apheresis Science.   S1473-0502 ( 19 )   30123 - 30125   2019.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    researchmap

  • High dose chemotherapy with autologous stem cell transplantation in primary central nervous system lymphoma: Data from the japan society for hematopoietic cell transplantation (JSHCT) registry Reviewed

    Kondo Eisei, Ikeda Takashi, Izutsu Koji, Chihara Dai, Shimizu-Koresawa Risa, Fujii Nobuharu, Sakai Tomoyuki, Kondo Tadakazu, Kubo Kohmei, Kato Yuichi, Akasaka Takashi, Fukuda Takahiro, Ichinohe Tatsuo, Atsuta Yoshiko, Suzumiya Junji, Suzuki Ritsuro

    BONE MARROW TRANSPLANTATION   54   453 - 455   2019.7

  • High-Dose Chemotherapy with Autologous Stem Cell Transplantation in Primary Central Nervous System Lymphoma: Data From the Japan Society for Hematopoietic Cell Transplantation Registry Reviewed

    Kondo E, Ikeda T, Izutsu K, Chihara D, Shimizu-Koresawa R, Fujii N, Sakai T, Kondo T, Kubo K, Kato Y, Akasaka T, Fukuda T, Ichinohe T, Atsuta Y, Suzumiya J, Suzuki R; Adult Lymphoma Working Group of the Japan Society for Hematopoietic Cell Transplantation.

    Biol Blood Marrow Transplant.   25 ( 5 )   899 - 905   2019.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    researchmap

  • Cyclophosphamide(CY)が奏効した難治性TAFRO症候群の一例

    浦田 知宏, 遠西 大輔, 水原 健太郎, 阿部 将也, 住居 優一, 藤原 悠紀, 佐伯 恭昌, 廻 勇輔, 淺田 騰, 西森 久和, 藤井 伸治, 藤井 敬子, 佐藤 康晴, 松岡 賢市, 吉野 正, 前田 嘉信

    日本リンパ網内系学会会誌   59   141 - 141   2019.5

     More details

    Language:Japanese   Publisher:(一社)日本リンパ網内系学会  

    researchmap

  • EBV陽性びまん性大細胞型B細胞リンパ腫に対する化学療法施行後に血管免疫芽球性T細胞リンパ腫を発症した1例

    渡邊 真衣, 水原 健太郎, 遠西 大輔, 阿部 将也, 住居 優一, 浦田 知宏, 藤原 悠紀, 佐伯 恭昌, 廻 勇輔, 淺田 騰, 西森 久和, 松岡 賢市, 藤井 伸治, 吉野 正, 前田 嘉信

    日本リンパ網内系学会会誌   59   153 - 153   2019.5

     More details

    Language:Japanese   Publisher:(一社)日本リンパ網内系学会  

    researchmap

  • Salvage Haploidentical Transplantation Using Low-dose ATG for Early Disease Relapse after First Allogeneic Transplantation: A Retrospective Single-center Review. Reviewed

    Sachiyo Okamoto, Ken-Ichi Matsuoka, Maiko Sakamoto, Yoshiaki Usui, Yuki Fujiwara, Takumi Kondo, Katsuma Tani, Kyosuke Saeki, Yusuke Meguri, Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Keiko Fujii, Nobuharu Fujii, Yoshinobu Maeda

    Acta medica Okayama   73 ( 2 )   161 - 171   2019.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Second allogeneic stem cell transplantation (allo-SCT) is a potentially curative therapy for patients who relapse after first allo-SCT. Human leukocyte antigen (HLA)-haploidentical related donors provide the broad opportunity to conduct second SCT at the appropriate time, but the efficacy of second SCT from haploidentical donors after relapse has not been established. We retrospectively analyzed the records of 33 patients who underwent second SCT. Twenty patients underwent haplo-SCT with low-dose antithymocyte globulin (ATG), and the other 13 patients underwent conventional- SCTs, including HLA-matched related peripheral blood, unrelated bone marrow or cord blood. Three years after the second SCT, the overall survival (OS) and progression-free survival (PFS) of all patients were 32.5% and 23.9%. Multivariate analyses indicated that non-complete response at second SCT, less than 1-year interval to relapse after first- SCT, and total score ≥ 3 on the hematopoietic cell transplantation-specific comorbidity index were significantly associated with a lower PFS rate. The haplo- and conventional- SCT groups showed equivalent results regarding OS, PFS, cumulative incidences of relapse, non-relapse mortality and graft-versus-host disease. The neutropenic period after transplantation was significantly shorter in haplo- SCT than conventional- SCT (10.5 days vs. 16 days, p=0.001). Our analysis revealed that haplo-SCT could be an alternative therapeutic option for relapsed patients after first SCT.

    DOI: 10.18926/AMO/56652

    PubMed

    researchmap

  • 自家と同種におけるCD34陽性細胞回収率の違いからみた処理量決定 末梢血幹細胞採取を効率よく終わらせるために

    藤井 敬子, 藤井 伸治, 清家 圭介, 三道 康永, 中村 真, 閘 結稀, 池田 亮, 浅野 尚美, 小郷 博昭, 高木 尚江, 大塚 文男

    日本輸血細胞治療学会誌   65 ( 2 )   349 - 349   2019.4

     More details

    Language:Japanese   Publisher:(一社)日本輸血・細胞治療学会  

    researchmap

  • Long-term outcomes in patients treated in the intensive care unit after hematopoietic stem cell transplantation. Reviewed

    Makoto Nakamura, Nobuharu Fujii, Kazuyoshi Shimizu, Shuntaro Ikegawa, Keisuke Seike, Tomoko Inomata, Yasuhisa Sando, Keiko Fujii, Hisakazu Nishimori, Ken-Ichi Matsuoka, Hiroshi Morimatsu, Yoshinobu Maeda

    International journal of hematology   108 ( 6 )   622 - 629   2018.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    The number of patients who are successfully discharged from the intensive care unit (ICU) after hematopoietic stem cell transplantation (HSCT) remains limited. Most previous studies have evaluated short-term outcomes using ICU mortality; there have been comparatively fewer reports of long-term outcomes. We retrospectively analyzed 39 HSCT patients admitted to the ICU for the first time between April 2008 and July 2014. Performance status was evaluated in four long-term survivors in July 2016. Median age at ICU admission was 54 years (range 30-68). In total, 33 patients (70.2%) required mechanical ventilation and 31 patients (66%) required dialysis. The median OS from first ICU admission was 41 days (95% confidence interval [CI]: 22-64) and the 1-year survival rate was 12.8% (95% CI 4.7-25.2). No statistically significant factors were associated with short-term outcomes. Among long-term outcomes, a second or subsequent HSCT and neutropenia at ICU admission were significant risk factors. Four of 10 ICU survivors have survived with good performance status for a median of 1994 (1203-2633) days. Our results suggest that the number of prior transplants and neutropenia at ICU admission may influence OS.

    DOI: 10.1007/s12185-018-2536-x

    PubMed

    researchmap

  • Neurolymphomatosis in the cauda Equina Diagnosed by an Open Biopsy. Reviewed

    Sasaki R, Ohta Y, Yamada Y, Tadokoro K, Takahashi Y, Sato K, Shang J, Takemoto M, Hishikawa N, Yamashita T, Yasuhara T, Date I, Ikegawa S, Fujii N, Abe K.

    Intern Med   57 ( 23 )   3463 - 3465   2018.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    researchmap

  • 抗Fybに加え新たに抗KANNOを産生した1症例

    池田 亮, 小郷 博昭, 浅野 尚美, 閘 結稀, 清家 圭介, 三道 康永, 中村 真, 高木 尚江, 藤井 敬子, 藤井 伸治, 大塚 文男

    日本輸血細胞治療学会誌   64 ( 6 )   829 - 830   2018.12

     More details

    Language:Japanese   Publisher:(一社)日本輸血・細胞治療学会  

    researchmap

  • アルブミン製剤の輸血部管理による使用目的の把握について

    小郷 博昭, 浅野 尚美, 池田 亮, 閘 結稀, 清家 圭介, 三道 康永, 中村 真, 高木 尚江, 藤井 敬子, 藤井 伸治, 大塚 文男

    日本輸血細胞治療学会誌   64 ( 6 )   834 - 835   2018.12

     More details

    Language:Japanese   Publisher:(一社)日本輸血・細胞治療学会  

    researchmap

  • Villous atrophy in the terminal ileum is a specific endoscopic finding correlated with histological evidence and poor prognosis in acute graft-versus-host disease after allo-hematopoietic stem cell transplantation. Reviewed International journal

    Yuusaku Sugihara, Sakiko Hiraoka, Nobuharu Fujii, Shiho Takashima, Yasushi Yamasaki, Toshihiro Inokuchi, Masahiro Takahara, Kenji Kuwaki, Keita Harada, Takehiro Tanaka, Hiroyuki Okada

    BMC gastroenterology   18 ( 1 )   111 - 111   2018.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Graft-versus-host disease (GVHD) is a common complication of allo-hematopoietic stem cell transplantation (allo-HSCT). Endoscopic biopsy can provide a definitive diagnosis, but the optimal endoscopic approach for diagnosis remains uncertain. This study evaluated whether ileocolonoscopic imaging can predict acute GVHD severity after allo-HSCT. METHODS: Consecutive patients who underwent allo-HSCT were referred to our institution, and those diagnosed with acute GVHD by pathology were included in this retrospective study. RESULTS: Fifty-one of 261 patients who underwent ileocolonoscopy were suspected to have acute intestinal GVHD. We performed univariate and multivariate conditional logistic regression with stepwise variable selection; villous atrophy in the terminal ileum remained a statistically significant predictor of GVHD severity (odds ratio, 4.69; 95% confidence interval, 1.07-20.60, P = 0.04). Patients were classified into three groups based on ileal endoscopic findings in the terminal ileum: group S, GVHD with severe villous atrophy; group M, mild atrophy; and group N, no atrophy. Compared with patients in groups M and N, those in group S had significant clinical GVHD at diagnosis (P = 0.03). In group S, three of four, compared with five of 13 patients in groups M and N, required the addition of second-line agents (P = 0.02). CONCLUSIONS: This study showed that severe atrophy of the terminal ileum predicts severe clinical GVHD that is likely to be refractory to steroid treatment. Thus, the severity of terminal ileum atrophy may serve as a tool in predicting clinically severe GVHD. TRIAL REGISTRATION: Trial Registration Number UMIN 000022805 , Registration date July 1, 2016.

    DOI: 10.1186/s12876-018-0829-4

    PubMed

    researchmap

  • Adverse Events Associated With Infusion of Hematopoietic Stem Cell Products: A Prospective and Multicenter Surveillance Study. Reviewed International journal

    Kazuhiko Ikeda, Hitoshi Ohto, Yoshiki Okuyama, Minami Yamada-Fujiwara, Heiwa Kanamori, Shin-Ichiro Fujiwara, Kazuo Muroi, Takehiko Mori, Kinuyo Kasama, Tohru Iseki, Tokiko Nagamura-Inoue, Nobuharu Fujii, Takashi Ashida, Kazuaki Kameda, Junya Kanda, Asao Hirose, Tsutomu Takahashi, Kazuhiro Nagai, Keiji Minakawa, Ryuji Tanosaki

    Transfusion medicine reviews   2018.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Adverse events (AEs) associated with blood transfusions, including component-specific red cell, platelet, and plasma products, have been extensively surveyed. In contrast, surveillance of AEs associated with hematopoietic stem cell (HSC) products in HSC transplantation (HSCT) has been less rigorous, even though HSC products include a diversity of immature and mature hematopoietic cells, substantial plasma, and dimethyl sulfoxide (DMSO) in the case of cryopreserved HSC products. HSC infusion-related AEs have been attributed to DMSO toxicity, but AEs associated with the infusion of noncryopreserved HSC products are not uncommon. To quantify the frequencies, types, and risk factors of HSC infusion-related AEs, we implemented national surveillance for AEs observed within 24 hours after infusion. Herein we report on 1125 HSCTs, including 570 peripheral blood stem cell transplantations (PBSCTs) (290 autologous [auto-] and 280 allogeneic [allo-]), 332 allo-bone marrow transplantations (allo-BMTs) and 223 allo-cord blood transplantations (allo-CBTs). Unexpectedly, incidences of grade ≥ 2 AEs were most frequent in allo-BMTs (37.7%) with no DMSO in any product compared with auto-/allo-PBSCTs (20.9%, P < .001) and allo-CBTs (19.3%, P < .001) typically cryopreserved with DMSO. Hypertension was most often noted in BMTs, whereas nausea/vomiting, fever, and allergic reactions were most frequent in allo-PBSCTs. In a multivariate analysis, a history of transfusion reactions was a risk factor for overall AEs in all HSCTs (odds ratio [OR] = 1.459, P = .045). For grade ≥ 2 AEs in allo-HSCTs, a history of transfusion reactions (OR = 1.551, P = .044) for overall AEs, and high infusion volume (OR = 7.544, P = .005) and allo-PBSCTs (versus BMTs, OR = 9.948, P = .002) for allergic reactions were identified as risk factors. These findings suggest that some factors unrelated to DMSO, such as allo-antigens, contribute to HSC infusion-related AEs. As severe AEs, a total of 117 grade ≥ 3 AEs were reported in 1125 HSCTs, including life-threatening complications in 3 (0.3%) HSCTs: 1 allo-CBT (anaphylaxis) and 2 allo-PBSCTs (hypoxia, kidney injury) with cryopreserved product. Our data show that HSC infusion risks vary by product, can be severe, and should be monitored with the same rigor as modern transfusion hemovigilance programs.

    DOI: 10.1016/j.tmrv.2018.05.005

    PubMed

    researchmap

  • 自己血輸血の変遷 貯血式・希釈式・回収式症例数と時代背景を顧みて

    藤井 敬子, 高木 尚江, 清家 圭介, 三道 康永, 中村 真, 閘 結稀, 池田 亮, 浅野 尚美, 小郷 博昭, 藤井 伸治, 大塚 文男

    日本輸血細胞治療学会誌   64 ( 2 )   442 - 442   2018.4

     More details

    Language:Japanese   Publisher:(一社)日本輸血・細胞治療学会  

    researchmap

  • 同種造血幹細胞移植後の好中球減少患者に対する顆粒球輸注療法

    藤井 伸治, 池川 俊太郎, 藤井 敬子, 佐伯 恭昌, 廻 勇輔, 浅田 騰, 西森 久和, 松岡 賢市, 大塚 文男, 前田 嘉信

    日本輸血細胞治療学会誌   64 ( 2 )   453 - 453   2018.4

     More details

    Language:Japanese   Publisher:(一社)日本輸血・細胞治療学会  

    researchmap

  • Progressive multifocal leukoencephalopathy after T-cell replete HLA-haploidentical transplantation with post-transplantation cyclophosphamide graft-versus-host disease prophylaxis. International journal

    Shuntaro Ikegawa, Nobuharu Fujii, Koh Tadokoro, Kota Sato, Miki Iwamoto, Masayuki Matsuda, Tomoko Inomata, Hiroyuki Sugiura, Takeru Asano, Shohei Yoshida, Hisakazu Nishimori, Ken-Ichi Matsuoka, Yoshinobu Maeda

    Transplant infectious disease : an official journal of the Transplantation Society   20 ( 2 )   e12850   2018.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    A 52-year-old man suffered from progressive multifocal leukoencephalopathy (PML) after human leukocyte antigen (HLA)-haploidentical transplantation with post-transplantation cyclophosphamide (PTCY). Mirtazapine, mefloquine, and cytarabine failed to improve his symptoms, and he finally died 4.5 months after PML onset. This is the first case report of a patient with PML after HLA-haploidentical transplantation with PTCY. Although T-cell replete HLA-haploidentical transplantation with PTCY has enabled early immune reconstitution, PML should be considered if a patient's mental condition deteriorates.

    DOI: 10.1111/tid.12850

    PubMed

    researchmap

  • Progressive multifocal leukoencephalopathy after T-cell replete HLA-haploidentical transplantation with post-transplantation cyclophosphamide graft-versus-host disease prophylaxis. Reviewed

    Ikegawa S, Fujii N, Tadokoro K, Sato K, Iwamoto M, Matsuda M, Inomata T, Sugiura H, Asano T, Yoshida S, Nishimori H, Matsuoka KI, Maeda Y.

    Transpl Infect Dis   20 ( 2 )   e12850 - e12850   2018.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    researchmap

  • Mild renal dysfunction defined by creatinine clearance rate has limited impact on clinical outcomes after allogeneic hematopoietic stem cell transplantation. Reviewed

    Ikegawa S, Matsuoka KI, Inomata T, Ikeda N, Sugiura H, Kuroi T, Asano T, Yoshida S, Nishimori H, Fujii N, Kondo E, Maeda Y, Tanimoto M.

    International Journal of Hematology   107 ( 5 )   568 - 577   2018.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    researchmap

  • Neurolymphomatosis in the Cauda Equina Diagnosed by an Open Biopsy

    Ryo Sasaki, Yasuyuki Ohta, Yuto Yamada, Koh Tadokoro, Yoshiaki Takahashi, Kota Sato, Jingwei Shang, Mami Takemoto, Nozomi Hishikawa, Toru Yamashita, Takao Yasuhara, Isao Date, Shuntaro Ikegawa, Nobuharu Fujii, Koji Abe

    INTERNAL MEDICINE   57 ( 23 )   3463 - 3465   2018

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:JAPAN SOC INTERNAL MEDICINE  

    Neurolymphomatosis is a rare form of extranodal malignant lymphoma defined as the infiltration of malignant lymphocytes into the central or peripheral nerve. We herein report a case of neurolymphomatosis in the cauda equina diagnosed by an open surgical biopsy. He presented with muscle weakness, atrophy, numbness and hypoesthesia in the bilateral lower extremities with the accumulation of (18)fluoro-2-deoxyglucose (FDG) in the bilateral cauda equina. Cerebrospinal fluid cytology (three times) and flow cytometry (two times) and biopsies of the left rural nerve, bone marrow, paranasal sinus and left testis were all negative for malignancy, so finally we performed a surgical open biopsy of the cauda equina by laminectomy and diagnosed him with diffuse large B-cell lymphoma in the cauda equina. He was successfully treated with the disappearance of the FDG accumulation for a long time. The present case suggested that an early open biopsy of the cauda equina may be considered for cases of suspected neurolymphomatosis in the cauda equina for a good outcome.

    DOI: 10.2169/internalmedicine.1049-18

    Web of Science

    researchmap

  • 健常人ドナーにおけるクエン酸中毒 CMNCモードとMNCモードで違いがあるのか

    藤井 敬子, 清家 圭介, 三道 康永, 中村 真, 高木 尚江, 閘 結稀, 池田 亮, 浅野 尚美, 小郷 博昭, 藤井 伸治, 大塚 文男

    日本輸血細胞治療学会誌   63 ( 6 )   823 - 823   2017.12

     More details

    Language:Japanese   Publisher:(一社)日本輸血・細胞治療学会  

    researchmap

  • A nationwide survey of hypoplastic myelodysplastic syndrome (a multicenter retrospective study) Reviewed

    Kobayashi T, Nannya Y, Ichikawa M, Oritani K, Kanakura Y, Tomita A, Kiyoi H, Kobune M, Kato J, Kawabata H, Shindo M, Torimoto Y, Yonemura Y, Hanaoka N, Nakakuma H, Hasegawa D, Manabe A, Fujishima N, Fujii N, Tanimoto M, Morita Y, Matsuda A, Fujieda A, Katayama N, Ohashi H, Nagai H, Terada Y, Hino M, Sato K, Obara N, Chiba S, Usuki K, Ohta M, Imataki O, Uemura M, Takaku T, Komatsu N, Kitanaka A, Shimoda K, Watanabe K, Tohyama K, Takaori-Kondo A, Harigae H, Arai S, Miyazaki Y, Ozawa K, Kurokawa M

    Am J Hematol.   2017.9

     More details

    Language:Japanese  

    researchmap

  • Successful use of etoposide for pyoderma gangrenosum associated with myelodysplastic syndrome and trisomy 8: cytokine profiles during treatment Reviewed

    Dan Fujiwara, Toshihisa Hamada, Osamu Yamasaki, Yasuhisa Sando, Kyosuke Saeki, Nobuharu Fujii, Yoshio Kawakami, Keiji Iwatsuki

    EUROPEAN JOURNAL OF DERMATOLOGY   27 ( 5 )   525 - 527   2017.9

     More details

    Language:English   Publisher:JOHN LIBBEY EUROTEXT LTD  

    DOI: 10.1684/ejd.2017.3067

    Web of Science

    PubMed

    researchmap

  • Predictors of vasovagal reactions during preoperative autologous blood donation: a single-institution analysis. Reviewed

    Hisakazu Nishimori, Nobuharu Fujii, Keiko Fujii, Tohru Ikeda, Naomi Asano, Hiroaki Ogo, Miwa Yamakawa, Naoe Takagi, Fumio Otsuka, Kazuma Ikeda

    International journal of hematology   105 ( 6 )   812 - 818   2017.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Studies examining risk factors associated with vasovagal reactions (VVRs) during autologous blood donations, especially in younger subjects, have been limited. The aim of the present study was to define risk factors for VVRs during preoperative autologous blood donation in patients, including those younger than 18 years old. We retrospectively analyzed 4192 autologous, preoperative blood donations between 2007 and 2015 at Okayama University Hospital. Eighty-seven (2.08%) of the patients experienced VVRs. VVRs occurred approximately three times as often in patients 0-17 years old (16/320, 5.0%) than in patients 18 years and older (71/3872, 1.8%). In particular, VVRs occurred more frequently in those 10-13 years old, and decreased with older age (P = 0.006). In a univariate analysis, younger age, lower body mass index, lower systolic blood pressure, lower body weight, lower total blood volume, female gender, first-time collection, and higher heart rate were associated with a higher incidence of VVRs. In a multivariate analysis, lower systolic blood pressure (P < 0.001), higher heart rate (P = 0.007), and first-time collection (P = 0.015), remained independent predictors of VVRs. These results emphasize the need for careful attention during blood collection.

    DOI: 10.1007/s12185-017-2204-6

    PubMed

    researchmap

  • 赤血球プライム下の骨髄濃縮 小児科、低体重児における骨髄処理

    藤井 敬子, 中村 真, 谷 勝真, 佐伯 恭昌, 高木 尚江, 閘 結稀, 池田 亮, 浅野 尚美, 小郷 博昭, 今田 昌秀, 藤井 伸治, 大塚 文男

    日本輸血細胞治療学会誌   63 ( 3 )   424 - 424   2017.6

     More details

    Language:Japanese   Publisher:(一社)日本輸血・細胞治療学会  

    researchmap

  • Graft-versus-leukemia effect with a WT1-specific T-cell response induced by azacitidine and donor lymphocyte infusions after allogeneic hematopoietic stem cell transplantation. Reviewed International journal

    Tatsunori Ishikawa, Nobuharu Fujii, Masahide Imada, Michinori Aoe, Yusuke Meguri, Tomoko Inomata, Hiromi Nakashima, Keiko Fujii, Shohei Yoshida, Hisakazu Nishimori, Ken-Ichi Matsuoka, Eisei Kondo, Yoshinobu Maeda, Mitsune Tanimoto

    Cytotherapy   19 ( 4 )   514 - 520   2017.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Azacitidine (Aza) and donor lymphocyte infusion (DLI) therapy has recently been reported as an effective salvage therapy for relapsed acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Despite the high response rate and relatively long period of remission, most patients relapse again. The immunologic mechanism of the response and limited efficacy remain unknown. CASE REPORT: Aza + DLI therapy was performed for a patient with therapy-related MDS (t-MDS), who had relapsed after allogeneic peripheral blood stem cell transplantation. We observed a powerful graft-versus-leukemia (GVL) effect accompanied by an evident Wilms tumor antigen 1 (WT1)-specific CD8 T-cell response. Remission continued for 15 months, but finally the patient relapsed. The kinetics of the WT1-specific CD8 T cells were inversely associated with WT1 messenger RNA (mRNA), suggesting a WT1-driven GVL effect. DISCUSSION: A difference of T-cell phenotype between the whole T cells and the WT1-specific CD8 T cells was observed. It is of note that the memory phenotype of the WT1-specific T cell was limited and decreased early. The immunoescape mechanism was partly supported by loss of the memory phenotype due to failure of expansion and differentiation. CONCLUSION: Our data suggested that a WT1-specific T-cell response at least partly contributes to the GVL effect induced by Aza + DLI. A strategy for maximizing and maintaining the memory phenotype of the CTL may be required for durable remission.

    DOI: 10.1016/j.jcyt.2016.12.007

    PubMed

    researchmap

  • Phase II study of intrabone single unit cord blood transplantation for hematological malignancies Reviewed

    Makoto Murata,Yoshinobu Maeda*,Masayoshi Masuko,Yasushi Onishi,Tomoyuki Endo,Seitaro Terakura,Yuichi Ishikawa,Chisako Iriyama,Yoko Ushijima,Tatsunori Goto,Nobuharu Fujii*,Mitsune Tanimoto,Hironori Kobayashi,Yasuhiko Shibasaki,Noriko Fukuhara,Yoshihiro Inamoto,Ritsuro Suzuki,Yoshihisa Kodera,Tadashi Matsushita,Hitoshi Kiyoi,Tomoki Naoe,Tetsuya Nishida

    Cancer Science, Japanese Journal of Cancer Research, Gann, The Japanese Journal of Cancer Research   202 - 16   2017.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/cas.13291

    researchmap

  • Ruxolitinib treatment for GvHD in patients with myelofibrosis Reviewed

    Y. Mori ,K. Ikeda,T. Inomata ,G. Yoshimoto,N. Fujii*,H. Ago,T. Teshima

    Bone Marrow Transplantation   51 ( 12 )   1584 - 1587   2016.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1038/bmt.2016.256

    researchmap

  • Spectra Optiaを用いた骨髄濃縮 小児科、低体重児における骨髄処理

    藤井 敬子, 中村 真, 谷 勝真, 佐伯 恭昌, 閘 結稀, 池田 亮, 浅野 尚美, 小郷 博昭, 今田 昌秀, 高木 尚江, 藤井 伸治, 大塚 文男

    日本輸血細胞治療学会誌   62 ( 6 )   754 - 754   2016.12

     More details

    Language:Japanese   Publisher:(一社)日本輸血・細胞治療学会  

    researchmap

  • シミュレーションを用いた輸血当直業務トレーニング

    浅野 尚美, 小郷 博昭, 池田 亮, 閘 結稀, 高木 尚江, 中村 真, 谷 勝真, 佐伯 恭昌, 藤井 敬子, 藤井 伸治, 大塚 文男

    日本輸血細胞治療学会誌   62 ( 6 )   756 - 757   2016.12

     More details

    Language:Japanese   Publisher:(一社)日本輸血・細胞治療学会  

    researchmap

  • Treatment of thrombotic microangiopathy after hematopoietic stem cell transplantation with recombinant human soluble thrombomodulin. Reviewed International journal

    Hideaki Fujiwara, Yoshinobu Maeda, Yasuhisa Sando, Makoto Nakamura, Katsuma Tani, Tatsunori Ishikawa, Hisakazu Nishimori, Ken-Ichi Matsuoka, Nobuharu Fujii, Eisei Kondo, Mitsune Tanimoto

    Transfusion   56 ( 4 )   886 - 92   2016.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Transplant-associated thrombotic microangiopathy (TA-TMA) after hematopoietic stem cell transplantation (HSCT) remains a severe complication associated with underlying endothelial damage. TMA has a high mortality rate with no definite treatments and effective treatments are needed. STUDY DESIGN AND METHODS: The study objective was to retrospectively analyze the outcome of patients receiving recombinant human soluble thrombomodulin (rTM), which has cytoprotective effects against calcineurin inhibitor-induced endothelial cell damage, or other therapeutics for TA-TMA from 254 consecutive HSCT recipients between 2009 to 2014 at a single institution. We hypothesized that patients receiving rTM as a first-line treatment would receive a benefit. RESULTS: Sixteen patients were diagnosed as TA-TMA. Of these 16 patients, nine were treated with rTM (rTM group), and seven received treatment other than rTM (control group) as a first-line therapy. Seven of the nine patients in the rTM group recovered from TA-TMA without complications, but none in the control group recovered. The rTM group showed a significantly better overall survival after TA-TMA onset than did the control group (median, 123.0 days vs. 45.5 days, respectively; p = 0.045). The cumulative incidence of acute graft-versus-host disease was the same in both groups (56% vs. 57%, respectively; p = 0.52) on Day 100 after TA-TMA onset. CONCLUSION: This is the first report evaluating rTM administration for TA-TMA compared with previous treatments. Our data suggests that rTM might offer a better clinical outcome in patients with TA-TMA.

    DOI: 10.1111/trf.13437

    PubMed

    researchmap

  • Vigorous inflammatory responses in noninfectious pulmonary complication induced by donor lymphocyte infusion. Reviewed International journal

    Miyuki Nishie, Nobuharu Fujii, Yusuke Mimura, Takeru Asano, Yuka Mimura-Kimura, Keisuke Aoe, Michinori Aoe, Hiromi Nakashima, Hideaki Fujiwara, Hisakazu Nishimori, Ken-Ichi Matsuoka, Eisei Kondo, Yoshinobu Maeda, Mitsune Tanimoto

    Transfusion   56 ( 1 )   231 - 236   2016.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Donor lymphocyte infusion (DLI) is used for treatment of hematologic malignancy relapse or mixed chimerism after allogeneic hematopoietic stem cell transplantation. Although graft-versus-host disease is well recognized as one of the adverse effects of DLI, there are limited reports on noninfectious pulmonary complications (NIPCs) after DLI. CASE REPORT: A 55-year-old woman with acute myeloid leukemia received DLI for conversion from recipient predominant to complete donor chimerism on Day +193 after allogeneic HSCT. Eight weeks later, she complained of dyspnea with fever; chest computed tomography revealed diffuse, bilateral, ground glass opacity and reticular appearance. She was diagnosed as having NIPC based on serum and bronchoalveolar lavage fluid (BALF) findings. She was successfully treated with prednisolone (PSL) and completely recovered. DISCUSSION: We analyzed the cell profile from the BALF and 27 cytokines and chemokines in the serum using the Bio-Plex platform. The cells consisted of recipient predominant macrophages and T cells. The serum cytokine and chemokine profile showed significant elevation of interleukin (IL)-1β, IL-6, IL-8, tumor necrosis factor-α, macrophage inflammatory protein (MIP)-1α, and MIP-1β, which declined with the improvement of symptoms after initiation of PSL treatment. CONCLUSION: Inflammatory effectors by recipient cells, rather than allogeneic responses by donor cells, played an important role in the pathogenesis of NIPCs after DLI in the present case.

    DOI: 10.1111/trf.13283

    PubMed

    researchmap

  • 輸血当直における各業務過程の所要時間Turn-around Time(TAT)についての検討

    小郷 博昭, 浅野 尚美, 池田 亮, 閘 結稀, 石川 立則, 吉岡 尚徳, 小林 優人, 高木 尚江, 藤井 敬子, 藤井 伸治, 大塚 文男

    日本輸血細胞治療学会誌   61 ( 6 )   590 - 590   2015.12

     More details

    Language:Japanese   Publisher:(一社)日本輸血・細胞治療学会  

    researchmap

  • 末梢血幹細胞採取時の健常人ドナーにおけるクエン酸中毒発現、電解質異常についての解析

    藤井 敬子, 石川 立則, 吉岡 尚徳, 廻 勇輔, 藤原 英晃, 小林 優人, 高木 尚江, 閘 結稀, 池田 亮, 浅野 尚美, 小郷 博昭, 藤井 伸治, 大塚 文男

    日本輸血細胞治療学会誌   61 ( 6 )   593 - 593   2015.12

     More details

    Language:Japanese   Publisher:(一社)日本輸血・細胞治療学会  

    researchmap

  • Magnifying Endoscopic Observation of Duodenal Involvement of Follicular Lymphoma before and after Chemotherapy Reviewed

    Iwamuro Masaya, Okada Hiroyuki, Takata Katsuyoshi, Fujii Nobuharu, Kawano Seiji, Kawahara Yoshiro, Yoshino Tadashi, Yamamoto Kazuhide

    Japanese Journal of Medicine   54 ( 14 )   1741 - 1745   2015.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:The Japanese Society of Internal Medicine  

    A 60-year-old Japanese man was diagnosed with systemic follicular lymphoma with duodenal, jejunal, and ileal involvement. The duodenal lesion showed typical endoscopic features with multiple whitish granules. Chemotherapy with bendamustine and rituximab was administered, and complete remission was confirmed by CT scanning and positron emission tomography scanning. Although the duodenal granular lesions did not completely disappear, magnifying observation for the remaining lesions showed no evidence of residual lymphoma. Complete remission was pathologically confirmed by biopsy examinations. This case suggests the usefulness of magnifying observation in evaluating the effects of treatment for duodenal follicular lymphoma lesions.<br>

    DOI: 10.2169/internalmedicine.54.4390

    CiNii Article

    researchmap

    Other Link: http://search.jamas.or.jp/link/ui/2016310064

  • ADVIA2120を用いたRDWおよびHDWによる大球性貧血疾患の鑑別

    今田 昌秀, 日野 佳弥, 青江 伯規, 高橋 孝英, 狩山 由貴, 榊原 佳奈枝, 渡部 俊幸, 藤井 伸治, 谷本 光音

    日本検査血液学会雑誌   16 ( 学術集会 )   S165 - S165   2015.6

     More details

    Language:Japanese   Publisher:(一社)日本検査血液学会  

    researchmap

  • Anti-IL-12/23 p40 antibody attenuates experimental chronic graft-versus-host disease via suppression of IFN-γ/IL-17-producing cells. Reviewed International journal

    Sachiyo Okamoto, Hideaki Fujiwara, Hisakazu Nishimori, Ken-ichi Matsuoka, Nobuharu Fujii, Eisei Kondo, Takehiro Tanaka, Akihiko Yoshimura, Mitsune Tanimoto, Yoshinobu Maeda

    Journal of immunology (Baltimore, Md. : 1950)   194 ( 3 )   1357 - 1363   2015.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Chronic graft-versus-host disease (GVHD) is a major cause of late death and morbidity after allogeneic hematopoietic cell transplantation. Recently, in addition to Th2 cells, Th1 and Th17 cells have been shown to contribute to chronic GVHD progression. IL-12 induces Th1 cells and IL-23 plays a role in stabilizing and/or amplifying Th17 cells, as well as in inducing IFN-γ/IL-17 double-producing cells. Because mAb targeting the p40 subunit common to both IL-12 and IL-23 can inhibit both IL-12R and IL-23R-mediated signaling, we investigated the effects of anti-p40 mAb on a well-defined chronic GVHD mice model. Treatment of anti-p40 mAb in allogeneic recipients significantly reduced the severity of clinical and pathological chronic GVHD. Intracellular staining revealed that IFN-γ single-positive (IL-17(-)) and IFN-γ/IL-17 double-positive cells were suppressed in anti-p40 mAb-treated allogeneic recipients compared with control recipients. The cytokine levels of IFN-γ and IL-17 were also decreased in serum from anti-p40 mAb-treated allogeneic recipients. T-bet expression of donor IL-17(+) CD4(+) T cells was reduced significantly in anti-p40 mAb-treated recipients, and this reduction in T-bet expression was associated with IL-22 production by donor T cells. These results suggested that anti-p40 mAb attenuated chronic GVHD via suppression of IFN-γ/IL-17-producing cells, and that targeting the IL-12/IL-23 pathway may represent a promising therapeutic strategy for preventing and treating chronic GVHD.

    DOI: 10.4049/jimmunol.1400973

    PubMed

    researchmap

  • 多発転移に伴い血小板減少を合併した頭部血管肉腫の1例 Reviewed

    (瀧口 徹也, 山崎 修, 牧野 麻貴,) 佐伯 恭昌, 藤井 伸治, (濱田 和俊, 岩月 啓氏)

    Skin Cancer   29 ( 3 )   323 - 327   2015.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:(一社)日本皮膚悪性腫瘍学会  

    35歳、男性。2012年3月より前頭部に紅斑が出現し、その後結節病変が徐々に隆起し周囲に紫斑が拡大した。近医での生検にて血管肉腫と診断され、5月に当院紹介受診。前頭部に暗紫色の嚢腫状結節を認め、周囲に出血斑を伴っていた。6月より電子線照射とweeklyパクリタキセル療法4コース、monthlyパクリタキセル療法3コース施行。2013年1月に血小板14000/μLと急激な減少のため、入院した。抗血小板抗体陰性、PA-IgG陽性、ヘリコバクター・ピロリIgG陽性。DICの所見は認めなかった。骨髄生検では巨核球十分、腫瘍の浸潤も認めなかった。ITPが疑われ、血小板輸血を施行し、免疫グロブリン大量療法とプレドニゾロン(PSL)を開始した。入院後のCT、MRIで両側耳下腺、胸椎、右寛骨、肺転移を認め、緩和目的に骨転移に対してX線治療した。その後、血小板は上昇したためPSLを漸減し、3月よりweeklyドセタキセル療法を開始した。しかし転移は徐々に進行し、血小板は再度減少した。10月肺転移による呼吸不全のため永眠された。臨床経過からは血小板減少は転移の進行による腫瘍内での血小板消費と考えた。(著者抄録)

    researchmap

    Other Link: https://search-tp.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2015&ichushi_jid=J02197&link_issn=&doc_id=20150316140017&doc_link_id=10.5227%2Fskincancer.29.323&url=https%3A%2F%2Fdoi.org%2F10.5227%2Fskincancer.29.323&type=J-STAGE&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00007_2.gif

  • Primary Duodenal Follicular Lymphoma Treated With Rituximab Monotherapy and Followed-up for 15 Years Reviewed

    Seki A, Iwamuro M, Yoshioka M, Fujii N, Okada H, Nose S, Takata K, Yoshino T, Yamamoto K

    Acta Med Okayama   69 ( 5 )   2015.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    researchmap

  • With regard to our manuscripts on the commercial saliva substitute, Oralbalance®--its formula has been changed. Reviewed International journal

    Yuko Sugiura, Yoshihiko Soga, Ichiro Tanimoto, Susumu Kokeguchi, Sachiko Morishige-Nishide, Kotoe Itami-Kono, Kanayo Takahashi, Nobuharu Fujii, Fumihiko Ishimaru, Mitsune Tanimoto, Kokoro Yamabe, Soichiro Tsutani, Fusanori Nishimura, Shogo Takashiba

    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer   22 ( 12 )   3121 - 3122   2014.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s00520-014-2432-8

    PubMed

    researchmap

  • PD-1 pathway in host tissues ameliorates Th17/Th1 mediated experimental chronic graft-versus-host disease Reviewed

    Fujiwara H, Maeda Y, Kobayashi K, Nishimori H, Matsuoka K, Fujii N, Kondo E, (Tanaka T, Chen L, Azuma M, Yagita H), Tanimoto M.

    J Immunol   193 ( 5 )   2565 - 2573   2014.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    researchmap

  • 非血縁者間同種骨髄移植後にドナー由来の抗Jraが検出された慢性骨髄性白血病の1例 Reviewed

    池田亮、小郷博昭、浅野尚美、浅田騰、藤井敬子、藤井伸治

    Japanese Journal of Transfusion and Cell Therapy   60 ( 3 )   483 - 487   2014.7

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    researchmap

  • Low-grade B-cell lymphoma presenting primarily in the bone marrow Reviewed

    Iwatani Kayoko, Takata Katsuyoshi, Sato Yasuharu, Miyata-Takata Tomoko, Iwaki Noriko, Cui Wei, Sawada-Kitamura Seiko, Sonobe Hiroshi, Tamura Maiko, Saito Katsuhiko, Miyatani Katsuya, Yamasaki Rie, Yamadori Ichiro, Fujii Nobuharu, Terasaki Yasushi, Maeda Yoshinobu, Tanimoto Mitsune, Nakamura Naoya, Yoshino Tadashi

    Human Pathology   45 ( 7 )   1379 - 1387   2014.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.humpath.2014.02.010

    CiNii Article

    researchmap

  • Primary cutaneous γδT-cell lymphomaに対し、臍帯血移植を施行した1例 Reviewed

    佐伯 恭昌, 石川 立則, 谷 勝真, 山本 宜和, 塩手 康弘, 松岡 賢市, 藤井 伸治, 近藤 英生, 前田 嘉信, 品川 克至, 谷本 光音

    臨床血液   55 ( 5 )   587 - 587   2014.5

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    researchmap

  • 慢性C型肝炎ウイルス感染症の血清AFP値を除鉄療法は改善する Reviewed

    (木村 文昭, 三島 康男, 重戸 伸幸, 福田 智子, 山原 茂裕, 佐原 亜衣, 松村 正,) 藤井 伸治, 谷本 光音

    日本老年医学会雑誌   51 ( 3 )   293 - 293   2014.5

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    researchmap

  • Bronchiolitis obliterans with allogeneic hematopoietic cell transplantation: a 10-year experience of the Okayama BMT Group. Reviewed

    Nobuharu Fujii, Koichi Nakase, Shoji Asakura, Keitaro Matsuo, Yuichiro Nawa, Kazutaka Sunami, Hisakazu Nishimori, Ken-Ichi Matsuoka, Eisei Kondo, Yoshinobu Maeda, Katsuji Shinagawa, Masamichi Hara, Mitsune Tanimoto

    International journal of hematology   99 ( 5 )   644 - 651   2014.5

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

    Bronchiolitis obliterans (BO) is a devastating complication of allogeneic hematopoietic stem cell transplantation (HSCT). We retrospectively studied 465 patients who underwent HSCT in the Okayama BMT Group between 2000 and 2009, and describe the detailed clinical features of 13 patients with BO. The 5-year cumulative incidence of BO was 3.43 %. The median time from transplantation to onset of BO was 15 months. In seven of the 13 patients, the primary symptom was only cough, indicating that cough was an important initial symptom for early diagnosis. The median duration from the onset of BO to the requirement of O2 supplementation was 13 months and the main cause of death was respiratory failure. History of chronic graft-versus-host disease was a significant risk factor. Furthermore, female recipients were at greater risk of BO than male recipients; however, no other previously reported risk factors were detected. It is currently difficult to prevent BO on the basis of the reported risk factors. A novel strategy for the early diagnosis and treatment of BO is required.

    DOI: 10.1007/s12185-014-1556-4

    PubMed

    researchmap

  • Mammalian Target of Rapamycin Inhibitors Permit Regulatory T Cell Reconstitution and Inhibit Experimental Chronic Graft-versus-Host Disease Reviewed

    Sugiyama Haruko, Maeda Yoshinobu, Nishimori Hisakazu, Yamasuji Yoshiko, Matsuoka Ken-ichi, Fujii Nobuharu, Kondo Eisei, Shinagawa Katsuji, Tanaka Takehiro, Takeuchi Kengo, Teshima Takanori, Tanimoto Mitsune

    Biology of Blood and Marrow Transplantation   20 ( 2 )   183 - 191   2014.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.bbmt.2013.11.018

    CiNii Article

    researchmap

  • 新しい全自動型血液成分分離装置Spectra Optiaを用いた末梢血幹細胞採取-COBE Spectraと比較して- Reviewed

    藤井敬子,藤井伸治,淺田騰,西森久和,狩山由貴,池田亮,浅野尚美,小郷博昭,岩月啓氏

    日本輸血細胞治療学会誌   59 ( 6 )   799 - 804   2014.1

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    researchmap

  • Complete resolution of steroid-resistant organizing pneumonia associated with myelodysplastic syndrome following allogeneic hematopoietic cell transplantation. Reviewed International journal

    Takeru Asano, Nobuharu Fujii, Daigo Niiya, Hisakazu Nishimori, Keiko Fujii, Ken-Ichi Matsuoka, Koichi Ichimura, Toshihisa Hamada, Eisei Kondo, Yoshinobu Maeda, Yasushi Tanimoto, Katsuji Shinagawa, Mitsune Tanimoto

    SpringerPlus   3   3 - 3   2014.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Pulmonary complications in patients with hematological malignancies are often caused by infection but are sometimes associated with an underlying disease such as organizing pneumonia (OP). Here, we report a case of life-threatening steroid-resistant OP associated with myelodysplastic syndrome (MDS) and successfully performed allogeneic hematopoietic cell transplantation (HSCT). A 33-year-old female with refractory anemia with excess blasts-1 that had progressed from refractory anemia with ringed sideroblasts and concomitant Sweet's syndrome was admitted. Multiple pulmonary infiltrates were revealed on a chest computed tomography scan, which progressively worsened even after chemotherapy and corticosteroid therapy. No evidence of infection was observed in bronchoalveolar lavage fluid. A histological examination of a transbronchial lung biopsy specimen showed lymphocyte invasion with fibrosis, indicating that the pulmonary infiltrates were OP associated with MDS. Before transplantation, she suffered from respiratory failure and required oxygen supplementation. She developed idiopathic pneumonitis syndrome on day 61 that responded well to corticosteroid therapy, and the OP pulmonary infiltrates improved gradually after HSCT, She was discharged on day 104 and is well without recurrence of OP or MDS 2 years after HSCT.

    DOI: 10.1186/2193-1801-3-3

    PubMed

    researchmap

  • 健常人ドナー末梢血幹細胞採取時における副作用、電解質異常について

    藤井 敬子, 淺田 騰, 藤原 英晃, 山川 美和, 熊本 貴子, 狩山 由貴, 池田 亮, 浅野 尚美, 小郷 博昭, 藤井 伸治, 岩月 啓氏

    日本輸血細胞治療学会誌   59 ( 6 )   865 - 865   2013.12

     More details

    Language:Japanese   Publisher:(一社)日本輸血・細胞治療学会  

    researchmap

  • Pre-transplant risk factors for cryptpgenic organizing pneumonia/brnchiolitis obliterans organizing pneumonia after hematopoietic cell transplantation. Reviewed

    Nakasone H, Onizuka M, Suzuki N, Fujii N, Taniguchi S, Kakihana K, Ogawa H, Miyamura K, Eto T, Sakamaki H, Yabe H, Morishima Y, Kato K, Suzuki R, Fukuda T.

    Bone Marrow Transplantation   1 - 7   2013.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    researchmap

  • Erdheim-Chester病が強く疑われた下垂体機能低下症の一例 Reviewed

    三好智子,大塚文男,稲垣謙一,田中康司,越智可奈子,藤井一恭,藤井伸治,当真貴志雄,中村絵里,塚本尚子,武田昌也,三村由香里,小倉俊郎,景山甚郷,槇野博史

    日本内分泌学会誌   89 ( Suppl. )   21 - 23   2013.6

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    J-GLOBAL

    researchmap

  • 輸血検査の検体間違いに関するインシデントの検討

    浅野 尚美, 池田 亮, 小郷 博昭, 山口 麻由美, 西森 久和, 藤井 敬子, 藤井 伸治, 池田 和眞, 岩月 啓氏

    日本輸血細胞治療学会誌   57 ( 6 )   507 - 507   2011.12

     More details

    Language:Japanese   Publisher:(一社)日本輸血・細胞治療学会  

    researchmap

  • 悪性リンパ腫に対する臍帯血移植23例の検討

    西之原 正昭, 藤原 英晃, 廻 勇輔, 吉岡 尚徳, 新谷 大悟, 近藤 英正, 藤井 伸治, 前田 嘉信, 品川 克至, 谷本 光音

    日本リンパ網内系学会会誌   51   83 - 83   2011.6

     More details

    Language:Japanese   Publisher:(一社)日本リンパ網内系学会  

    researchmap

  • Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens Reviewed

    WARREN EH

    Blood   115   3869 - 3878   2010.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    CiNii Article

    researchmap

  • Total bacterial counts on oral mucosa after using a commercial saliva substitute in patients undergoing hematopoietic cell transplantation. Reviewed

    SIgiura Y, Soga Y, Yamabe K, Tsutani S, Tanimoto I, Maeda H, Kokeguchi S, Fujii N, Ishimaru F, Tanimoto M, Nishimura F, Takashiba S.

    Support Care Cancer   2010.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    researchmap

  • Total bacterial counts on oral mucosa after using a commercial saliva substitute in patients undergoing hematopoietic cell transplantation Reviewed

    Yuko Sugiura, Yoshihiko Soga, Kokoro Yamabe, Soichiro Tsutani, Ichiro Tanimoto, Hiroshi Maeda, Susumu Kokeguchi, Nobuharu Fujii, Fumihiko Ishimaru, Mitsune Tanimoto, Fusanori Nishimura, Shogo Takashiba

    SUPPORTIVE CARE IN CANCER   18 ( 3 )   395 - 398   2010.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:SPRINGER  

    The commercial saliva substitute OralbalanceA (R) has been reported to alleviate symptoms of postradiotherapy xerostomia in head and neck cancer patients. OralbalanceA (R) may also be effective for xerostomia in patients undergoing hematopoietic cell transplantation (HCT) with high-dose chemotherapy and total-body irradiation. However, HCT patients are in a severely compromised condition, and saliva substitute must not promote infection. We reported previously that OralbalanceA (R) has antimicrobial effects against microbial species detected during HCT in vitro. This study was performed to determine the in vivo effects of OralbalanceA (R) on oral mucosal total bacterial counts in patients undergoing HCT.
    A total of 18 neutropenic patients undergoing HCT were enrolled in this study. Before and after 1 week of OralbalanceA (R) use, bacterial samples were obtained from patients by wiping an area of I center dot 1 cm on the buccal mucosa with sterilized cotton swabs. Total bacterial counts of the obtained samples were examined by quantitative polymerase chain reaction amplification of the bacterial 16S ribosomal RNA gene. As controls, bacterial samples were also obtained from ten healthy subjects, and total bacterial counts were examined.
    No significant increase in bacterial count was observed with use of OralbalanceA (R). None of the patients showed bacterial counts above the range found in healthy controls after using OralbalanceA (R).
    In neutropenic patients undergoing HCT, OralbalanceA (R) did not increase the total counts of oral mucosal bacteria beyond the range found in healthy controls. Oral care using OralbalanceA (R) may alleviate the symptoms induced by hyposalivation without promoting infection.

    DOI: 10.1007/s00520-009-0789-x

    Web of Science

    PubMed

    researchmap

  • A distinct subset of self-renewing human memory CD8+T cells survives cytotoxic chemotherapy Reviewed

    TURTLE CJ

    Immunity   31   834 - 834   2009.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    CiNii Article

    researchmap

  • Efficacy and feasibility of IDEA therapy for refractory or relapsed non-Hodgkin's lymphoma. Reviewed International journal

    Hisakazu Nishimori, Nobuharu Fujii, Yoshinobu Maeda, Ken-Ichi Matsuoka, Katsuto Takenaka, Katsuji Shinagawa, Kazuma Ikeda, Keitaro Matsuo, Mine Harada, Mitsune Tanimoto

    Anticancer research   29 ( 5 )   1749 - 54   2009.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: The effects of a novel salvage regimen, IDEA (ifosfamide, cytosine arabinoside, etoposide and dexamethasone), which does not include anthracycline or platinum, in patients with non-Hodgkin's lymphoma (NHL) were examined. PATIENTS AND METHODS: Thirty-four patients with refractory or relapsed NHL were treated with IDEA. RESULTS: The overall remission and complete remission rates were 67.6% and 35.3%, respectively. The toxicity of IDEA was tolerable. With a median follow-up of 14 months, one-year overall survival (OS) and progression-free survival rates were 75.1% and 43.7%, respectively. Adequate numbers of CD34(+) cells were obtained in 77.8% of the patients assigned to receive autologous peripheral blood stem cell (PBSC) transplantation. High-dose chemotherapy with autologous PBSC transplantation was carried out in 14 patients; their 3-year OS was 75.0%, with a median follow-up of 38 months. CONCLUSION: IDEA is an effective second-line chemotherapy regimen for NHL patients and has an excellent PBSC-mobilizing effect.

    PubMed

    researchmap

  • The effect of adding rituximab to CHOP-based therapy on clinical outcomes for Japanese patients with diffuse large B-cell lymphoma : a propensity score matching analysis Reviewed

    NISHIMORI Hisakazu, MATSUO Keitaro, MAEDA Yoshinobu, NAWA Yuichiro, SUNAMI Kazutaka, TOGITANI Kazuto, TAKIMOTO Hidetaka, HIRAMATSU Yasushi, KIGUCHI Toru, YANO Tomofumi, YAMANE Hiromichi, TABAYASHI Takayuki, TAKEUCHI Makoto, MAKITA Masanori, SEZAKI Nobuo, YAMASUJI Yoshiko, SUGIYAMA Haruko, TABUCHI Takahiro, KATAOKA Itaru, FUJII Nobuharu, ISHIMARU Fumihiko, SHINAGAWA Katsuji, IKEDA Kazuma, HARA Masamichi, YOSHINO Tadashi, TANIMOTO Mitsune, the West-Japan Hematology and Oncology Group West-JHOG

    Int J Hematol.   89 ( 3 )   326 - 331   2009.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    CiNii Article

    CiNii Books

    researchmap

  • Use of micafungin versus fluconazole for antifungal prophylaxis in neutropenic patients receiving hematopoietic stem cell transplantation Reviewed

    HIRAMATSU Yasushi, MAEDA Yoshinobu, FUJII Nobuharu, SAITO Takashi, NAWA Yuichiro, HARA Masamichi, YANO Tomofumi, ASAKURA Shoji, SUNAMI Kazutaka, TABAYASHI Takayuki, MIYATA Akira, MATSUOKA Ken-ichi, SHINAGAWA Katsuji, IKEDA Kazuma, MATSUO Keitaro, TANIMOTO Mitsune, for the West-Japan Hematology and Oncology Group West-JHOG

    88 ( 5 )   588 - 595   2008.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    CiNii Article

    CiNii Books

    researchmap

  • Evaluation of xerostomia in hematopoietic cell transplantation by a simple capacitance method device. Reviewed International journal

    Yuko Sugiura, Yoshihiko Soga, Sachiko Nishide, Kotoe Kono, Kanayo Takahashi, Nobuharu Fujii, Fumihiko Ishimaru, Mitsune Tanimoto, Fusanori Nishimura, Shogo Takashiba

    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer   16 ( 10 )   1197 - 200   2008.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    GOALS: Hematopoietic cell transplantation (HCT) may lead to the development of xerostomia. However, there have been few reports of xerostomia in HCT patients based on objective data. We investigated moisture in the oral mucosa in patients undergoing HCT by the capacitance method using a convenient device, Moisture Checker for Mucus (MCM; Life Co., Ltd., Saitama, Japan). SUBJECTS AND METHODS: Thirty-six patients undergoing HCT at Okayama University Hospital of Medicine and Dentistry (Male = 22, Female = 14; age = 41.6 +/- 16.2 years old) were enrolled in this study. Moisture in the oral mucosa was measured by MCM in accordance with the manufacturer's instructions. The results were obtained as MCM values (%), which are the weight percentage of water content in the oral mucosal epithelium. As controls, moisture of the oral mucosa was also examined in healthy volunteers (Male = 27, Female = 35; age = 43.0 +/- 14.6 years old). MAIN RESULTS: Throughout the examination period, MCM values were significantly lower in patients who underwent HCT than in controls. The degree of mucosal moisture in HCT patients showed wide interindividual differences. CONCLUSION: The degree of mucosal moisture in HCT patients was low and showed wide interindividual differences. Evaluation of xerostomia using such a device may contribute to appropriate oral care with saliva substitute.

    DOI: 10.1007/s00520-008-0470-9

    PubMed

    researchmap

  • C19orf48 encodes a minor histocompatibility antigen recognized by CD8+ cytotoxic T cells from renal cell carcinoma patients. Reviewed

    Tykodi SS, Fujii N, Vigneron N, Lu SM, Mito JK, Miranda MX, Chou J, Voong LN, Thompson JA, Sandmaier BM, Cresswell P, Van den Eynde BJ, Riddell SR, Warren EH.

    Clinical Cancer Research   2008.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    researchmap

  • DDX3Y encodes a class I MHC-restricted H-Y antigen that is expressed in leukemic stem cells Reviewed

    Rosinski KV, Fujii N, Mito JK, Koo KK, Xuereb SM, Sala-Torra O, Gibbs JS, Radich JP, Akatsuka Y, Van den Eynde BJ, Riddell SR, Warren EH.

    Blood   2008.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    researchmap

  • Antimicrobial effects of the saliva substitute, Oralbalance, against microorganisms from oral mucosa in the hematopoietic cell transplantation period. Reviewed International journal

    Yuko Sugiura, Yoshihiko Soga, Ichiro Tanimoto, Susumu Kokeguchi, Sachiko Nishide, Kotoe Kono, Kanayo Takahashi, Nobuharu Fujii, Fumihiko Ishimaru, Mitsune Tanimoto, Kokoro Yamabe, Soichiro Tsutani, Fusanori Nishimura, Shogo Takashiba

    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer   16 ( 4 )   421 - 4   2008.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    GOALS: The commercially available saliva substitute Oralbalance has been reported to alleviate symptoms of post-radiotherapy xerostomia in head and neck cancer patients. Oralbalance may also be effective for xerostomia in patients undergoing hematopoietic cell transplantation (HCT) with high-dose chemotherapy and total-body irradiation. However, HCT patients are severely compromised, and saliva substitute must therefore not promote infection. This study was performed to determine the effects of Oralbalance on microbial species identified during HCT. PATIENTS AND METHODS: Microbial identification of oral mucosa was performed in 28 patients undergoing HCT. The antimicrobial effects of Oralbalance against bacteria and fungi detected in the HCT period were examined in vitro. Briefly, bacteria and fungi were spread on agar plates, and 0.1g of Oralbalance gel was applied (about phi1cm). After incubation at 37 degrees C for 24h, the presence of a transparent zone of inhibition around Oralbalance was observed. MAIN RESULTS: Not only bacterial species constituting normal flora of the oral mucosa but also those not usually constituting normal flora, e.g., coagulase-negative Staphylococcus, were detected. A transparent zone was observed around Oralbalance in all bacterial species examined. No transparent zone was observed for Candida albicans, but growth was inhibited in the area where Oralbalance was applied. CONCLUSIONS: Oralbalance does not facilitate increases in microorganisms in the HCT period. Oral care with Oralbalance does not promote infection in patients undergoing HCT.

    DOI: 10.1007/s00520-007-0391-z

    PubMed

    researchmap

  • Appearance of multidrug-resistant opportunistic bacteria on the gingiva during leukemia treatment. Reviewed International journal

    Yoshihiko Soga, Takashi Saito, Fusanori Nishimura, Fumihiko Ishimaru, Junji Mineshiba, Fumi Mineshiba, Hirokazu Takaya, Hideaki Sato, Chieko Kudo, Susumu Kokeguchi, Nobuharu Fujii, Mitsune Tanimoto, Shogo Takashiba

    Journal of periodontology   79 ( 1 )   181 - 6   2008.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Dentists generally recognize the importance of periodontal treatment in patients with leukemia, with the most attention paid to preventing the development of odontogenic infection. For physicians, the worst type of infection is one caused by multidrug-resistant bacteria. Here, we report a patient with an abnormal increase in multidrug-resistant opportunistic bacteria in the gingiva during hematopoietic cell transplantation (HCT). METHODS: A 53-year-old woman receiving HCT for leukemia had an insufficient blood cell count for invasive periodontal treatment before HCT. Even brushing caused difficulties with hemostasis. Therefore, frequent pocket irrigation and local minocycline administration were performed. RESULTS: The multidrug-resistant opportunistic bacterium Stenotrophomonas maltophilia was detected first in phlegm 2 days before HCT, and it was detected in a gingival smear and a blood sample 7 and 11 days after HCT, respectively. The patient developed sepsis on day 11 and died 14 days after HCT. Frequent irrigation and local antibiotic application were ineffective against S. maltophilia on the gingiva. Inflammatory gingiva without scaling and root planing showed bleeding tendency, and this interfered with the eradication of this bacterium. CONCLUSIONS: The gingiva in patients undergoing leukemia treatment acts as sites of proliferation and reservoirs for multidrug-resistant opportunistic bacteria. Severe systemic infection by multidrug-resistant bacteria in such patients with leukemia also may involve the gingiva. To prevent abnormal increases in such bacteria on the gingiva, scaling and/or root planing before chemotherapy, which reduces bleeding on brushing during the neutropenic period caused by chemotherapy, may contribute to infection control in such patients, although it was impossible in this case.

    DOI: 10.1902/jop.2008.070205

    PubMed

    researchmap

  • Predominant Infiltration of Monocytes in Chronic Graft-Versus-Host Disease

    Namba Noriko, Shinagawa Katsuji, Fujii Nobuharu, Maeda Yoshinobu, Ishimaru Fumihiko, Ikeda Kazuma, Matsui Toshimitsu, Tanimoto Mitsune, Katayama Yoshio

    Transplantation   83 ( 2 )   220 - 224   2007.1

     More details

    Language:English   Publisher:Lippincott  

    DOI: 10.1097/01.tp.0000245080.71722.87

    CiNii Article

    researchmap

  • Loss or down-regulation of HLA class I expression at the allelic level in freshly isolated leukemic blasts International journal

    Kozo Masuda, Akio Hiraki, Nobuharu Fujii, Toshiyuki Watanabe, Motoyuki Tanaka, Kosei Matsue, Yoichiro Ogama, Mamoru Ouchida, Kenji Shimizu, Kazuma Ikeda, Mitsune Tanimoto

    CANCER SCIENCE   98 ( 1 )   102 - 108   2007.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:BLACKWELL PUBLISHING  

    Loss or down-regulation of human leukocyte antigen (HLA) class I expression has been demonstrated in a variety of solid tumors. To date, such altered HLA expression has not been studied extensively in freshly isolated leukemic blasts. If it occurs, leukemic cells could escape T-cell surveillance as a consequence. Genotypes of nine leukemic cell lines were determined using a polymerase chain reaction for HLA classes I and II. Cells were also examined for HLA beta 2-microglobulin, and allele-specific HLA protein expression using flow cytometry. Next, 44 samples of freshly isolated leukemic blasts from 43 patients with malignant hematological diseases were examined for allele-specific HLA expression using flow cytometry. Microsatellite analysis was performed to determine heterozygosity in the HLA region on chromosome 6. Genotype analysis for HLA class I together with microsatellite analysis demonstrated loss of HLA haplotype in HL-60 cells. No loss of HLA haplotype was observed in 44 samples of freshly isolated leukemic blasts. As reported previously, flow cytometric analysis rarely demonstrated loss or down-regulation of HLA expression at initial diagnosis (3/39; 7.7%); however, this was evident in two of five cases in relapse (40.0%), which contrasts with previous reports. In one patient with acute leukemia, HLA-A2 cell surface expression was present at initial diagnosis, lost at relapse, and completely restored after 48 h of culture in the presence of interferon-gamma. These results suggest loss of allele-specific HLA expression may be involved in the pathogenesis of relapse in patients with leukemia. The findings should be valuable in designing new strategies for clinical immunotherapy.

    DOI: 10.1111/j.1349-7006.2006.00356.x

    Web of Science

    PubMed

    researchmap

  • Early kinetics of engraftment following reduced-intensity stem cell transplantation: Fludarabine and cyclophosphamide versus fludarabine and busulfan. Reviewed

    Teruhiko Kozuka, Fumihiko Ishimaru, Keitaro Matsuo, Hiromi Nakashima, Nobuharu Fujii, Kenichi Matsuoka, Eisei Kondo, Yoshio Katayama, Yoshinobu Maeda, Katsuji Shinagawa, Kazuma Ikeda, Mitsune Tanimoto

    BLOOD   108 ( 11 )   838A - 838A   2006.11

     More details

    Language:English   Publisher:AMER SOC HEMATOLOGY  

    DOI: 10.1182/blood.V108.11.2957.2957

    Web of Science

    researchmap

  • Calcineurin inhibitor-induced irreversible neuropathic pain after allogeneic hematopoietic stem cell transplantation Reviewed

    N Fujii, K Ikeda, M Koyama, K Aoyama, T Masunari, E Kondo, T Matsuzaki, S Mizobuchi, A Hiraki, T Teshima, K Shinagawa, F Ishimaru, M Tanimoto

    INTERNATIONAL JOURNAL OF HEMATOLOGY   83 ( 5 )   459 - 461   2006.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:CARDEN JENNINGS PUBL CO LTD  

    The calcineurin inhibitors (Cls) cyclosporine A and tacrolimus are essential for graft-versus-host disease prophylaxis but are associated with adverse effects, including neurotoxicity We report a case of irreversible Cl-induced neuropathic pain following allogeneic hematopoietic stem cell transplantation. The patient developed dysesthesia, electric shock-like pain. and severe itching followed by intractable analgesic-resistant pain in the lower extremities. There were no abnormal radiographic findings, and there was no improvement with a reduction of Cl dosage or with administration of a calcium channel blocker. These clinical findings are similar to but inconsistent with Cl-induced musculoskeletal pain syndromes previously reported in organ transplantation.

    DOI: 10.1532/IJH97.05154

    Web of Science

    Scopus

    researchmap

    Other Link: http://orcid.org/0000-0003-0995-9405

  • Serum cytokine concentrations and acute graft-versus-host disease after allogeneic peripheral blood stem cell transplantation: Concurrent measurement of ten cytokines and their respective ratios using cytometric bead array Reviewed

    N Fujii, A Hiraki, K Aoe, T Murakami, K Ikeda, K Masuda, K Matsuo, K Shinagawa, F Ishimaru, K Sugi, Z Darzynkiewicz, M Tanimoto

    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE   17 ( 5 )   881 - 885   2006.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:PROFESSOR D A SPANDIDOS  

    Both inflammatory and anti-inflammatory cytokines have been reported to be associated with acute graft-versus-host disease (aGVHD). However, their role and possible mutual interactions during aGVHD are not well understood. Eight patients with aGVHD and eight without who had undergone allogeneic HLA-identical peripheral blood stem cell transplantation were studied. The patients had no other complications known to affect serum concentration of cytokines, including infection. Serum concentrations of IL-1B, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, TNF-alpha and IFN-gamma were concurrently measured by a new technique, the cytometric bead array (CBA). We found that serum concentrations of IL-5, IL-6 and IL-10 were significantly higher in patients with aGVHD than in patients without it. By ratiometric analysis, the ratios of IL-5/IL-2, IL-5/IL-4, IL-6/IL-4 in patients with aGVHD were increased compared to the patients with no evidence of aGVHD. ROC analysis demonstrated that the ratio of IL-5/IL-4 was the most sensitive parameter associated with aGVHD. The second best marker of aGVHD was increased IL-5 concentration. Thus, our results indicate that the ratio of a particular cytokine/cytokine could be a potential diagnostic marker for aGVHD, more sensitive that the serum level of a given cytokine. This observation is consistent with a cross-talk among some cytokines and their possible interactions via respective receptors on cytokine-producing cells; these interactions may play an important role in pathogenesis of aGVHD. Further studies including a large number of patients and concurrent measurement of a variety of cytokines are needed to fully assess the diagnostic value of the cytokine ratiometric analysis. The CBA methodology provides a convenient and useful tool in such studies.

    Web of Science

    Scopus

    researchmap

    Other Link: http://orcid.org/0000-0003-1761-6314

  • Activated human umbilical cord blood dendritic cells kill tumor cells without damaging normal hematological progenitor cells Reviewed

    J Shi, K Ikeda, N Fujii, E Kondo, K Shinagawa, F Ishimaru, K Kaneda, M Tanimoto, Li, X, Q Pu

    CANCER SCIENCE   96 ( 2 )   127 - 133   2005.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:WILEY-BLACKWELL  

    Apart from their role as antigen presenting cells, human peripheral blood monocyte and CD34+ cell-derived dendritic cells (DC), have been demonstrated to exert cytotoxicity against some tumor cells, and their tumoricidal activity can be enhanced by some stimili. However, there have been no reports concerning the tumoricidal activity of human cord blood dendritic cells (CBDC). In this article, we report that human cord blood monocyte-derived DC acquire the ability to kill hematological tumor cells, after activation with lipopolysaccharicle (LIPS) or gamma-interferon (IFN-gamma), associated with the enhanced TNF-alpha-related apoptosis-inducing ligand (TRAIL) expression in CBDC cytoplasm. The CD14-positive cells collected from cord blood were induced to CBDC in vitro. After activation with IFN-gamma for 12 h, CBDC exhibited cytotoxicity against HL60 and Jurkat cells, while activation with LPS induced cytotoxicity against Daudi and Jurkat cells. However, both LPS- and IFN-gamma-stimulatecl CBDC showed no cytotoxic activity against normal CD14-negative cord blood mononuclear cells. The formation of umbilical cord hematopoietic progenitor colonies, identified as burst-forming unit-erythroid and colony-forming unit granulocyte-macrophage, was not inhibited by stimulated or unstimulated CBDC. IFN-gamma or LPS stimulation enhanced intracellular but not cellular surface TRAIL, and neither intracellular nor cellular surface tumor necrosing factor-alpha and Fas Ligand as analyzed by flow cytometry. Our results show that activated CBDC can serve as cytotoxic cells against hematological tumor cells without damaging the normal hematopoietic progenitor cells.

    DOI: 10.1111/j.1349-7006.2005.00017.x

    Web of Science

    Scopus

    researchmap

    Other Link: http://orcid.org/0000-0003-0995-9405

  • Expression of SOCS3 mRNA in bone marrow cells from CML patients associated with cytogenetic response to IFN-alpha. Reviewed International journal

    Kazuto Takeuchi, Ikuya Sakai, Hirosi Narumi, Masaki Yasukawa, Kensuke Kojima, Yoko Minamoto, Tomoaki Fujisaki, Kazushi Tanimoto, Masamichi Hara, Akihiko Numata, Hisashi Gondo, Masuhiro Takahashi, Nobuharu Fujii, Kozo Masuda, Shigeru Fujita

    Leukemia research   29 ( 2 )   173 - 8   2005.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Previously, we have demonstrated that constitutive expression of suppressor of cytokine signaling-3 (SOCS3) affects the sensitivity of chronic myelogenous leukemia (CML) cell lines to interferon-alpha (IFN-alpha). In the present study, we analyzed the expression of SOCS3 mRNA in bone marrow cells from patients with CML at diagnosis, with the aid of real-time polymerase chain reaction. SOCS3 mRNA expression in bone marrow cells from CML patients who responded well to IFN-alpha therapy was significantly lower than that in cells from healthy volunteers and patients who were resistant to IFN-alpha therapy. Methylation of SOCS3 promoter was absent in bone marrow cells from all CML patients examined. These results indicate that the expression of SOCS3 mRNA is inversely associated with the sensitivity to IFN-alpha both in vitro and in vivo and that differences in SOCS3 mRNA expression are not due to the methylation status of SOCS3 promoters.

    PubMed

    researchmap

  • FLJ10849, a septin family gene, fuses MLL in a novel leukemia cell line CNLBC1 derived from chronic neutrophilic leukemia in transformation with t(4;11)(q21;q23)

    KOJIMA K

    Leukemia   18   998 - 1005   2004.4

  • High frequency of allele-specific down-regulation of HLA class I expression in lung cancer cell lines.

    Hiraki A, Fujii N, Murakami T, Kiura K, Aoe K, Yamane H, Masuda K, Maeda T, Sugi K, Darzynkiewicz Z, Tanimoto M, Harada M

    Anticancer Res   2004.4

     More details

  • 好中球減少時の発熱に対するCefozopranの有効性に関する検討.

    齋藤 崇、原 雅道、品川克至、名和由一郎、中瀬浩一、竹内 誠、宮田 明、福田俊一、角南一貴、今城健二、矢野朋文、小島研介、豊嶋崇徳、藤井伸治、石丸文彦、池田和真、原田実根、谷本光音

    癌と化学療法   2004.4

     More details

  • Peripheral blood circulating immature cell counts predict CD34+ cell yields in G-CSF-induced PBPC mobilization in healthy donors

    Kozuka T, Ikeda K, Teshima T, Yoshida C, Shinagawa K, Kojima K, Matsuo K, Bessho A, Sunami K, Hiramatsu Y, Maeda Y, Noguchi T, Yamamoto K, Fujii N, Imai T, et.al

    Transfusion   2004.4

     More details

  • Peripheral blood circulating immature cell counts predict CD34+ cell yields in G-CSF-induced PBPC mobilization in healthy donors. Reviewed International journal

    Teruhiko Kozuka, Kazuma Ikeda, Takanori Teshima, Chikamasa Yoshida, Katsuji Shinagawa, Kensuke Kojima, Keitaro Matsuo, Akihiro Bessho, Kazutaka Sunami, Yasushi Hiramatsu, Yoshinobu Maeda, Toshio Noguchi, Kazuhiko Yamamoto, Nobuharu Fujii, Toshi Imai, Kinuyo Kaneda Kusumoto, Kozo Masuda, Katsuto Takenaka, Fumihiko Ishimaru, Kenji Niiya, Norio Koide, Mitsune Tanimoto, Mine Harada

    Transfusion   44 ( 4 )   526 - 32   2004.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: It has been previously reported that the number of circulating immature cells (CIC) in peripheral blood (PB) estimates the number of CD34+ cells collected in G-CSF plus chemotherapy-induced PBPC mobilization. The correlation of CIC counts in PB with CD34+ cell yield and its usefulness was evaluated in G-CSF-induced PBPC mobilization for healthy donors. STUDY DESIGN AND METHODS: CIC counts in PB and CD34+ cell counts in the apheresis product from 122 collections were assessed, and the relationship between these two variables was evaluated with the Pearson rank correlation analysis, the chi-squared test, and the U-test. RESULTS: CIC counts were correlated weakly with the number of CD34+ cells per L of blood processed in the apheresis product (Pearson rank correlation analysis; r=0.357, p<0.0001). When a level of 1.7 x 10(9) CICs per L was selected as a cutoff value, the sensitivity and specificity for collecting more than 20 x 10(6) CD34+ cells per L of blood processed were 63.6 and 77.5 percent, respectively. CONCLUSION: The present study suggests that the number of CICs in PB may estimate the number of CD34+ cells collected. The data indicate that CIC counts above 1.7 x 10(9) per L can be used as a good predictor for PBPC collections containing more than 20 x 10(6) CD34+ cells per L of blood processed in a single apheresis procedure.

    PubMed

    researchmap

  • [Clinical evaluation of cefozopran as treatment for febrile neutropenia].

    Takashi Saito, Masamichi Hara, Katsuji Shinagawa, Yuichiro Nawa, Koichi Nakase, Makoto Takeuchi, Akira Miyata, Shunnichi Fukuda, Kazutaka Sunami, Kenji Imajoh, Tomofumi Yano, Kensuke Kojima, Takanori Teshima, Nobuharu Fujii, Fumihiko Ishimaru, Kazuma Ikeda, Mine Harada, Mitsune Tanimoto

    Gan to kagaku ryoho. Cancer & chemotherapy   31 ( 1 )   61 - 5   2004.1

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    Clinical effects and safety of cefozopran (CZOP) were evaluated by the Okayama Bone Marrow Transplantation Group. Twenty-five patients expected to experience febrile neutropenia during induction chemotherapy or consolidation chemotherapy of acute leukemia were enrolled between July 2000 and November 2002. CZOP was administrated by drip infusion at 4g/day bid for a minimum of 3 days. The clinical effects and safety were evaluated in 20 patients with fever of 37.5 degrees C or more from a clinically suspected infection. The underlying disease was acute myeloid leukemia in 17 patients, acute lymphoid leukemia in 1 and acute promyelogeneous leukemia in 1. The complicating infections were sepsis and suspected sepsis. Clinical efficacy was excellent in 11 patients, good in 1, fair in 2 and poor in 6, with an efficacy rate of 60.0%. The efficacy rate in patients whose albumin levels before therapy were less than 3.8 g/dl was 37.5%, whereas the rate in patients whose albumin levels before therapy were between 3.8 g/dl and 5.3 g/dl was 80.0%. The efficacy rate in patients whose neutrophil counts before therapy were less than 100/microliter was 50.0%, whereas the rate in patients whose neutrophil counts after therapy were less than 100/microliter was 53.8%. The efficacy rate in patients whose neutrophil counts both before and after therapy were less than 100/microliter was 37.5%. Side effect of exanthema was observed in 1 patient. These results indicate that CZOP is an effective and safe antibiotic for the treatment of febrile neutropenia in patients with hematological malignancies.

    PubMed

    researchmap

  • Cyclic thrombocytopenia and polycythemia vera

    KOJIMA K

    Ann Hematol.   82   61 - 63   2003.4

  • Plasma stromal cell-derived factor-1 during granulocyte colony-stimulating factor-induced peripheral blood stem cell mobilization.

    Kozuka T, Ishimaru F, Fujii K, Masuda K, Kaneda K, Imai T, Fujii N, Ishikura H, Hongo S, Watanabe T, Shinagawa K, Ikeda K, Niiya K, Harada M, Tanimoto M

    Bone Marrow Transplant   2003.4

     More details

  • Human herpes virus-8-negative primary effusion lymphoma in a patient with common variable immunodeficiency.

    Hisamoto A, Yamane H, Hiraki A, Maeda Y, Fujii N, Sasaki K, Miyake T, Sasaki T, Nakamura T, Kiura K, Tanimoto M, Kamei H

    Leuk Lymphoma   2003.4

     More details

  • 成人B細胞性急性リンパ性白血病(ALL L3)における長期予後の改善.

    石丸文彦, 近藤英生, 藤井伸治, 豊嶋崇徳, 品川克至, 池田和眞, 谷本光音

    内科専門医会誌   2003.4

     More details

  • Potential limitations in using minor histocompatibility antigen-specific cytotoxic T cells for targeting solid tumor cells

    MIYAZAKI M

    Clin Immunol.   107   198 - 201   2003.4

  • Successful treatment with cyclosporin A of myelodysplastic syndrome with erythroid hypoplasia associated with t(6;8) (q15;q22)

    TAKATA S

    Cancer Genet Cytogenet   140   167 - 169   2003.4

  • A novel fusion variant of the MORF and CBP genes detected in therapy-related myelodysplastic syndrome with t(10;16)(q22;p13) Reviewed

    K Kojima, K Kaneda, C Yoshida, H Dansako, N Fujii, T Yano, K Shinagawa, M Yasukawa, S Fujita, M Tanimoto

    BRITISH JOURNAL OF HAEMATOLOGY   120 ( 2 )   271 - 273   2003.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:BLACKWELL PUBLISHING LTD  

    We report a case of therapy-related myelodysplastic syndrome (t-MDS) with t(10;16)(q22;p13), in which novel fusion transcripts of the MORF and CBP genes were detected. In one MORF-CBP fusion transcript, exon 15 of the MORF gene was fused in frame with exon 5 of the CBP gene. In a reciprocal CBP-MORF transcript, exon 4 of the CBP gene was fused in frame with exon 16 of the MORF gene. This is the first reported case of t-MDS associated with t(10;16), and provides molecular evidence that the novel MORF-CBP and/or CBP-MORF fusion protein(s) might play an important role in the development of t-MDS.

    Web of Science

    researchmap

  • Predictive value of circulating immature cell counts in peripheral blood for timing of peripheral blood progenitor cell collection after G-CSF plus chemotherapy-induced mobilization Reviewed

    T Kozuka, K Ikeda, T Teshima, K Kojima, K Matsuo, A Bessho, K Sunami, Y Hiramatsu, Y Maeda, T Noguchi, K Yamamoto, N Fujii, T Imai, K Takenaka, K Shinagawa, F Ishimaru, K Niiya, N Koide, M Tanimoto, M Harada

    TRANSFUSION   42 ( 11 )   1514 - 1522   2002.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:AMER ASSOC BLOOD BANKS  

    Background: Enumeration of CD34+ cells in peripheral blood (PB) before apheresis predicts the number of CD34+ cells collected, although flow cytometric techniques used are complex and expensive. In an attempt to determine the optimal timing for peripheral blood progenitor cell (PBPC) collection, the usefulness of circulating immature cell (CIC) counts in PB was evaluated.
    Study design and methods: CIC counts in PB and CD34+ cell counts in the apheresis product from 249 collections were assessed, and the relationship between these two parameters was evaluated by with the Pearson rank correlation analysis, the Fisher exact test, and the U-test.
    Results: CIC counts were correlated significantly with the number of CD34+ cells per kg of patient's body weight in the apheresis product (Pearson rank correlation analysis: r=0.635, p&lt;0.0001). When a level of 1x10(9) CICs per L was selected as a cutoff value, the sensitivity and specificity for collecting more than 1x10(6) CD34+ cells per kg of body weight were 75.7 and 85.5 percent, respectively.
    Conclusion: The present study strongly suggests that the number of CICs in PB may estimate the number of CD34+ cells collected. The data indicate that CIC counts above 1x10(9) per L can be used as a good predictor for PBPC collections containing more than 1x10(6) CD34+ cells per kg of body weight in a single apheresis procedure.

    Web of Science

    Scopus

    researchmap

    Other Link: http://orcid.org/0000-0003-1761-6314

  • Tandem high-dose chemotherapy supported by autologous peripheral blood stem cell transplantation for recurrent soft tissue sarcoma Reviewed

    Teruhiko Kozuka, Katsuyuki Kiura, Hideki Katayama, Nobuharu Fujii, Fumihiko Ishimaru, Kazuma Ikeda, Hiroshi Ueoka, Shuuji Hamasaki, Tadashi Yoshino, Yoshio Kashihara, Hiroshi Date, Mitsune Tanimoto, Mine Harada

    Anticancer Research   22 ( 5 )   2939 - 2944   2002.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Background: Patients with recurrent soft tissue sarcoma (STS) are seldom curable, with 5-year survival rates of less than 10% in all large series. The role of high-dose chemotherapy (HDC) with hematopoietic stem cell support in this disease has not been established. Case Report: We report on two patients with recurrent STS who were treated with tandem HDC supported by autologous peripheral blood stem cell transplantation (PBSCT). One patient with malignant fibrous histiocytoma recurred with multiple lung metastases. This patient achieved a partial response after two cycles of induction chemotherapy consisting of ifosfamide and epirubicin. During four cycles of induction chemotherapy, peripheral blood stem cells (PBSCs) were harvested. Tandem high-dose ICE regimen (ifosfamide 3 g/m2 on days - 7 to - 3, carboplatin 400 mg/m2 on days - 7, - 5 and 3, etoposide 500 mg/m2 on days - 7, - 5 and 3) supported by autologous PBSCT gave rise to further regression of the tumors. Another patient with malignant hemangiopericytoma was treated by tandem high-dose ICE regimen supported by autologous PBSCT after the 3rd removal of abdominal tumors. Relapse-free intervals until the 1st, 2nd and 3rd relapses were 40, 19 and 22 months, respectively. Tandem high-dose ICE regimen might delay the relapse. Conclusion: These observations suggest that a tandem high-dose ICE regimen with autologous PBSCT is feasible with some clinical efficacy in the control of refractory STS.

    Scopus

    PubMed

    researchmap

  • 固形腫瘍におけるマイナー組織適合性抗原HA-1の発現の検討

    平木 章夫, 藤井 伸治, 池田 和眞, 木浦 勝行, 田端 雅弘, 上岡 博, 原田 実根, 谷本 光音

    日本癌学会総会記事   60回   243 - 243   2001.9

     More details

    Language:Japanese   Publisher:(一社)日本癌学会  

    researchmap

  • Retrospective Analysis on Time Requirements and Cost Effectiveness of Collection and Cryopreservation of Autologous Blood Stem Cells.

    Hiramatsu Yasushi, Sunami Kazutaka, Maeda Yoshinobu, Fujii Nobuharu, Bessho Akihiro, Asano Naomi, Ogo Hiroaki, Takenaka Katsuto, Shinagawa Katsuji, Ikeda Kazuma, Harada Mine

    Japanese Journal of Transfusion and Cell Therapy   46 ( 1 )   1 - 6   2000

     More details

    Language:Japanese   Publisher:The Japan Society of Transfusion Medicine and Cell Therapy  

    Autologous blood stem cell transplantation (auto-PBSCT) has increasingly been incorporated into the treatment of various malignancies. Auto- PBSCT provides several advantages over auto-BMT, but sometimes requires several collections of PBSC. We have retrospectively analyzed the time requirements and cost effectiveness of PBSC collection in Okayama University Hospital between 1994 and 1997, in which PBSCs were mobilized by chemotherapy and granulocyte colony-stimulating factor in 85 patients. During the 1994-1995 period, PBSCs were collected by apheresis, which was timed by leukocyte count and carried out by attending physicians, and cryopreserved at<5×107cells/ml concentrations. During 1996-1997, PBSC harvests, in which the number of apheresis was adjusted by the number of CD34+ cells collected at each harvest, were predicted by circulating immature myeloid cell count, and carried out by personnel of the Division of Blood Transfusion. Collected cells were cryopreserved at<1×108cells/ml. From the 1994-1995 to 1996-1997 periods, the average number of apheresis, the number of cryopreserved bags, and the time and cost required for aphereses and cryopreservation decreased from 3.5 to 1.4 aphereses, from 12.1 to 4.5 bags, from 13.6 to 7.1 hours and from 317 to 113 thousand yen per patient, respectively. Our experience suggests that the time requirements and cost effectiveness of PBSC harvest may be improved with precisely timed apheresis by skilled personnel and with appropriately defined cryopreservation.

    DOI: 10.3925/jjtc1958.46.1

    CiNii Article

    researchmap

  • 492 ヒト末梢血幹細胞培養好塩基球におけるsuperoxide産生能の検討

    濱田 昇, 谷本 安, 高尾 和志, 藤井 誠, 藤井 伸治, 金廣 有彦, 原田 実根, 池田 和真, 片岡 幹男, 今城 健二, 高橋 清

    アレルギー   49 ( 9 )   1015 - 1015   2000

     More details

    Language:Japanese   Publisher:一般社団法人 日本アレルギー学会  

    DOI: 10.15036/arerugi.49.1015_4

    CiNii Article

    researchmap

▼display all

Books

  • 血液疾患 最新の治療 2020-2022

    藤井伸治( Role: Joint author ,  造血器腫瘍における小児・思春期・若年がん患者の妊孕性の温存)

    南江堂  2019.10 

     More details

    Responsible for pages:56-60   Language:Japanese

    researchmap

  • 改訂第4版 日本輸血・細胞治療学会認定医制度指定カリキュラム

    西森 久和, 藤井伸治, 池田 和眞( Role: Joint author ,  同種血輸血の院内採血)

    一般社団法人 日本輸血・細胞治療学会  2019.5 

     More details

    Responsible for pages:410-413   Language:Japanese

    researchmap

  • 改訂第4版 日本輸血・細胞治療学会認定医制度指定カリキュラム

    藤井 敬子, 藤井伸治, 池田 和眞( Role: Joint author ,  顆粒球コロニー刺激因子)

    一般社団法人 日本輸血・細胞治療学会  2019.5 

     More details

    Responsible for pages:230-231   Language:Japanese

    researchmap

  • 産科と婦人科

    藤井伸治( Role: Sole author ,  小児, 思春期・若年がん患者の妊孕性温存に関する診療ガイドラインに沿った臨床の展開 11. 造血器)

    診断と治療社  2019.4 

     More details

    Responsible for pages:475-479   Language:Japanese

    researchmap

  • 臨床雑誌内科

    藤井伸治( Role: Sole author ,  輸血に伴う急性の有害事象・アナフィラキシー)

    南江堂  2018.10 

     More details

    Responsible for pages:761-763   Language:Japanese

    researchmap

  • がんの分子標的と治療薬 4章細胞表面のマーカー CD33

    谷本光音、藤井伸治( Role: Joint author)

    羊土社  2010.10 

     More details

    Language:Japanese

    researchmap

▼display all

MISC

  • Tisagenlecleucelのためのリンパ球採取-末梢血CD3+数と採取効率による処理量決定とロングアフェレーシスでの工夫-

    藤井敬子, 阿部将也, 住居優一, 谷勝真, 浦田知宏, 高木尚江, 閘結稀, 池田亮, 浅野尚美, 小郷博昭, 北村亘, 清家圭介, 大塚文男, 藤井伸治, 藤井敬子, 阿部将也, 住居優一, 谷勝真, 浦田知宏, 高木尚江, 北村亘, 清家圭介, 大塚文男, 藤井伸治

    日本輸血細胞治療学会誌   69 ( 2 )   2023

  • Clinical significance of gynecological examinations in LTFU

    鴨井千尋, 鴨井千尋, 藤井伸治, 藤井伸治, 松岡敬典, 藤原英晃, 淺田騰, 遠西大輔, 西森久和, 藤井敬子, 藤井敬子, 松岡賢市, 前田嘉信

    日本造血・免疫細胞療法学会総会プログラム・抄録集   44th   2022

  • Analysis of cryopreserved unrelated donor bone marrow transplantation under the COVID-19 pandemic

    松村彰文, 藤原英晃, 植田裕子, 守山喬史, 村上裕之, 住井優一, 浦田知宏, 木村真衣子, 近藤匠, 浅田騰, 遠西大輔, 西森久和, 松岡賢市, 藤井敬子, 藤井伸治, 鴨井千尋, 前田嘉信

    日本造血・免疫細胞療法学会総会プログラム・抄録集   44th   2022

  • Open-label, randomized study to calcium drink for prevention of citrate toxicity of PBSC donor

    藤井敬子, 藤井敬子, 藤井伸治, 藤井伸治, 三橋利晴, 住居優一, 住居優一, 谷勝真, 谷勝真, 浦田知宏, 浦田知宏, 木村真衣子, 木村真衣子, 近藤匠, 藤原英晃, 淺田騰, 遠西大輔, 西森久和, 松岡賢市, 大塚文男, 前田嘉信

    日本造血・免疫細胞療法学会総会プログラム・抄録集   45th   2022

  • Modification of post-transplant cyclophosphamide and tacrolimus in haploidentical transplantation

    寺尾俊紀, 松岡賢市, 近藤匠, 高須賀裕樹, 鴨井千尋, 植田裕子, 松村彰文, 松原千哲, 近藤歌穂, 藤原英晃, 淺田騰, 遠西大輔, 西森久和, 藤井敬子, 藤井伸治, 前田嘉信

    日本造血・免疫細胞療法学会総会プログラム・抄録集   45th   2022

  • Influence of oral microbiota on graft-versus-host disease and its role as a therapeutic target

    神原由依, 藤原英晃, 山本晃, 國廣まり, 大山矩史, 近藤匠, 淺田騰, 遠西大輔, 西森久和, 藤井伸治, 藤井敬子, 松岡賢市, 前田嘉信, 前田嘉信

    日本造血・免疫細胞療法学会総会プログラム・抄録集   45th   2022

  • Gilteritinib maintenance therapy post-SCT improves the prognosis of patients with R/R FLT3mut AML

    寺尾俊紀, 松岡賢市, 植田裕子, 松村彰文, 松原千哲, 近藤歌穂, 近藤匠, 藤原英晃, 淺田騰, 遠西大輔, 西森久和, 藤井敬子, 藤井伸治, 前田嘉信

    日本造血・免疫細胞療法学会総会プログラム・抄録集   45th   2022

  • Prognostic impact of Day 30 WT1 after PTCY-haplo in myeloid neoplasm: A multi-center study from OHSG

    北村亘, 藤井伸治, 藤井伸治, 名和由一郎, 杉浦弘幸, 藤下惠悟, 吉岡尚徳, 藤原悠紀, 大山矩史, 村上裕之, 高須賀裕樹, 池内一廣, 池川俊太郎, 池川俊太郎, 藤原英晃, 淺田騰, 遠西大輔, 遠西大輔, 西森久和, 藤井敬子, 松岡賢市, 木口亨, 今井利, 平松靖史, 前田嘉信

    日本血液学会学術集会抄録(Web)   83rd   2021

  • EBV viremia with NK/T cells as well as B cells after hematopoietic stem cell transplantation

    大山矩史, 西森久和, 村上裕之, 高須賀裕樹, 北村亘, 藤原英晃, 淺田騰, 藤井敬子, 藤井伸治, 遠西大輔, 松岡賢市, 前田嘉信

    日本血液学会学術集会抄録(Web)   83rd   2021

  • 移植後シクロホスファミドを用いた血縁者間HLA半合致移植後に最重症遅発性肝類洞閉塞症候群を合併した非定型慢性骨髄性白血病

    北村亘, 藤井伸治, 藤井伸治, 大西秀樹, 高須賀裕樹, 大山矩史, 村上裕之, 木村真衣子, 近藤匠, 松田真幸, 池川俊太郎, 池川俊太郎, 藤原英晃, 淺田騰, 遠西大輔, 遠西大輔, 西森久和, 藤井敬子, 藤井敬子, 松岡賢市, 木口亨, 柳井広之, 吉野正, 前田嘉信

    臨床血液   62 ( 6 )   654 - 655   2021

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    J-GLOBAL

    researchmap

  • Marfan症候群に先天性第XI因子欠乏症とvon Willebrand病(VWD)を合併した患者の心臓弁膜症手術の周術期管理

    大山矩史, 淺田騰, 末澤孝徳, 新谷憲治, 廣田真規, 池内一廣, 北村亘, 高須賀裕樹, 藤原英晃, 遠西大輔, 西森久和, 藤井伸治, 松岡賢市, 笠原真悟, 前田嘉信

    臨床血液   62 ( 6 )   663 - 663   2021

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    J-GLOBAL

    researchmap

  • Efficacy of HLA virtual cross-matched platelet transfusions for platelet transfusion refractoriness in hematopoietic stem cell transplantation (vol 60, pg 473, 2020)

    Keisuke Seike, Nobuharu Fujii, Naomi Asano, Shigenori Ohkuma, Yasushi Hirata, Keiko Fujii, Yasuhisa Sando, Makoto Nakamura, Kazunori Naito, Yusuke Meguri, Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Ken-ichi Matsuoka, Kazuo Tsubaki, Fumio Otsuka, Yoshinobu Maeda

    TRANSFUSION   60 ( 11 )   2765 - 2765   2020.11

     More details

    Language:English   Publisher:WILEY  

    DOI: 10.1111/trf.15872

    Web of Science

    researchmap

  • 肝膿瘍を合併した急性骨髄性白血病の造血幹細胞移植時に顆粒球輸注が有効であった1例

    谷岡桃子, 福見拓也, 神原由依, 池内一廣, 小林宏紀, 廻勇輔, 淺田騰, 遠西大輔, 西森久和, 藤井伸治, 松岡賢市, 前田嘉信

    臨床血液   61 ( 10 )   1529 - 1529   2020

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    J-GLOBAL

    researchmap

  • 急性骨髄性白血病に対する臍帯血移植後に発症しバンコマイシン髄注と顆粒球輸注が有効であったEnterococcus faecium髄膜炎の1例

    上田 弥生, 水原 健太郎, 松岡 賢市, 阿部 将也, 浦田 知宏, 神原 由依, 住居 優一, 藤原 悠紀, 佐伯 恭昌, 廻 勇輔, 淺田 騰, 遠西 大輔, 西森 久和, 藤井 伸治, 前田 嘉信

    臨床血液   60 ( 5 )   508 - 508   2019.5

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    J-GLOBAL

    researchmap

  • 二度の同種造血幹細胞移植に続く脳死肺移植後に骨髄異形成症候群を発症し臍帯血移植を施行した1例

    伊藤 啓, 藤原 悠紀, 住居 優一, 阿部 将也, 水原 健太郎, 浦田 知宏, 佐伯 恭昌, 廻 勇輔, 淺田 騰, 遠西 大輔, 西森 久和, 松岡 賢市, 藤井 伸治, 前田 嘉信

    臨床血液   60 ( 5 )   511 - 511   2019.5

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    J-GLOBAL

    researchmap

  • 消化管出血(静脈瘤破裂を除く)の予後不良症例の検討 急性消化管GVHDにおいて回腸末端の内視鏡所見は予後・重症度・治療反応性と関連するか?

    杉原 雄策, 平岡 佐規子, 安富 絵里子, 岡 昌平, 山崎 泰史, 井口 俊博, 衣笠 秀明, 高原 政宏, 原田 馨太, 藤井 伸治, 田中 健大, 岡田 裕之

    日本消化管学会雑誌   3 ( Suppl. )   161 - 161   2019.2

     More details

    Language:Japanese   Publisher:(一社)日本消化管学会  

    researchmap

  • Efficacy of HLA-Matched PLT Transfusions for Platelet Transfusion Refractoriness in HSCT Patients

    Keisuke Seike, Nobuharu Fujii, Keiko Fujii, Yasuhisa Sando, Makoto Nakamura, Kyosuke Saeki, Yusuke Meguri, Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Ken-Ichi Matsuoka, Yoshinobu Maeda

    BLOOD   132   2018.11

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC HEMATOLOGY  

    0

    DOI: 10.1182/blood-2018-99-112365

    Web of Science

    researchmap

  • PD-1阻害薬使用後の自家造血幹細胞移植におけるサイトカイン放出症候群の病態解析(Mechanistic analysis of cytokine release syndrome after autologous HSCT following PD-1 blockade)

    碓井 喜明, 松岡 賢市, 廻 勇輔, 岩本 美紀, 三道 康永, 坂本 真衣子, 藤原 悠紀, 近藤 匠, 谷 勝真, 佐伯 恭昌, 岡本 幸代, 淺田 騰, 西森 久和, 藤井 伸治, 近藤 英生, 前田 嘉信

    臨床血液   59 ( 9 )   1542 - 1542   2018.9

     More details

    Language:English   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • 造血幹細胞移植における患者指定適合血小板輸血の有効性についての検討(Efficacy of HLA-matched PLT transfusion for platelet transfusion refractoriness in HSCT patients)

    清家 圭介, 藤井 伸治, 藤井 敬子, 三道 康永, 中村 真, 佐伯 恭昌, 廻 勇輔, 淺田 騰, 遠西 大輔, 西森 久和, 松岡 賢市, 前田 嘉信

    臨床血液   59 ( 9 )   1541 - 1541   2018.9

     More details

    Language:English   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • Marginal zone B cell lymphoma治療後に、複視を契機にneurolymphomatosisとして再発したと考えられる1例

    松田 真幸, 坂本 真衣子, 碓井 喜明, 藤原 悠紀, 近藤 匠, 谷 勝真, 佐伯 恭昌, 廻 勇輔, 岡本 幸代, 西森 久和, 近藤 英生, 藤井 伸治, 松岡 賢市, 前田 嘉信, 吉野 正

    臨床血液   59 ( 5 )   632 - 632   2018.5

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • 乳房腫脹を契機に診断されたperipheral T-cell lymphoma、with T follicular helper phenotypeの1例

    碓井 喜明, 松岡 賢市, 近藤 匠, 坂本 真衣子, 谷 勝真, 藤原 悠紀, 佐伯 恭昌, 廻 勇輔, 淺田 騰, 岡本 幸代, 西森 久和, 近藤 英生, 藤井 伸治, 吉野 正, 前田 嘉信

    臨床血液   59 ( 5 )   633 - 633   2018.5

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • 同種末梢血幹細胞移植後3年で抗リン脂質抗体症候群を発症した1例

    近藤 匠, 碓井 喜明, 松岡 賢市, 坂本 真衣子, 谷 勝真, 藤原 悠紀, 佐伯 恭昌, 廻 勇輔, 岡本 幸代, 西森 久和, 近藤 英生, 藤井 伸治, 前田 嘉信

    臨床血液   59 ( 5 )   642 - 642   2018.5

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    J-GLOBAL

    researchmap

  • 急性消化管GVHDの診断における上部消化管内視鏡検査と大腸内視鏡検査の比較

    杉原 雄策, 平岡 佐規子, 加藤 諒, 高嶋 志保, 山崎 泰史, 井口 俊博, 高原 政宏, 原田 馨太, 藤井 伸治, 田中 健大, 岡田 裕之

    Gastroenterological Endoscopy   60 ( Suppl.1 )   772 - 772   2018.4

     More details

    Language:Japanese   Publisher:(一社)日本消化器内視鏡学会  

    researchmap

  • Granulocyte Transfusions for Neutropenic Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation

    Shuntaro Ikegawa, Nobuharu Fujii, Keiko Fujii, Yusuke Meguri, Kyosuke Saeki, Noboru Asada, Hisakazu Nishimori, Ken-ichi Matsuoka, Yoshinobu Maeda

    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION   24 ( 3 )   S326 - S326   2018.3

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:ELSEVIER SCIENCE INC  

    DOI: 10.1016/j.bbmt.2017.12.382

    Web of Science

    researchmap

  • Granulocyte Transfusions for Neutropenic Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation

    Shuntaro Ikegawa, Nobuharu Fujii, Keiko Fujii, Yusuke Meguri, Kyosuke Saeki, Noboru Asada, Hisakazu Nishimori, Ken-ichi Matsuoka, Yoshinobu Maeda

    BLOOD   130   2017.12

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC HEMATOLOGY  

    0

    Web of Science

    researchmap

  • 大腸内視鏡を用いた急性GVHDの診断における「回腸末端の絨毛の萎縮」の臨床的意義 後方視的多施設共同研究

    杉原 雄策, 平岡 佐規子, 高嶋 志保, 竹井 大介, 井口 俊博, 高原 政宏, 森藤 由紀, 高橋 索真, 桑木 健志, 原田 馨太, 藤井 伸治, 田中 健大, 岡田 裕之

    Gastroenterological Endoscopy   59 ( Suppl.2 )   2238 - 2238   2017.9

     More details

    Language:Japanese   Publisher:(一社)日本消化器内視鏡学会  

    researchmap

  • 極めて大量のフェントラミン持続静注を要した終末期悪性褐色細胞腫の一例

    灘 隆宏, 木村 耕介, 花山 宜久, 藤井 伸治, 近藤 英生, 大塚 文男

    日本病院総合診療医学会雑誌   13 ( 1 )   119 - 119   2017.7

     More details

    Language:Japanese   Publisher:(一社)日本病院総合診療医学会  

    researchmap

  • 健常人ドナー末梢血幹細胞採取時のクエン酸中毒発現、電解質異常についての解析

    中村 真, 藤井 敬子, 佐伯 恭昌, 谷 勝真, 黒井 大雅, 高木 尚江, 猪股 知子, 池川 俊太郎, 杉浦 弘幸, 池田 直人, 浅野 豪, 吉田 将平, 西森 久和, 松岡 賢市, 近藤 英生, 前田 嘉信, 藤井 伸治, 谷本 光音

    臨床血液   58 ( 5 )   553 - 553   2017.5

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • 成長ホルモン治療中に多血症およびMDSを合併した一例

    当真 貴志雄, 越智 可奈子, 細谷 武史, 藤澤 諭, 西山 悠紀, 原 孝行, 稲垣 兼一, 和田 淳, 藤井 伸治, 大塚 文男

    日本内分泌学会雑誌   93 ( 1 )   316 - 316   2017.4

     More details

    Language:Japanese   Publisher:(一社)日本内分泌学会  

    researchmap

  • Impact of Incomplete Blood Count Recovery Prior to Allogeneic Hematopoietic Stem Cell Transplantation on Engraftment and Early Infection in Patients with Acute Myeloid Leukemia

    Takeru Asano, Shuntaro Ikegawa, Tomoko Inomata, Naoto Ikeda, Hiroyuki Sugiura, Taiga Kuroi, Shohei Yoshida, Hisakazu Nishimori, Ken-ichi Matsuoka, Nobuharu Fujii, Eisei Kondo, Yoshinobu Maeda, Mitsune Tanimoto

    BLOOD   128 ( 22 )   2016.12

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC HEMATOLOGY  

    Web of Science

    researchmap

  • Intrabone Transplantation of a Single Cord Blood Unit Using Non-Irradiated Reduced-Intensity Conditioning

    Makoto Murata, Yoshinobu Maeda, Masayoshi Masuko, Yasushi Onishi, Tomoyuki Endo, Seitaro Terakura, Yuichi Ishikawa, Chisako Iriyama, Yoko Ushijima, Tatsunori Goto, Nobuharu Fujii, Mitsune Tanimoto, Hironori Kobayashi, Yasuhiko Shibasaki, Noriko Fukuhara, Yoshihiro Inamoto, Ritsuro Suzuki, Tadashi Matsushita, Yoshihisa Kodera, Hitoshi Kiyoi, Tomoki Naoe, Tetsuya Nishida

    BLOOD   128 ( 22 )   2016.12

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC HEMATOLOGY  

    Web of Science

    researchmap

  • Successful Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Mild Renal Dysfunction Calculated By Creatinin Clearance

    Shuntaro Ikegawa, Tomoko Inomata, Naoto Ikeda, Hiroyuki Sugiura, Taiga Kuroi, Takeru Asano, Shohei Yoshida, Hisakazu Nishimori, Ken-ichi Matsuoka, Nobuharu Fujii, Eisei Kondo, Yoshinobu Maeda, Mitsune Tanimoto

    BLOOD   128 ( 22 )   2016.12

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC HEMATOLOGY  

    Web of Science

    researchmap

  • Terminal Ileum Imaging With Colonoscopy Is Marker for Evaluation of Acute Graft-Versus-Host Disease Severity After Allogeneic Bone Marrow Transplantation

    Yuusaku Sugihara, Sakiko Hiraoka, Shiho Takashima, Daisuke Takei, Toshihiro Inokuchi, Asuka Nakarai, Masahiro Takahara, Kenji Kuwaki, Keita Harada, Nobuharu Fujii, Takehiro Tanaka, Hiroyuki Okada

    GASTROINTESTINAL ENDOSCOPY   83 ( 5 )   AB325 - AB325   2016.5

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:MOSBY-ELSEVIER  

    Web of Science

    researchmap

  • リンパ節、肺・心嚢への進展を伴った皮膚原発ALK陰性ALCLの1例

    為房 宏輔, 猪股 知子, 松岡 賢市, 吉田 将平, 西森 久和, 近藤 英生, 藤井 伸治, 前田 嘉信, 谷本 光音

    臨床血液   57 ( 5 )   663 - 663   2016.5

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    J-GLOBAL

    researchmap

  • 同種骨髄移植後にBKウイルス性出血性膀胱炎に罹患し、両側腎瘻・膀胱瘻造設術を要した骨髄異形成症候群の1症例

    鴨井 千尋, 三道 康永, 藤井 伸治, 吉田 将平, 西森 久和, 松岡 賢市, 近藤 英生, 前田 嘉信, 谷本 光音, 児島 宏典, 森 聰博, 藤尾 圭, 堀川 雄平, 松本 裕子, 和田 耕一郎, 那須 保友

    臨床血液   57 ( 5 )   669 - 669   2016.5

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    J-GLOBAL

    researchmap

  • Analysis of Prognostic Factors of Hematopoietic Stem Cell Transplantation Patients Admitted to ICU

    Malcoto Nakamura, Nobuharu Fujii, Kazuyoshi Shimizu, Hisakazu Nishimori, Ken-ichi Matsuoka, Eisei Kondo, Yoshinobu Maeda, Hiroshi Morimatsu, Mitsune Tanimoto

    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION   22 ( 3 )   S293 - S293   2016.3

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:ELSEVIER SCIENCE INC  

    Web of Science

    researchmap

  • Magnifying Endoscopic Features of Follicular Lymphoma Involving the Stomach: A Report of Two Cases

    Masaya Iwamuro, Katsuyoshi Takata, Seiji Kawano, Nobuharu Fujii, Yoshiro Kawahara, Tadashi Yoshino, Hiroyuki Okada

    CASE REPORTS IN GASTROINTESTINAL MEDICINE   2016   1 - 6   2016

     More details

    Language:English   Publisher:HINDAWI LTD  

    A 70-year-old woman presented with follicular lymphoma involving the stomach, duodenum, jejunum, bone, and lymph nodes. Esophagogastroduodenoscopy revealed multiple depressed lesions in the stomach. Examination with magnifying endoscopy showed branched abnormal vessels along with gastric pits, which were irregularly shaped but were preserved. The second case was a 45-year-old man diagnosed with stage II 1 follicular lymphoma with duodenal, ileal, and colorectal involvement, as well as lymphadenopathy of the mesenteric lymph nodes. Esophagogastroduodenoscopy performed six years after the diagnosis revealed multiple erosions in the gastric body and angle. Magnifying endoscopic observation with narrow-band imaging showed that the gastric pits were only partially preserved and were destroyed in most of the stomach. Branched abnormal vessels were also seen. Pathological features were consistent with follicular lymphoma in both cases. The structural differences reported between the two cases appear to reflect distinct pathologies. Disappearance of gastric pits in the latter case seems to result from loss of epithelial cells, probably due to chronic inflammation. In both cases, branched abnormal vasculature was observed. These two cases suggest that magnified observations of abnormal branched microvasculature may facilitate endoscopic detection and recognition of the extent of gastric involvement in patients with follicular lymphoma.

    DOI: 10.1155/2016/2082698

    Web of Science

    researchmap

  • Terminal ileum imaging with colonoscopy to evaluate acute graft-versus-host disease severity after allogeneic bone marrow transplantation

    Yuusaku Sugihara, Sakiko Hiraoka, Shiho Takashima, Daisuke Takei, Inokuchi Toshihiro, Asuka Nakarai, Masahiro Takahara, Keita Harada, Hiroyuki Okada, Nobuharu Fujii

    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY   30   172 - 172   2015.12

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:WILEY-BLACKWELL  

    Web of Science

    researchmap

  • 慢性活動性EBウイルス感染症に対して同種移植を行った5例

    三道 康永, 藤原 英晃, 西森 久和, 松岡 賢市, 近藤 英生, 藤井 伸治, 前田 嘉信, 谷本 光音

    日本リンパ網内系学会会誌   55   107 - 107   2015.6

     More details

    Language:Japanese   Publisher:(一社)日本リンパ網内系学会  

    researchmap

  • イマチニブ療法に対して難治性であったRosai-Dorfman病の2症例 症例報告と文献考察(Two cases of Rosai-Dorfman Disease refractory to Imatinib therapy: Case report and review of literature)

    谷 勝真, 藤井 伸治, 石川 立則, 山本 宣和, 塩手 康弘, 佐伯 恭昌, 清家 圭介, 三道 康永, 中村 真, 藤原 英晃, 西森 久和, 松岡 賢市, 近藤 英生, 前田 嘉信, 谷本 光音, 高田 尚良, 吉野 正

    日本リンパ網内系学会会誌   55   97 - 97   2015.6

     More details

    Language:English   Publisher:(一社)日本リンパ網内系学会  

    researchmap

  • 限局期CD5陽性びまん性大細胞型B細胞リンパ腫の治療成績についての検討

    中村 真, 藤原 英晃, 清家 圭介, 三道 康永, 石川 立則, 西森 和久, 松岡 賢市, 近藤 英生, 藤井 伸治, 前田 嘉信, 谷本 光音

    日本リンパ網内系学会会誌   55   101 - 101   2015.6

     More details

    Language:Japanese   Publisher:(一社)日本リンパ網内系学会  

    researchmap

  • 皮膚病変を契機にtrisomy 8を含む複雑核型染色体異常を伴うMDSが判明し、VP-16が奏効したSweet病の1例

    藤原 暖, 土井 裕子, 加持 達弥, 濱田 利久, 岩月 啓氏, 三道 康永, 佐伯 恭昌, 藤井 伸治, 川上 佳夫

    西日本皮膚科   77 ( 3 )   305 - 305   2015.6

     More details

    Language:Japanese   Publisher:日本皮膚科学会-西部支部  

    researchmap

  • 当院において集中治療を要した造血幹細胞移植症例についての検討

    中村 真, 藤井 伸治, 清家 圭介, 三道 康永, 石川 立則, 藤原 英晃, 西森 和久, 松岡 賢市, 近藤 英生, 前田 嘉信, 谷本 光音

    臨床血液   56 ( 5 )   539 - 539   2015.5

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • 自家末梢血造血幹細胞移植の前処置において、抗がん剤投与量はBMIに応じて増減すべきか

    谷 勝真, 藤原 英晃, 西森 久和, 松岡 賢市, 藤井 伸治, 近藤 英生, 前田 嘉信, 谷本 光音, 廻 勇輔, 小林 優人, 藤井 敬子

    臨床血液   56 ( 5 )   537 - 537   2015.5

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • 造血幹細胞移植後thrombotic microangiopathyに対するrecombinant thrombomodulin投与とその意義

    藤原 英晃, 前田 嘉信, 三道 康永, 中村 真, 谷 勝真, 石川 隆則, 西森 久和, 松岡 賢市, 藤井 伸治, 近藤 英生, 谷本 光音

    臨床血液   56 ( 5 )   534 - 534   2015.5

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • CNS浸潤伴う治療抵抗性ALK陽性ALCLに対しCrizotinibを使用した1例

    濱崎 豊, 石川 立則, 近藤 英生, 吉野 正, 長谷川 詠子, 瀬崎 伸夫, 藤原 英晃, 西森 久和, 松岡 賢市, 藤井 伸治, 前田 嘉信, 谷本 光音

    臨床血液   56 ( 5 )   527 - 528   2015.5

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • 同種造血幹細胞移植とGranulicatella adiacens敗血症

    三道 康永, 松岡 賢市, 谷 勝真, 能勢 資子, 藤原 英晃, 西森 久和, 近藤 英生, 藤井 伸治, 前田 嘉信, 谷本 光音

    臨床血液   56 ( 5 )   538 - 538   2015.5

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • 難治性Sweet病を合併したMDSに対して同種造血幹細胞移植を施行した1例

    本倉 恵美, 三道 康永, 佐伯 恭昌, 藤井 伸治, 藤原 英晃, 西森 久和, 松岡 賢市, 近藤 英生, 前田 嘉信, 谷本 光音, 廻 勇輔, 小林 優人, 藤井 敬子, 藤原 暖, 土井 裕子, 加持 達弥, 岩月 啓氏

    臨床血液   56 ( 5 )   538 - 538   2015.5

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • 血液疾患患者におけるHLA適合血小板輸血後の有効性評価

    藤井 伸治, 小郷 博昭, 小林 優人, 藤井 敬子, 近藤 英生, 浅野 尚美, 池田 亮, 山川 美和, 高木 尚江, 平田 康司

    日本輸血細胞治療学会誌   61 ( 2 )   258 - 258   2015.4

     More details

    Language:Japanese   Publisher:(一社)日本輸血・細胞治療学会  

    researchmap

  • Anti-IL-12/23 p40 Antibody Attenuates Chronic Graft Versus Host Disease Via Suppression of IFN-gamma/IL-17-Producing Cells

    Taiga Kuroi, Sachiyo Okamoto, Kyosuke Saeki, Yujin Kobayashi, Hisakazu Nishimori, Hideaki Fujiwara, Ken-ichi Matsuoka, Nobuharu Fujii, Eisei Kondo, Mitsune Tanimoto, Yoshinobu Maeda

    BLOOD   124 ( 21 )   2014.12

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC HEMATOLOGY  

    Web of Science

    researchmap

  • Use of Recombinant Thrombomodulin for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation Ameliorate Disease Severity

    Hideaki Fujiwara, Yoshinobu Maeda, Yasuhisa Sando, Makoto Nakamura, Katsuma Tani, Takanori Ishikawa, Hisakazu Nishimori, Ken-ichi Matsuoka, Nobuharu Fujii, Eisei Kondo, Mitsune Tanimoto

    BLOOD   124 ( 21 )   2014.12

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC HEMATOLOGY  

    Web of Science

    researchmap

  • 治療抵抗性DLBCLの自己末梢血幹細胞移植併用大量化学療法(HDT/ASCT)後の再発に対しHLA半合致同種造血幹細胞移植(haploHSCT)を行い完全寛解となった一例

    塩手 康弘, 近藤 英生, 石川 立則, 佐伯 恭昌, 谷 勝真, 山本 宜和, 松岡 賢市, 西森 久和, 藤井 伸治, 前田 嘉信, 谷本 光音, 吉野 正

    日本リンパ網内系学会会誌   54   122 - 122   2014.6

     More details

    Language:Japanese   Publisher:(一社)日本リンパ網内系学会  

    researchmap

  • 皮膚γδT細胞リンパ腫に対し臍帯血移植を施行した一例

    佐伯 恭昌, 石川 立則, 谷 勝真, 松岡 賢市, 藤井 伸治, 近藤 英生, 前田 嘉信, 谷本 光音

    日本リンパ網内系学会会誌   54   121 - 121   2014.6

     More details

    Language:Japanese   Publisher:(一社)日本リンパ網内系学会  

    researchmap

  • 当院における70歳以上の高齢血液疾患患者に対する同種造血幹細胞移植

    近藤 正太郎, 前田 嘉信, 松岡 賢市, 品川 克至, 藤井 敬子, 藤井 伸治, 近藤 英生, 谷本 光音

    日本老年医学会雑誌   51 ( 3 )   293 - 293   2014.5

     More details

    Language:Japanese   Publisher:(一社)日本老年医学会  

    researchmap

  • マウス慢性GVHDモデルにおけるPD-1経路の重要性

    藤原英晃, 前田嘉信, 西之原正昭, 岡本幸代, 西森久和, 松岡賢市, 藤井伸治, 近藤英生, 品川克至, 谷本光音

    日本造血細胞移植学会総会プログラム・抄録集   36th   2014

  • MTX中止直後に一過性の白血球増多を認め、その後自然退縮したMTX-LPDの一例

    近藤 英生, 葛島 清隆, 市村 浩一, 前田 嘉信, 藤井 伸治, 松岡 賢市, 品川 克至, 長谷川 詠子, 黒井 大雅, 佐伯 恭昌, 浅野 豪, 高田 尚良, 佐藤 康晴, 吉野 正, 谷本 光音

    日本リンパ網内系学会会誌   53   133 - 133   2013.4

     More details

    Language:Japanese   Publisher:(一社)日本リンパ網内系学会  

    researchmap

  • Mediastinal gray zone lymphomaに対しRituximab併用DA-EPOCH療法を施行した3症例

    吉岡 尚徳, 佐伯 恭昌, 浅野 豪, 松岡 賢市, 藤井 伸治, 近藤 英生, 前田 嘉信, 品川 克至, 吉野 正, 谷本 光音

    日本内科学会雑誌   102 ( Suppl. )   187 - 187   2013.2

     More details

    Language:Japanese   Publisher:(一社)日本内科学会  

    researchmap

  • Contribution of the PD-1-PD-L Pathway to Chronic Graft-Versus-Host Disease

    Hideaki Fujiwara, Koichiro Kobayashi, Hisakazu Nishimori, Masaaki Nishinohara, Sachiyo Okamoto, Ken-ichi Matsuoka, Eisei Kondo, Nobuharu Fujii, Katsuji Shinagawa, Mitsune Tanimoto, Yoshinobu Maeda

    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION   19 ( 2 )   S324 - S325   2013.2

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:ELSEVIER SCIENCE INC  

    Web of Science

    researchmap

  • 新しい全自動型血液成分分離装置Spectra Optiaを用いた末梢血幹細胞採取Cobe Spectraと比較して

    藤井 敬子, 淺田 騰, 西森 久和, 山川 美和, 森 繰代, 狩山 由貴, 池田 亮, 浅野 尚美, 小郷 博昭, 藤井 伸治, 岩月 啓氏

    日本輸血細胞治療学会誌   59 ( 1 )   91 - 91   2013.2

     More details

    Language:Japanese   Publisher:(一社)日本輸血・細胞治療学会  

    J-GLOBAL

    researchmap

  • 当院同種造血幹細胞移植症例におけるDisease risk indexの有用性の検討

    浅野豪, 近藤英生, 佐伯恭昌, 長谷川詠子, 黒井大雅, 西森久和, 松岡賢市, 浅田騰, 藤井敬子, 藤井伸治, 藤井伸治, 前田嘉信, 品川克至, 谷本光音

    日本造血細胞移植学会総会プログラム・抄録集   35th   2013

  • 非血縁者間骨髄移植後再発に対してドナーリンパ球輸注療法が著効したGATA2変異を有するMonoMac症候群の1例

    増成太郎, 枝廣暁, 大倉浩子, 鈴木優子, 長澤紗詠子, 木村耕介, 木口亨, 瀬崎伸夫, 石井啓太, 吉岡尚徳, 西森久和, 新谷大悟, 藤井伸治, 前田嘉信, 品川克至, 村松秀城, 小島勢二, 新谷憲治

    日本造血細胞移植学会総会プログラム・抄録集   35th   2013

  • Erdheim-Chester病が強く疑われた下垂体機能低下症の一例

    三好 智子, 大塚 文男, 稲垣 兼一, 田中 康司, 越智 可奈子, 藤井 一恭, 藤井 伸治, 当真 貴志雄, 中村 絵里, 塚本 尚子, 武田 昌也, 三村 由香里, 小倉 俊郎, 景山 甚郷, 槇野 博史

    日本内分泌学会雑誌   88 ( 3 )   1017 - 1017   2012.12

     More details

    Language:Japanese   Publisher:(一社)日本内分泌学会  

    researchmap

  • Mediastinal gray zone lymphomaに対しRituximab併用DA-EPOCH療法を施行した3症例

    佐伯 恭昌, 吉岡 尚徳, 淺野 豪, 黒井 大雅, 長谷川 詠子, 松岡 賢市, 藤井 伸治, 近藤 英生, 前田 嘉信, 品川 克至, 吉野 正, 谷本 光音

    日本癌治療学会誌   47 ( 3 )   2508 - 2508   2012.10

     More details

    Language:Japanese   Publisher:(一社)日本癌治療学会  

    researchmap

  • 骨髄内骨髄移植はidiopathic pneumonia syndromeの発症を予防する

    山筋 好子, 西森 久和, 杉山 暖子, 小林 孝一郎, 門久 幸代, 近藤 英生, 藤井 伸治, 品川 克至, 谷本 光音, 前田 嘉信, 金蔵 拓郎

    西日本皮膚科   74 ( 4 )   455 - 456   2012.8

     More details

    Language:Japanese   Publisher:日本皮膚科学会-西部支部  

    researchmap

  • 縦隔原発悪性リンパ腫に対しRituximab併用DA-EPOCH療法を施行した2症例

    吉岡 尚徳, 藤原 英晃, 淺野 豪, 廻 勇輔, 黒井 大雅, 長谷川 詠子, 松岡 賢市, 藤井 伸治, 近藤 英生, 前田 嘉信, 品川 克至, 吉野 正, 谷本 光音

    日本リンパ網内系学会会誌   52   124 - 124   2012.5

     More details

    Language:Japanese   Publisher:(一社)日本リンパ網内系学会  

    researchmap

  • 日本輸血・細胞治療学会による細胞療法の体制に関する全国調査

    藤井 敬子, 西森 久和, 藤井 伸治, 池田 亮, 浅野 尚美, 小郷 博昭, 岩月 啓氏, 池田 和眞, 田中 朝志, 佐川 公矯, 大戸 斉, 高橋 孝喜

    日本輸血細胞治療学会誌   57 ( 6 )   511 - 512   2011.12

     More details

    Language:Japanese   Publisher:(一社)日本輸血・細胞治療学会  

    J-GLOBAL

    researchmap

  • Prevention of Idiopathic Pneumonia Syndrome by Intra-Bone Marrow Injection of Donor Cells

    Yoshiko Yamasuji, Hisakazu Nishimori, Haruko Sugiyama, Koichiro Kobayashi, Sachiyo Okamoto, Eisei Kondo, Nobuharu Fujii, Katsuji Shinagawa, Takuro Kanekura, Mitsune Tanimoto, Yoshinobu Maeda

    BLOOD   118 ( 21 )   830 - 830   2011.11

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC HEMATOLOGY  

    Web of Science

    researchmap

  • 同種造血細胞移植後の閉塞性細気管支炎 岡山BMTグループ3施設での経験

    藤井 伸治, 中瀬 浩一, 朝倉 昇司, 原 嘉孝, 松岡 賢市, 近藤 英生, 前田 嘉信, 名和 由一郎, 角南 一貴, 品川 克至, 池田 和眞, 原 雅道, 谷本 光音

    臨床血液   52 ( 9 )   1108 - 1108   2011.9

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • 中枢神経系悪性リンパ腫に対する自己末梢血幹細胞移植併用大量化学療法

    近藤 英生, 市川 智継, 前田 嘉信, 黒川 和彦, 青山 一利, 吉田 将平, 原 嘉孝, 新谷 大悟, 西森 久和, 藤井 敬子, 藤井 伸治, 品川 克至, 谷本 光音

    臨床血液   52 ( 9 )   1127 - 1127   2011.9

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • 同種末梢血幹細胞採取における至適タイミングの検討

    藤井 敬子, 西森 久和, 藤井 伸治, 池田 和真, 谷本 光音

    臨床血液   52 ( 9 )   1174 - 1174   2011.9

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    J-GLOBAL

    researchmap

  • 中枢神経系悪性リンパ腫に対する自己末梢血幹細胞移植併用大量化学療法

    近藤 英生, 前田 嘉信, 青山 一利, 吉田 将平, 原 嘉孝, 廻 勇輔, 新谷 大悟, 品川 克至, 西森 久和, 藤井 敬子, 藤井 伸治, 黒住 和彦, 市川 智継, 谷本 光音

    日本リンパ網内系学会会誌   51   98 - 98   2011.6

     More details

    Language:Japanese   Publisher:(一社)日本リンパ網内系学会  

    researchmap

  • BRONCHIOLITIS OBLITERANS SYNDROME AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: ANALYSIS OF SINGLE CENTER EXPERIENCE

    N. Fujii, Y. Hara, N. Nishinohara, E. Kondo, Y. Maeda, K. Shinagawa, M. Tanimoto

    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION   17 ( 2 )   S243 - S243   2011.2

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:ELSEVIER SCIENCE INC  

    Web of Science

    researchmap

  • 早期から末梢血に異常細胞が出現したIVLの一例

    杉山 暖子, 前田 嘉信, 小林 孝一郎, 田淵 貴大, 西森 久和, 山筋 好子, 松岡 賢市, 藤井 伸治, 品川 克至, 石丸 文彦, 池田 和真, 谷本 光音

    臨床血液   47 ( 9 )   1128 - 1128   2006.9

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • Diffuse large B-cell lymphoma(DLBCL)に対するCHOPとR-CHOPの多施設共同後方視的比較検討

    名和 由一郎, 松尾 恵太郎, 角南 一貴, 砥谷 和人, 滝本 秀隆, 西森 久和, 平松 靖史, 木口 亨, 矢野 朋文, 山根 弘路, 多林 孝之, 藤井 総一郎, 宮田 明, 竹内 誠, 牧田 雅典, 瀬崎 伸夫, 山筋 好子, 杉山 暖子, 田淵 貴大, 片岡 到, 藤井 伸治, 前田 嘉信, 品川 克至, 石丸 文彦, 池田 和真, 原 雅道, 谷本 光音, 西日本血液腫瘍研究グループ

    臨床血液   47 ( 9 )   1005 - 1005   2006.9

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • 再発・治療抵抗性非ホジキンリンパ腫に対するIDEA療法の有効性と安全性の検討

    西森 久和, 藤井 伸治, 松尾 恵太郎, 小林 孝一郎, 杉山 暖子, 田淵 貴大, 山筋 好子, 久保西 四郎, 難波 寛子, 松岡 賢市, 片山 義雄, 前田 嘉信, 品川 克至, 石丸 文彦, 池田 和真, 谷本 光音

    臨床血液   47 ( 9 )   1134 - 1134   2006.9

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • 発熱で発症し診断に苦慮したIVLの一例

    杉山 暖子, 前田 嘉信, 田淵 貴大, 西森 久和, 山筋 好子, 藤井 伸治, 品川 克至, 石丸 文彦, 池田 和真, 谷本 光音

    日本リンパ網内系学会会誌   46   76 - 76   2006.6

     More details

    Language:Japanese   Publisher:(一社)日本リンパ網内系学会  

    researchmap

  • 進行期低悪性度リンパ腫に対する骨髄非破壊的同種造血幹細胞移植

    久保西 四郎, 田淵 貴大, 山筋 好子, 杉山 暖子, 西森 久和, 藤井 伸治, 前田 嘉信, 品川 克至, 石丸 文彦, 池田 和真, 谷本 光音

    日本リンパ網内系学会会誌   46   100 - 100   2006.6

     More details

    Language:Japanese   Publisher:(一社)日本リンパ網内系学会  

    researchmap

  • Hodgkin/Reed-Sternberg様細胞を散在性に認めるLymphoplasmacytic lymphomaの一例

    小山 幹子, 品川 克至, 青山 一利, 増成 太郎, 近藤 英生, 藤井 伸治, 豊嶋 崇徳, 石丸 文彦, 池田 和真, 谷本 光音, 佐藤 由美子, 市村 浩一, 吉野 正

    日本リンパ網内系学会会誌   44   129 - 129   2004.6

     More details

    Language:Japanese   Publisher:(一社)日本リンパ網内系学会  

    researchmap

  • 8.自己末梢血幹細胞至適採取時期決定における末梢血CIC countの有効性に関する検討(一般演題)(日本アフェレシス学会第22回関西地方会抄録)

    吉田 親正, 池田 和真, 小塚 輝彦, 久保西 四郎, 小出 典男, 豊嶋 崇徳, 藤井 伸治, 品川 克至, 石丸 文彦, 谷本 光音

    日本アフェレシス学会雑誌   23 ( 2 )   207 - 207   2004

     More details

    Language:Japanese   Publisher:日本アフェレシス学会  

    CiNii Article

    CiNii Books

    researchmap

    Other Link: http://id.nii.ac.jp/1141/00150445/

  • Peripheral blood circulating immature cell counts predict CD34+cell yields in granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cell collection in healthy donors.

    K Ikeda, T Kozuka, T Teshima, C Yoshida, S Kubonishi, K Sunami, K Matsuo, K Masuda, N Fujii, K Takenaka, K Shinagawa, F Ishimaru, N Koide, M Harada, M Tanimoto

    BLOOD   102 ( 11 )   414B - 414B   2003.11

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC HEMATOLOGY  

    Web of Science

    researchmap

  • Multilineage involvement in hypereosinophilic syndrome terminating in granulocytic sarcoma and leukaemic transformation with trisomy 8

    N Fujii, K Ikeda, N Takahashi, K Kojima, Y Kobayashi, A Ashiba, K Takenaka, S Fukuda, K Shinagawa, F Ishimaru, K Niiya, Miura, I, M Tanimoto, M Harada

    BRITISH JOURNAL OF HAEMATOLOGY   119 ( 3 )   716 - 719   2002.12

     More details

    Language:English   Publisher:BLACKWELL PUBLISHING LTD  

    We report a patient with hypereosinophilic syndrome (HES), which, 8 years later, transformed into granulocytic sarcoma in the brain and, subsequently, into acute myelocytic leukaemia. Repeated chromosome analyses showed a normal karyotype, until the time of leukaemic transformation when trisomy 8 was confirmed in cells from the bone marrow and cerebrospinal fluid. The combined techniques of May-Grunwald-Giemsa staining and fluorescence in situ hybridization identified trisomy 8 not only in blasts and eosinophils but also in neutrophils and erythroblasts. Our observation suggests that HES is a multilineage myeloproliferative disorder involving precursors of at least the eosinophil, neutrophil and erythroid lineages.

    DOI: 10.1046/j.1365-2141.2002.03922.x

    Web of Science

    researchmap

  • Differentiation of monoblastic cell line UG3 into leukemic dendritic cells

    N Fujii, T Ikeda, K Ikeda, A Hiraki, K Kawakami, K Masuda, Y Maeda, K Hatake, K Motoyoshi, M Harada, M Tanimoto

    INTERNATIONAL JOURNAL OF ONCOLOGY   21 ( 3 )   617 - 620   2002.9

     More details

    Language:English   Publisher:PROFESSOR D A SPANDIDOS  

    Dendritic cells (DCs) are known to be generated from leukemic clone from patients with acute and chronic leukemia when cultured in the presence of combination of granulocyte-macrophage colony-stimulating factor (GM-CSF), tumor necrosis factor-alpha (TNF-alpha) and interleukin-4. However, there have been few reports that showed DCs could be effectively differentiated from human leukemia cell lines. In this study, we have shown that a human monoblastic cell line, UG3, was inducible to differentiate into DCs in the presence of GM-CSF and TNF-alpha along monocyte-macrophage lineage. These DCs, consistently displayed dendritic morphology, phenotypes and allogeneic T-cell stimulating capacity. UG3 cells thus may represent a suitable model to further elucidate characteristics of DC differentiation.

    Web of Science

    researchmap

  • Successful Treatment of Progressive NK Cell Lymphoma with Allogeneic Peripheral Stem Cell Transplantation Followed by Early Cyclosporine Tapering and Donor Leukocyte Infusions

    MAKITA Masanori, MAEDA Yoshinobu, TAKENAKA Katsuto, SHINAGAWA Katsuji, SUNAMI Kazutaka, HIRAMATSU Yasushi, FUJII Nobuharu, ISHIMARU Fumihiko, IKEDA Kazuma, NIIYA Kenji, YOSHINO Tadashi, HARADA Mine

    Int J Hematol   76 ( 1 )   94 - 97   2002.7

     More details

  • Expression of minor histocompatibility antigen, HA-1, in solid tumor cells

    N Fujii, A Hiraki, K Ikeda, Y Ohmura, Nozaki, I, K Shinagawa, F Ishimaru, K Kiura, N Shimizu, M Tanimoto, M Harada

    TRANSPLANTATION   73 ( 7 )   1137 - 1141   2002.4

     More details

    Language:English   Publisher:LIPPINCOTT WILLIAMS & WILKINS  

    Background. Minor histocompatibility antigen (mHag) induces and mounts graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Among several mHags, HA-1 is one that acts alone and is the most studied. It is suggested that HA-1 may be one of the immunodominant antigens inducing not only graft-versus-host disease but also graft-versus-malignancy effects. There are some reports that mHag HA-1-specific cytotoxic T lymphocytes generated from an HA-1-negative donor can lyse HA-1-positive leukemic cells. However, the tissue distribution of HA-1 has been described as restricted to the cells of the hematopoietic lineage.
    Methods. We examined the HA-1 expression in peripheral blood mononuclear cells (PBMNC), leukemia/lymphoma cell lines, solid tumor cell lines, and paired samples of tumor and normal tissues from individual cancer patients by quantitative reverse-transcription polymerase chain reaction.
    Results. We found that mRNA of HA-1 is expressed in all leukemia/lymphoma cell lines and PBMNC. Most of the leukemia/lymphoma cell lines have the same levels of HA-1 expression as a leukemia/lymphoma cell line, Raji. The expression levels of human PBMNC were 14- to 19-fold higher than those of Raji. Among 32 solid tumor cell lines, 7 showed &gt;50% expression levels compared with Raji.
    Conclusions. HA-1 expression in the mRNA level is higher in cells of hematopoietic origin, but this tissue distribution is not strictly restricted. Some solid tumor cells and tissues express HA-1 gene equal to hematopoietic cells.

    Web of Science

    researchmap

  • Differentiation of monoblastic cell line UG3 into leukemic dendritic cells.

    Fujii N, Ikeda T, Ikeda K, Hiraki A, Kawakami K, Masuda K, Maeda Y, Hatake K, Motoyoshi K, Harada M, Tanimoto M.

    Int J Oncol.   21 ( 3 )   617   2002

     More details

  • Expression of minor histocompatibility antigen, HA-1, in solid tumor cells. International journal

    Nobuharu Fujii, Akio Hiraki, Kazuma Ikeda, Yasushi Ohmura, Isao Nozaki, Katsuji Shinagawa, Fumihiko Ishimaru, Katsuyuki Kiura, Nobuyoshi Shimizu, Mitsune Tanimoto, Mine Harada

    Transplantation   73 ( 7 )   1137 - 41   2002

     More details

    Language:English  

    BACKGROUND: Minor histocompatibility antigen (mHag) induces and mounts graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Among several mHags, HA-1 is one that acts alone and is the most studied. It is suggested that HA-1 may be one of the immunodominant antigens inducing not only graft-versus-host disease but also graft-versus-malignancy effects. There are some reports that mHag HA-1-specific cytotoxic T lymphocytes generated from an HA-1-negative donor can lyse HA-1-positive leukemic cells. However, the tissue distribution of HA-1 has been described as restricted to the cells of the hematopoietic lineage. METHODS: We examined the HA-1 expression in peripheral blood mononuclear cells (PBMNC), leukemia/lymphoma cell lines, solid tumor cell lines, and paired samples of tumor and normal tissues from individual cancer patients by quantitative reverse-transcription polymerase chain reaction. RESULTS: We found that mRNA of HA-1 is expressed in all leukemia/lymphoma cell lines and PBMNC. Most of the leukemia/lymphoma cell lines have the same levels of HA-1 expression as a leukemia/lymphoma cell line, Raji. The expression levels of human PBMNC were 14- to 19-fold higher than those of Raji. Among 32 solid tumor cell lines, 7 showed >50% expression levels compared with Raji. CONCLUSIONS: HA-1 expression in the mRNA level is higher in cells of hematopoietic origin, but this tissue distribution is not strictly restricted. Some solid tumor cells and tissues express HA-1 gene equal to hematopoietic cells.

    PubMed

    researchmap

  • Multilineage involvement on hypereosinophilic symdrome terminating in granulocytic sarcoma and leukaemic transformation with trisomy 8.

    Br J Haematol.   119 ( 3 )   716   2002

  • GM-CSF and TNF-alpha induce monoblastic line UG3 to differentiate into dendritic cells.

    K Masuda, N Fujii, K Ikeda, A Hiraki, T Ikeda, K Kawakami, M Harada, M Tanimoto

    BLOOD   98 ( 11 )   228A - 229A   2001.11

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC HEMATOLOGY  

    Web of Science

    researchmap

  • High-dose chemotherapy with hematopoietic stem cell transplantation is effective for nasal and nasal-type CD56(+) natural killer cell lymphomas

    K Takenaka, K Shinagawa, Y Maeda, M Makita, T Kozuka, A Ashiba, K Yamamoto, N Fujii, Y Nawa, Y Hiramatsu, K Sunami, F Ishimaru, T Yoshimo, K Kiura, M Harada

    LEUKEMIA & LYMPHOMA   42 ( 6 )   1297 - 1303   2001.11

     More details

    Language:English   Publisher:TAYLOR & FRANCIS LTD  

    CD56(+) natural killer (NK) cell lymphomas occur frequently in the nasal and nasopharyngeal regions and carry a poor prognosis. We have studied seven cases with NK-cell lymphomas. These lymphomas showed the following immunophenotype: CD56(+), CD2(+), sCD3(-) and Epstein-Barr virus-encoded small RNAs (EBERs)(+). Six patients had localized (stage I or II) disease involving the nasopharyngeal region, while one had stage III disease. One patient with stage I disease achieved a complete remission (CR) after treatment with involved-field irradiation, but subsequently relapsed and died. The remaining six patients received combination chemotherapy as primary treatment: five patients with localized stage I or II disease and one patient with advanced stage III disease. Responses to initial chemotherapy were generally poor. These six patients received a variety of salvage chemotherapy regimens, but never achieved a CR. Subsequently, four of six patients showed a highly aggressive clinical course and died of disseminated disease within 1 year from the diagnosis. Three of six patients received high-dose chemotherapy supported by syngeneic, autologous or allogeneic peripheral blood stem cell transplantation. Two of the three transplant patients achieved a CR and are now surviving in continuous CR. Our clinical experience suggests that myeloablative high-dose chemotherapy and bone marrow rescue by hematopoietic stem cell transplantation may be an effective salvage treatment modality for refractory NK-cell lymphomas and could be considered as a part of the initial therapy for these patients.

    DOI: 10.1080/10428190127500

    Web of Science

    researchmap

  • Hepatic graft-versus-host disease presenting as an acute hepatitis after allogeneic peripheral blood stem cell transplantation

    N Fujii, K Takenaka, K Shinagawa, K Ikeda, Y Maeda, K Sunami, Y Hiramatsu, K Matsuo, F Ishimaru, K Niiya, T Yoshino, N Hirabayashi, M Harada

    BONE MARROW TRANSPLANTATION   27 ( 9 )   1007 - 1010   2001.5

     More details

    Language:English   Publisher:NATURE PUBLISHING GROUP  

    Hepatic graft-versus-host disease (GVHD) generally presents as cholestatic jaundice, and increased serum alkaline phosphatase (ALP) is followed by hyperbilirubinemia and clinical jaundice. Currently accepted standards for evaluating the clinical severity of GVHD are based not on serum aminotransferase levels but on the serum bilirubin level. We describe a 17-year-old Japanese female who had increased aminotransferases without cholestasis on day 23 after allogeneic peripheral blood stem cell transplantation (allo-PBSCT), Liver biopsy revealed lymphocytic infiltration of the portal tracts and pericentral necrosis of the lobuli, The limiting plates were not clearly defined due to cellular infiltrates. There was periductal lymphocytic infiltration and vacuolization of the biliary epithelial cells with exocytosis, compatible with GVHD of cholangiohepatitic type. These findings indicate that acute hepatic GVHD may present as acute hepatitis and this should be included in the differential diagnosis for patients with increased aminotransferases after allogeneic stem cell transplantation.

    DOI: 10.1038/sj.bmt.1702997

    Web of Science

    researchmap

  • Lamivudine and glycyrrhizin for treatment of chemotherapy-induced hepatitis B virus (HBV) hepatitis in a chronic HBV carrier with non-Hodgkin lymphoma

    K Matsuo, K Takenaka, H Shimomura, N Fujii, K Shinagawa, K Kiura, M Harada

    LEUKEMIA & LYMPHOMA   41 ( 1-2 )   191 - 195   2001.3

     More details

    Language:English   Publisher:HARWOOD ACAD PUBL GMBH  

    We report a chronic hepatitis B virus (HBV) carrier with non-Hodgkin lymphoma (NHL) who developed HBV hepatitis following conventional dose chemotherapy and was successfully treated with lamivudine and glycyrrhizin. A 55 year-old male patient with primary testicular NHL (diffuse large B-cell type) relapsed. During the salvage chemotherapy, the patient showed elevated serum levels of transaminase and HBV-DNA due to HBV reactivation. Treatment with lamivudine. an antiviral nucleoside analog, was started at a dose of 100mg/day. Shortly after the treatment the HBV-DNA level was suppressed, and sustained elevation of transaminase levels were normalized after additional treatment with glycyrrhizin. This experience suggests that lamivudine combined with glycyrrhizin may be effective:e for controlling HBV replication and treating chemotherapy-induced HBV hepatitis in chronic HBV carriers with NHL.

    Web of Science

    researchmap

  • Hepatic graft-versus-host disease presenting as acute hepatitis after allogeneic peripheral blood stem cell transplantation

    FUJII N

    Bone Marrow Transplant   27 ( 9 )   1007 - 1010   2001

  • G-CSF投与健常人ドナーからの末梢血幹細胞採取の経験(一般演題,日本アフェレシス学会第19回関西地方会抄録)

    今井 利, 小塚 輝彦, 山本 和彦, 藤井 伸治, 前田 嘉信, 中 克斗, 品川 克至, 池田 和真, 原田 実根, 角南 一貴

    日本アフェレシス学会雑誌   20 ( 1 )   118 - 118   2001

     More details

    Language:Japanese   Publisher:日本アフェレシス学会  

    CiNii Article

    CiNii Books

    researchmap

    Other Link: http://id.nii.ac.jp/1141/00149750/

  • Successful engraftment of allogeneic peripheral blood stem cell transplant after nonmyeloablative preparative regimen with cytarabine and cyclophosphamide: Report of 2 cases

    N Fujii, Y Maeda, K Takenaka, K Shinagawa, T Imai, T Kozuka, K Ikeda, K Sunami, Y Hiramatsu, F Ishimaru, K Niiya, M Harada

    INTERNATIONAL JOURNAL OF HEMATOLOGY   72 ( 4 )   499 - 503   2000.12

     More details

    Language:English   Publisher:CARDEN JENNINGS PUBL CO LTD  

    We report our experience with allogeneic peripheral blood stem cell transplantation (allo-PBSCT) following a nonmyeloablative conditioning regimen consisting of cytarabine (8 g/m(2)) and cyclophosphamide (120 mg/kg) in the treatment of 2 patients aged 50 and 55 years with refractory chronic myelomonocytic leukemia and chronic myeloid leukemia in accelerated phase, respectively. Our nonmyeloablative regimen was well tolerated by older patients at high risk of regimen-related toxicity by the conventional conditioning regimen but was immunosuppressive enough to achieve mixed chimerism. After allo-PBSCT, we monitored chimerism in these patients by fluorescence in situ hybridization using X- and Y-specific probes and polymerase chain reaction-based analysis of a variable number of tandem repeats. We found that full chimerism and graft-versus-leukemia (GVL) effects could be induced in these patients by donor lymphocyte infusions and withdrawal of post transplantation immunosuppressive therapy. Our observations suggest that a nonmyeloablative conditioning regimen can establish mixed chimerism and that donor lymphocyte infusion may induce GVL effects in older patients at high risk of regimen-related toxicity. Int J Hematol. 2000;72:499-503. (C)2000 The Japanese Society of Hematology.

    Web of Science

    researchmap

  • Allogeneic peripheral blood stem cell transplantation for the treatment of chronic active Epstein-Barr virus infection

    N Fujii, K Takenaka, A Hiraki, Y Maeda, K Ikeda, K Shinagawa, A Ashiba, M Munemasa, K Sunami, Y Hiramatsu, F Ishimaru, K Niiya, T Yoshino, M Harada

    BONE MARROW TRANSPLANTATION   26 ( 7 )   805 - 808   2000.10

     More details

    Language:English   Publisher:NATURE PUBLISHING GROUP  

    The prognosis of chronic active Epstein-Barr virus infection (CAEBV) is very poor. We describe a 24-year-old male with severe CAEBV who was treated with allogeneic peripheral blood stem cell transplantation (allo-PBSCT), On admission, EBER-1 in lymphocytes infiltrating the liver, EBV-DNA in peripheral blood mononuclear cells (PBMC) and monoclonal NK cell proliferation were confirmed. After unsuccessful chemotherapy, he received an allo-PBSCT from his HLA-identical sister. Although he died of pulmonary hemorrhage on day +19, EBV-DNA was undetectable by PCR in PBMC, and the post-mortem liver showed no EBER-1-positive lymphocytes. This experience suggests that EBV-positive lymphocytes in CAEBV may be eradicated by allo-PBSCT, thereby raising the possibility of a new treatment modality.

    Web of Science

    researchmap

  • Allogeneic peripheral blood stem cell transplantation for the treatment of chronic active Epstein-Barr virus infection

    N Fujii, K Takenaka, A Hiraki, Y Maeda, K Ikeda, K Shinagawa, A Ashiba, M Munemasa, K Sunami, Y Hiramatsu, F Ishimaru, K Niiya, T Yoshino, M Harada

    BONE MARROW TRANSPLANTATION   26 ( 7 )   805 - 808   2000.10

     More details

    Language:English   Publisher:NATURE PUBLISHING GROUP  

    The prognosis of chronic active Epstein-Barr virus infection (CAEBV) is very poor. We describe a 24-year-old male with severe CAEBV who was treated with allogeneic peripheral blood stem cell transplantation (allo-PBSCT), On admission, EBER-1 in lymphocytes infiltrating the liver, EBV-DNA in peripheral blood mononuclear cells (PBMC) and monoclonal NK cell proliferation were confirmed. After unsuccessful chemotherapy, he received an allo-PBSCT from his HLA-identical sister. Although he died of pulmonary hemorrhage on day +19, EBV-DNA was undetectable by PCR in PBMC, and the post-mortem liver showed no EBER-1-positive lymphocytes. This experience suggests that EBV-positive lymphocytes in CAEBV may be eradicated by allo-PBSCT, thereby raising the possibility of a new treatment modality.

    Web of Science

    researchmap

  • Allogeneic Peripheral Blood Stem Cell Transplantation in 23 Adult Patients With Hematologic Malignancies: A Single-Center Experience

    TAKENAKA Katsuto, SHINAGAWA Katsuji, SUNAMI Kazutaka, FUJII Nobuharu, HIRAMATSU Yasushi, MAEDA Yoshinobu, NAWA Yuichiro, KATAYAMA Yoshio, TESHIMA Takanori, ISHIMARU Fumihiko, KIURA Katsuyuki, IKEDA Kazuma, HARADA Mine

    Int J Hematol   72 ( 3 )   362 - 370   2000.10

     More details

  • A CASE OF ANAPHYLAXIS AFTER PLATELET CONCENTRATE TRANSFUSION WITH ANTI-IGAM (1) AND C9 ANTIBODIES

    46 ( 3 )   324 - 329   2000

  • Successful engraftment of allogeneic peripheral blood stem cell transplant after nonmyeloablative preparative regimen

    Int J Hematol   72 ( 4 )   499   2000

     More details

  • Decreases in Ikaros activity correlate with blast crisis in patients with chronic myelogenous leukemia

    H Nakayama, F Ishimaru, N Avitahl, N Sezaki, N Fujii, K Nakase, Y Ninomiya, A Harashima, J Minowada, J Tsuchiyama, K Imajoh, T Tsubota, S Fukuda, T Sezaki, K Kojima, M Hara, H Takimoto, S Yorimitsu, Takahashi, I, A Miyata, S Taniguchi, Y Tokunaga, H Gondo, Y Niho, S Nakao, T Kyo, H Dohy, N Kamada, M Harada

    CANCER RESEARCH   59 ( 16 )   3931 - 3934   1999.8

     More details

    Language:English   Publisher:AMER ASSOC CANCER RESEARCH  

    Gene targeting studies in mice have shown that the lack of Ikaros activity leads to T-cell hyperproliferation and T-cell neoplasia, establishing the Ikaros gene as a tumor suppressor gene in mice. This prompted us to investigate whether mutations in Ikaros play a role in human hematological malignancies. Reverse transcription-PCR was used to determine the relative expression Levels of Ikaros isoforms in a panel of human leukemia/lymphoma cell lines and human bone marrow samples from patients with hematological malignancies. Among the cell lines examined, only BV-173, which was derived from a chronic myelogenous Leukemia (CML) patient in lymphoid blast crisis, overexpressed the dominant-negative isoform, Ik-6. In 9 of 17 samples of patients in blast crisis of CML, Ikaros activity had been reduced either by drastically reducing mRNA expression (4 of 17) or by overexpressing the dominant-negative isoform Ik-6 (5 of 17). Significantly, expression of Ikaros isoforms seemed normal in chronic phase CML patients and patients with other hematological malignancies. In some cases, overexpression of the dominant-negative Ik-6 protein was confirmed by Western blot analysis, and Southern blot analysis indicated that decreases in Ikaros activity correlated with a mutation in the Ikaros Locus. In summary, these findings suggest that a reduction of Ikaros activity may be an important step in the development of blast crisis in CML and provide further evidence that mutations that alter Ikaros expression may contribute to human hematological malignancies.

    Web of Science

    researchmap

  • Molecular characterization of total kininogen deficiency in Japanese patients

    F Ishimaru, H Dansako, K Nakase, N Fujii, N Sezaki, H Nakayama, N Fujii, Y Komiyama, K Iijima, K Takenaka, T Teshima, K Shinagawa, K Ikeda, K Niiya, M Harada

    INTERNATIONAL JOURNAL OF HEMATOLOGY   69 ( 2 )   126 - 128   1999.2

     More details

    Language:English   Publisher:CARDEN JENNINGS PUBL CO LTD  

    Kininogens are multifunctional plasma glycoproteins. There are two forms of human kininogen: low molecular weight kininogen (LK) and high molecular weight kininogen (HK). Both are derived from the same gene by alternative splicing. Same patients with kininogen deficiency have been reported to be deficient only in HK while others are deficient in both HK and LK (total kininogen deficiency). We analyzed three Japanese patients with total kininogen deficiency by the Csp45I digestion study of exon 5 as previously reported in Williams trait and found that two had the same point mutation of C to T at base 22 of exon 5, resulting in a transition of CGA (Arg) codon to TGA (Stop) codon. This is the first report of molecular characterization of total kininogen deficiency in the Japanese population. (C) 1999 The Japanese Society of Hematology.

    Web of Science

    researchmap

▼display all

Presentations

  • 骨髄非破壊的前処置による同種骨髄移植(RIST)で生着が得られた成人白質ジストロフィー(ALD)の1例

    浦田知宏、西森久和、藤井伸治

    第119回日本内科学会中国地方会 YIA  2019 

     More details

    Event date: 2019.11.17

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:広島  

    researchmap

  • 造血幹細胞移植患者に対する妊孕性温存治療実態の全国調査

    藤井伸治, 岡本幸代, 谷本光音, 前田嘉信、吉岡範人, 原田美由紀, 鈴木直, 大須賀穣

    第41回日本造血細胞移植学会総会  2019 

     More details

    Event date: 2019.3.7 - 2019.3.9

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:大阪  

    researchmap

  • Efficacy of HLA-matched PLT transfusions for platelet transfusion refractoriness in HSCT patients International conference

    Keisuke Seike, Nobuharu Fujii, Keiko Fujii, Yasuhisa Sando, Makoto Nakamura, Kyosuke Saeki, Yusuke Meguri, Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Kenichi Matsuoka, Yoshinobu Maeda

    60th ASH Annual Meeting and Exposition  2018 

     More details

    Event date: 2018.12.1 - 2018.12.4

    Language:English   Presentation type:Poster presentation  

    Venue:San Diego, CA, USA  

    researchmap

  • アルブミン製剤の輸血部管理による使用目的の把握について

    小郷博昭 , 浅野尚美 , 池田 亮, 閘 結稀, 清家圭介, 三道康永, 中村 真, 高木尚江, 藤井敬子, 藤井伸治, 大塚文男

    第63回日本輸血・細胞治療学会中国四国支部例会  2018 

     More details

    Event date: 2018.9.8

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:山口  

    researchmap

  • 抗Fybに加え新たに抗KANNOを産生した1症例

    池田 亮,小郷博昭 , 浅野尚美 , 閘 結稀, 清家圭介, 三道康永, 中村 真, 高木尚江, 藤井敬子, 藤井伸治, 大塚文男

    第63回日本輸血・細胞治療学会中国四国支部例会  2018 

     More details

    Event date: 2018.9.8

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:山口  

    researchmap

  • 当院における造血幹細胞輸注時の現状調査と改善?輸注時ガイドツール作成によるDay0看護の質向上をめざして?

    ?木尚江, 藤井敬子, 海内千春, 山成洋子, 中村 真, 三道康永, 清家圭介, 閘 結稀, 池田 亮, 浅野尚美, 小郷博昭, 藤井伸治, 大塚文男

    第66回日本輸血・細胞治療学会総会  2018 

     More details

    Event date: 2018.5.24 - 2018.5.26

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:栃木  

    researchmap

  • 自己血輸血の変遷 ?貯血式・希釈式・回収式症例数と時代背景を顧みて?

    藤井敬子, ?木尚江, 清家圭介, 三道康永, 中村 真, 閘 結稀, 池田 亮, 浅野尚美, 小郷博昭, 藤井伸治, 大塚文男

    第66回日本輸血・細胞治療学会総会  2018 

     More details

    Event date: 2018.5.24 - 2018.5.26

    Language:Japanese   Presentation type:Poster presentation  

    Venue:栃木  

    researchmap

  • 同種造血幹細胞移植後の好中球減少患者に対する顆粒球輸注療法

    藤井伸治, 池川俊太郎, 藤井敬子, 佐伯恭昌, 廻 勇輔, 淺田 騰, 西森久和, 松岡賢市, 大塚文男, 前田嘉信

    第66回日本輸血・細胞治療学会総会  2018 

     More details

    Event date: 2018.5.24 - 2018.5.26

    Language:Japanese   Presentation type:Poster presentation  

    Venue:栃木  

    researchmap

  • 0歳児の赤血球同種抗体に関する多施設共同研究

    玉井佳子, 大戸 斉, 藤井伸治, 小郷博昭, 矢澤百合香, 山本晃士, 阿南昌弘, 田崎哲典, 加藤陽子, 羽藤高明, 土居靖和, 三谷絹子, 篠原 茂, 上田恭典, 薮田吉弘, 久米田麻衣, 伊藤悦朗, 北澤淳一

    第66回日本輸血・細胞治療学会総会  2018 

     More details

    Event date: 2018.5.24 - 2018.5.26

    Language:Japanese   Presentation type:Symposium, workshop panel (public)  

    Venue:栃木  

    researchmap

  • 造血幹細胞輸注関連有害事象の発症頻度とリスク因子:前方視的多施設共同研究

    池田和彦, 奥山美樹 藤原実名美, 金森平和, 藤原慎一郎, 室井一男, 森 毅彦, 笠間絹代, 井関 徹, 長村井上登紀子 , 藤井伸治, 芦田隆司, 亀田和明, 廣瀬朝生, 高橋 勉,長井一浩, 皆川敬治, 田野崎隆二, 大戸 斉

    第66回日本輸血・細胞治療学会総会  2018 

     More details

    Event date: 2018.5.24 - 2018.5.26

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:栃木  

    researchmap

  • 菌状息肉症に対する同種造血幹細胞移植後にシドフォビルを投与したBKウイルスによる難治性出血性膀胱炎

    藤原 悠紀, 西森 久和, 碓井 喜明, 坂本 真衣子, 近藤 匠, 谷 勝真, 淺田 騰, 松岡 賢市, 藤井 伸治, 前田 嘉信

    第118回日本内科学会中国地方会 YIA  2018 

     More details

    Event date: 2018.5.19

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:米子  

    researchmap

  • Marginal zone B cell lymphoma治療後に,複視を契機にNeurolymphomatosisとし て再発したと考えられる一例

    松田 真幸, 坂本 真衣子, 碓井 喜明, 藤原 悠紀, 近藤 匠, 谷 勝真, 佐伯 恭昌, 廻 勇輔, 岡本 幸代, 西森 久和, 近藤 英生, 藤井 伸治, 松岡 賢市, 前田 嘉信, 吉野 正

    第57回日本血液学会中国四国地方会  2018 

     More details

    Event date: 2018.3.3

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:松江  

    researchmap

  • 同種末梢血幹細胞移植後3年で抗リン脂質抗体症候群を発症した1例

    近藤 匠, 碓井 喜明, 松岡 賢市, 坂本 真衣子, 谷 勝真, 藤原 悠紀, 佐伯 恭昌, 廻 勇輔, 岡本 幸代, 西森 久和, 近藤 英生, 藤井 伸治, 前田 嘉信

    第57回日本血液学会中国四国地方会  2018 

     More details

    Event date: 2018.3.3

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:松江  

    researchmap

  • 乳房腫脹を契機に診断されPeripheral T-cell lymphoma(PTCL), with T follicular helper phenotypeの1例

    碓井 喜明, 松岡 賢市, 坂本 麻衣子, 藤原 悠紀, 近藤 匠, 谷 勝真, 佐伯 恭昌, 廻 勇輔, 淺田 騰, 岡本 幸代, 西森 久和, 近藤 英生, 藤井 伸治, 吉野 正 , 前田 嘉信

    第57回日本血液学会中国・四国地方会  2018 

     More details

    Event date: 2018.3.3

    Language:Japanese   Presentation type:Poster presentation  

    Venue:松江  

    researchmap

  • Effect of Protein Sufficiency Rate on Hospital Length of Stay in Allogeneic HSCT Recipients International conference

    Shono M, Hasegawa Y, Sada H, Takahashi K, Shikata K , Nishimori H, Fujii N, Maeda Y

    2018 BMT tandem meetings  2018 

     More details

    Event date: 2018.2.22 - 2018.2.25

    Language:English   Presentation type:Poster presentation  

    Venue:Salt Lake City  

    researchmap

  • 健常人ドナーの負担軽減を目指した、開始時末梢血CD34陽性細胞カウントによる処理量の決定

    藤井敬子, 藤井伸治, 高橋孝英, 渡部俊幸, 岡田健, 今田昌秀, 小川弘子, 大塚文男

    第63回日本臨床検査医学会中国・四国支部総会  2018 

     More details

    Event date: 2018.2.17 - 2018.2.18

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:岡山  

    researchmap

  • 同種造血幹細胞移植患者におけるStenotrophomonas maltophilia菌血症の死亡リスク因子の検討

    碓井 喜明, 淺田 騰, 近藤 匠, 松田 真幸, 坂本 真衣子, 谷 勝真, 藤原 悠紀, 佐伯 恭昌, 廻 勇輔, 岡本 幸代, 西森 久和, 松岡 賢市, 藤井 伸治, 近藤 英生, 前田 嘉信

    第40回日本造血幹細胞移植学会総会  2018 

     More details

    Event date: 2018.2.1 - 2018.2.3

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:札幌  

    researchmap

  • 同種造血幹細胞移植におけるたんぱく質充足率が入院日数に与える影響について

    庄野 三友紀, 長谷川 祐子, 佐田 光, 高橋 郁名代, 四方 賢一 , 西森 久和, 藤井 伸治, 前田 嘉信

    第40回日本造血細胞移植学会総会  2018 

     More details

    Event date: 2018.2.1 - 2018.2.3

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:札幌  

    researchmap

  • 同種移植後再発に対する2nd HSCTの後方視的解析;Haploidentical移植の有用性の検討

    岡本 幸代, 松岡 賢市, 坂本 真衣子, 碓井 喜明, 藤原 悠紀, 近藤 匠, 松田 真幸, 谷 勝真, 佐伯 恭昌, 廻 勇輔, 淺田 騰, 西森 久和, 藤井 伸治, 近藤 英生, 前田 嘉信

    第40回日本造血細胞移植学会総会  2018 

     More details

    Event date: 2018.2.1 - 2018.2.3

    Language:Japanese   Presentation type:Poster presentation  

    Venue:札幌  

    researchmap

  • Myelin basic proteinが活動性の指標となりえた同種移植後のネララビン関連脊髄炎

    坂本真衣子, 碓井喜明, 藤原悠紀, 谷勝真, 近藤匠, 佐伯恭昌, 廻勇輔, 岡本幸代, 淺田騰, 西森久和, 松岡賢市, 藤井伸治, 近藤英生, 前田嘉信

    第40回日本造血細胞移植学会総会  2018 

     More details

    Event date: 2018.2.1 - 2018.2.3

    Language:Japanese   Presentation type:Poster presentation  

    Venue:札幌  

    researchmap

  • Dasatinib投与中にCMV出血性腸炎を発症したPh陽性ALL症例における、幹細胞移植後CMV-DNAモニタリングの有用性

    坂本真衣子, 淺田騰, 松田真幸, 碓井喜明, 近藤匠, 佐伯恭昌, 廻勇輔, 西森久和, 松岡賢市, 藤井伸治, 近藤英生, 前田嘉信

    日本内科学会第117回中国地方会  2017 

     More details

    Event date: 2017.11.18

    Language:Japanese   Presentation type:Poster presentation  

    Venue:島根  

    researchmap

  • 乳房原発PTCL,follicular helper typeの一例

    碓井 喜明, 藤原 悠紀, 近藤 匠, 坂本 真衣子, 松田 真幸, 佐伯 恭昌, 廻 勇輔, 岡本 幸代, 淺田 騰, 西森 久和, 藤井 伸治, 近藤 英生, 松岡 賢市, 前田 嘉信

    第24回中四リンパ腫カンファレンス  2017 

     More details

    Event date: 2017.10.28

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:岡山  

    researchmap

  • MZBL治療後にneurolymphomatosisとして再発したと考えられるCD5(+) bcl-2(+) c-myc(+) DLBCLの一例

    松田 真幸, 坂本 真衣子, 藤原 悠紀, 碓井 喜明, 近藤 匠, 佐伯 恭昌, 廻 勇輔, 岡本 幸代, 淺田 騰, 西森 久和, 藤井 伸治, 近藤 英生, 松岡 賢市, 前田 嘉信

    第24回中四リンパ腫カンファレンス  2017 

     More details

    Event date: 2017.10.28

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:岡山  

    researchmap

  • 自己血貯血における血管迷走神経反射の予測:単一施設 4192 例での検討

    西森 久和, 藤井 伸治, 藤井 敬子, 池田 亮, 浅野 尚美, 小郷 博昭, 山川 美和, 高木 尚江, 大塚 文男 , 池田 和眞

    第79回日本血液学会学術集会  2017 

     More details

    Event date: 2017.10.20 - 2017.10.22

    Language:Japanese   Presentation type:Poster presentation  

    Venue:東京  

    researchmap

  • An analysis about citrate intoxication and electrolytes during PBSCH of healthy donor.

    中村真, 藤井敬子, 三道康永, 佐伯恭昌, 谷勝真, 高木尚江, 西森久和, 松岡賢市, 近藤英生, 前田嘉信, 藤井伸治, 谷本光音

    第79回日本血液学会学術集会  2017 

     More details

    Event date: 2017.10.20 - 2017.10.22

    Language:Japanese   Presentation type:Poster presentation  

    Venue:東京  

    researchmap

  • Successful treatment of acute promyelocytic leukemia complicated with endometrial cancer using arsenic trioxide

    杉浦 弘幸, 西森 久和, 松岡 賢市, 藤井 伸治, 近藤 英生, 前田 嘉信, 谷本 光音, 松岡 敬典, 中川 圭一郎

    第15回日本臨床腫瘍学会学術集会  2017 

     More details

    Event date: 2017.7.27 - 2017.7.29

    Language:Japanese   Presentation type:Poster presentation  

    Venue:神戸  

    researchmap

  • MTX中止により寛解が得られているEBV関連T/NKリンパ増殖性疾患と考えられる1例

    松田 真幸, 西森 久和, 吉田 将平, 松岡 賢市, 藤井 伸治, 前田 嘉信, 谷本 光音, 近藤 英生, 森実 真, 吉野 正

    第116回日本内科学会中国地方会  2017 

     More details

    Event date: 2017.6.3

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:宇部  

    researchmap

  • 移植前Ccr値と同種移植成績への影響

    池川 俊太郎, 松岡 賢市, 佐伯 恭昌, 廻 勇輔, 淺田 騰, 西森 久和, 藤井 伸治, 近藤 英生, 前田 嘉信

    第31回岡山造血幹細胞移植研究会  2017 

     More details

    Event date: 2017.5.27

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:岡山  

    researchmap

  • Granulocyte Transfusions for Neutropenic Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation

    Shuntaro Ikegawa, Nobuharu Fujii, Keiko Fujii, Masayuki Matsuda, Tomoko Inomata, Hiroyuki Sugiura, Takeru Asano, Shohei Yoshida, Hisakazu Nishimori, Ken-ichi Matsuoka, Yoshinobu Maeda

    The 8 th JSH International Symposium 2017  2017 

     More details

    Event date: 2017.5.19 - 2017.5.20

    Language:English   Presentation type:Poster presentation  

    Venue:宮崎  

    researchmap

  • PTCL with EBV infection, IVL-likeが疑われたが、のちに子宮原発ENKLと診断された一例

    池川 俊太郎, 西森 久和, 松田 真幸, 猪股 知子, 杉浦 弘幸, 黒井 大雅, 浅野 豪、吉田 将平, 松岡 賢市, 近藤 英生, 藤井 伸治, 前田 嘉信

    第23回中四リンパ腫カンファレンス  2017 

     More details

    Event date: 2017.4.8

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:岡山  

    researchmap

  • HLA半合致末梢血幹細胞移植後に発症した進行性多巣性白質脳症の1例

    池川 俊太郎,藤井 伸治, 猪股 知子,池田 直人,杉浦 弘幸,黒井 大雅,浅野 豪,吉田 将平,西森 久和, 松岡 賢市,前田 嘉信,谷本 光音

    第56回日本血液学会中国四国地方会  2017 

     More details

    Event date: 2017.3.11

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:岡山  

    researchmap

  • 健常人ドナー末梢血幹細胞採取時のクエン酸中毒発現,電解質異常についての解析

    中村 真, 佐伯 恭昌, 谷 勝真, 黒井 大雅, 猪股 知子, 池川 俊太郎, 杉浦 弘幸, 池田 直人, 浅野 豪, 吉田 将平, 西森 久和, 松岡 賢市, 前田 嘉信, 藤井 伸治、藤井 敬子, 高木 尚江, 近藤 英生, 谷本 光音

    第56回日本血液学会中国四国地方会  2017 

     More details

    Event date: 2017.3.11

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:岡山  

    researchmap

  • Cord blood transplantation versus haploidentical peripheral blood stem cell transplantation as salvage transplantation for graft failure

    杉浦 弘幸, 池川 俊太郎, 猪俣 知子, 池田 直人, 黒井 大雅, 浅野 豪, 吉田 将平, 西森 久和, 松岡 賢市, 藤井 伸治, 近藤 英生, 前田 嘉信, 谷本 光音

    第39回日本造血細胞移植学会総会  2017 

     More details

    Event date: 2017.3.2 - 2017.3.4

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:島根  

    researchmap

  • 当院における抗MRSA薬の使用状況と治療効果; The use situation and efficacy of anti-MRSA antibiotics in our hospital

    吉田 将平, 池川 俊太郎, 猪股 知子, 杉浦 弘幸, 池田 直人, 黒井 大雅, 浅野 豪, 西森 久和, 松岡 賢市, 藤井 伸治, 近藤 英生, 前田 嘉信, 谷本 光音, 佐田 光

    第39回日本造血細胞移植学会総会  2017 

     More details

    Event date: 2017.3.2 - 2017.3.4

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:島根  

    researchmap

  • Prognostic impact of renal dysfunction before allogeneic hematopoietic stem cell transplantation

    池川 俊太郎、猪股 知子、池田 直人、杉浦 弘幸、黒井 大雅、浅野 豪、吉田 将平、西森 久和、松岡 賢市、藤井 伸治、近藤 英生、前田 嘉信、谷本 光音

    第39回日本造血細胞移植学会総会  2017 

     More details

    Event date: 2017.3.2 - 2017.3.4

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:島根  

    researchmap

  • 臍帯血移植にて寛解を維持しているTriple-hit Lymphomaの1例

    小柳太作, 猪股知子, 松岡賢市, 西森久和, 近藤英生, 藤井伸治, 前田嘉信, 谷本光音, 今 利

    第115回日本内科学会中国地方会  2016 

     More details

    Event date: 2016.11.26

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:岡山  

    researchmap

  • 胸腹水貯留と肝障害を伴い発症したaggressive large granular lymphocytic leukemiaの1例

    鴨井千尋, 三道康永, 西森久和,浅野豪, 吉田将平, 松岡賢市, 近藤英生, 藤井伸治, 前田嘉信, 谷本光音

    第115回日本内科学会中国地方会  2016 

     More details

    Event date: 2016.11.26

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:岡山  

    researchmap

  • Spectra Optiaを用いた骨髄濃縮-小児科,低体重児における骨髄処理-

    藤井敬子, 今田昌秀, 大塚文男 , 中村真, 谷勝真, 佐伯恭昌, 藤井伸治, 閘結稀, 池田亮, 浅野尚美, 小郷博昭, 高木尚江

    第61回日本輸血 細胞治療学会中国四国支部例会  2016 

     More details

    Event date: 2016.9.24

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:岡山  

    researchmap

  • びまん性大細胞B細胞リンパ腫に対する自己末梢血幹細胞移植後の涙腺MALTリンパ腫

    松尾俊彦,田中健大,藤井伸治

    第56回日本リンパ網内系学会総会  2016 

     More details

    Event date: 2016.9.1 - 2016.9.3

    Language:Japanese   Presentation type:Poster presentation  

    Venue:熊本  

    researchmap

  • Remarkable Graft-versus-Leukemia Effect with a WT1-specific Cell Response Induced by Aza+DLI after Allo-HSCT International conference

    Tatsunori Ishikawa, Nobuharu Fujii, Yusuke Meguri, Tomoko Inomata, Hiromi Nakashima, Keiko Fujii, Shohei Yoshida, Hisakazu Nishimori, Kenichi Matsuoka, Eisei Kondo, Yoshinobu Maeda, Mitsune Tanimoto, Masahide Imada, Michinori Aoe, Keiko Fujii

    The 7th JSH International Symposium 2016 in Awaj  2016 

     More details

    Event date: 2016.5.13

    Language:English   Presentation type:Poster presentation  

    Venue:兵庫県淡路市  

    researchmap

  • 岡山大学病院における分割血液製剤の使用状況の検討

    池田亮,小郷 博昭,浅野尚美,小林優人,藤井伸治, 高木尚江, 藤井敬子

    第64回日本輸血 細胞治療学会総会  2016 

     More details

    Event date: 2016.4.28 - 2016.4.30

    Language:Japanese   Presentation type:Poster presentation  

    Venue:京都  

    researchmap

  • 「血液疾患患者におけるHLA適合血小板輸血後の有効性評価」

    藤井伸治、小郷博昭、小林優人、藤井敬子、近藤英生、浅野尚美、池田亮、山川美和、高木尚江、平田康司

    第63回日本輸血細胞治療学会総会 

     More details

    Event date: 2015.12

    Language:Japanese   Presentation type:Poster presentation  

    researchmap

  • 同種造血幹細胞移植とGranulicatella adiacensm敗血症

    三道康永、松岡賢市、谷勝真、(能勢資子)、藤原英晃、西森久和、藤井伸治、近藤英生、前田嘉信、谷本光音

    第54回日本血液学会中国四国地方会. 

     More details

    Event date: 2015.12

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • 輸血副作用・予防と治療

    藤井伸治

    岡山県輸血研究会 

     More details

    Event date: 2015.12

    Language:Japanese   Presentation type:Oral presentation (invited, special)  

    researchmap

  • 難治性Sweet病を合併したMDSに対して同種造血幹細胞移植を施行した1例

    本倉恵美、三道康永、佐伯恭昌、藤井伸治、藤原英晃、西森久和、松岡賢市、近藤英生、前田嘉信、谷本光音、廻勇輔、小林優人、藤井敬子、藤原暖、土井裕子、加持達弥、岩月啓氏

    第54回日本血液学会中国四国地方会. 

     More details

    Event date: 2015.12

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • 血液疾患の診断と治療 ?特定疾患を中心に

    藤井伸治

    かかりつけ医のための特定疾患研修会 

     More details

    Event date: 2015.12

    Language:Japanese   Presentation type:Oral presentation (invited, special)  

    researchmap

  • CNS浸潤伴う治療抵抗性ALK陽性ALCLに対しCrizotinibを使用した一例

    濱崎豊、石川立則、近藤英生、(吉野正)、長谷川詠子、瀬崎伸夫、藤原英晃、西森久和、松岡賢市、藤井伸治、前田嘉信、谷本光音

    第54回日本血液学会中国四国地方会 

     More details

    Event date: 2015.12

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • 胸腺腫術後再発に合併したT細胞性急性リンパ性白血病の一例

    住居優一、中村真、藤井伸治、山本和彦、松岡賢市、田中健大、吉野正、谷本光音

    第54回日本血液学会中国四国地方会. 

     More details

    Event date: 2015.12

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • 当院において集中治療を要した造血幹細胞移植症例についての検討

    中村真、藤井伸治、清家圭介、三道康永、石川立則、谷勝真、藤原英晃、松岡賢市、西森久和、近藤英生、前田嘉信、谷本光音

    第37回日本造血細胞移植学会総会 

     More details

    Event date: 2015.12

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • Retrospective analysis of allogeneic stem cell transplantation for NHL patients in our institution.

    Saeki K, Ishikawa T, ani K, Fujiwara H, Matsuoka K, Fujii N, Kondo E, Maeda Y, Tanimoto M.

    第76回日本血液学会学術集会 

     More details

    Event date: 2015.12

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • 当院における臍帯血骨髄内投与の有用性についての検討

    清家圭介(石川立則、藤原英晃、中村真,三道康永、廻勇輔、吉田将平、西森久和、松岡賢市、 藤井伸治、近藤英生、前田嘉信、谷本光音)

    第77回日本血液学会学術集会 

     More details

    Event date: 2015.12

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • Engraftment efficacy of intra-bone marrow injection of uCBT International conference

    Tomoko Inomata, (Keisuke Seike, Makoto Nakamura, Yasuhisa Sando , Yusuke Meguri , Hisakazu Nishimori, Kenichi Matsuoka, Nobuharu Fujii, Eisei Kondo, Yoshinobu Maeda , Mitsune Tanimoto)

    APBMT2015 

     More details

    Event date: 2015.12

    Language:English   Presentation type:Oral presentation (general)  

    researchmap

  • Optia Spectraを用いた骨髄濃縮 ?利便性と回収率、さらに簡便な処理方法を模索して

    藤井敬子,小林優人、池田亮、浅野尚美、小郷博昭、藤井伸治

    第63回日本輸血細胞治療学会総会 

     More details

    Event date: 2015.12

    Language:Japanese   Presentation type:Poster presentation  

    researchmap

  • 再発/難治性の非ホジキンリンパ腫への自家末梢血造血幹細胞移植の前処置に、Gemcitabine、Busulfan、 Melphalanを使用した10例

    谷勝真、近藤英生、石川立則、清家圭介、三道康永、中村真、藤原英晃、西森久和、松岡賢市、藤井伸治、前田嘉信、谷本光音

    第37回日本造血細胞移植学会総会. 

     More details

    Event date: 2015.12

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • Analysis of Prognostic Factors of Hematopoietic Stem Cell Transplantation Patients Admitted to ICU International conference

    Makoto Nakamura,Nobuharu Fujii,Kazuyoshi Shimizu,Hisakazu Nishimori,Ken-ichi Matsuoka,Eisei Kondo,Yoshinobu Maeda,Hiroshi Morimatsu,Mitsune Tanimoto

    BMT Tandem Meeting 2016 

     More details

    Event date: 2015.12

    Language:English   Presentation type:Oral presentation (general)  

    researchmap

  • Anti-IL-12/23 p40 Antibody Attenuates Chronic Graft Versus Host Disease Via Suppression of IFN-γ/IL-17-Producing Cells International conference

    20140101

    56th American Society of hematology 

     More details

    Event date: 2014.12

    Language:English   Presentation type:Poster presentation  

    researchmap

  • Use of Recombinant Thrombomodulin for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation Ameliorate Disease Severity. International conference

    20140101

    56th American Society of hematology 

     More details

    Event date: 2014.12

    Language:English   Presentation type:Poster presentation  

    researchmap

  • 胸腺腫術後再発に合併したT細胞性急性リンパ性白血病の1例

    20141108

    日本内科学会中国支部 第111回中国地方会 

     More details

    Event date: 2014.11.8

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • Retrospective analysis of allogeneic stem cell transplantation for NHL patients in our institution.

    20141031

    第76回日本血液学会学術集会 

     More details

    Event date: 2014.10.31 - 2014.11.2

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • A case of B-cell polymorphocytic keukemia that was successfully treated with rituximba,

    20141031

    第76回日本血液学会学術集会 

     More details

    Event date: 2014.10.31 - 2014.11.2

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • Azacitidine and DLI for relapsed AML/MDS after allo-SCT, report of 3 cases.

    20141031

    第76回日本血液学会学術集会 

     More details

    Event date: 2014.10.31 - 2014.11.2

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • 皮膚γδ T細胞リンパ腫に対し臍帯血移植を施行した一例

    20140619

    第54回日本リンパ網内系学会総会 

     More details

    Event date: 2014.6.19 - 2014.6.21

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • 細胞療法のための院内細胞採取・処理・保管に関する全国調査

    20140517

    日本輸血細胞治療学会 

     More details

    Event date: 2014.5.7

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • 20年以上無増悪ののちに再発した血栓性血小板減少性紫斑病(TTP)の1例

    20140412

    第112回 日本内科学会総会・後援会 医学生・研修医の日本内科学会ことはじめ2015京都 

     More details

    Event date: 2014.4.11

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • マウス慢性GVHDモデルにおけるPD-1経路の重要性.

    20140308

    第36回日本造血細胞移植学会総会 

     More details

    Event date: 2014.3.7 - 2014.3.9

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • 当科における悪性リンパ腫に対する同種造血幹細胞移植79例について.

    20140307

    第36回日本造血細胞移植学会総会 

     More details

    Event date: 2014.3.7 - 2014.3.9

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • von Recklinghausen病に合併したフィラデルフィア染色体陽性T-ALLに対し非血縁者間骨髄移植を施行した1例; Unrelated bone marrow transplantation for Philadelphia chromosome positive T-ALL patient harboring von RecklingHausen disease.

    20140307

    第36回日本造血細胞移植学会総会 

     More details

    Event date: 2014.3.7 - 2014.3.9

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • Primary cutaneous γδT-cell lymphomaに対し、臍帯血移植を施行した一例.

    20140307

    第53回日本血液学会中国四国地方会 

     More details

    Event date: 2014.3.1

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • 急激な増大を認めた縦隔腫瘤の一例

    吉岡尚徳, 廻 勇輔, 藤原英晃, 新谷大悟, 藤井伸治, 近藤英生, 前田嘉信, 品川克至, 谷本光音

    第11回中四リンパ腫カンファレンス 

     More details

    Event date: 2010.11

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • ハプロフル移植後に致死的中枢神経合併症をきたした2症例

    新谷大悟, 吉田将平, 西之原正昭, 藤原英晃, 藤井伸治, 近藤英生, 前田嘉信, 品川克至, 谷本光音

    第24回岡山造血幹細胞移植研究会 

     More details

    Event date: 2010.5.2

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • 同種造血幹細胞移植を施行した、進行期・治療抵抗性 extranodal NK/T-cell lymphoma, nasal type10症例の単一施設での治療成績

    吉田将平, 遠西大輔, 前田嘉信, 西之原正昭, 近藤正太郎, 新谷大悟, 藤井伸治, 久保西四郎, 近藤英生, 品川克至, 谷本光音, (市村浩一, 吉野 正)

    第49回日本血液学会中国四国地方会 

     More details

    Event date: 2010.3.6

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • 当院で血栓性微小血管障害を発症した13例の検討

    吉田将平, 品川克至, 青山一利, 小林孝一郎, 近藤正太郎, 原 嘉孝, 遠西大輔, 新谷大悟, 藤井伸治, 近藤英生, 久保西四郎, 前田嘉信, 池田和眞, 谷本光音, 松下公紀

    第32回日本造血細胞移植学会総会 

     More details

    Event date: 2010.2.20

    Language:Japanese   Presentation type:Poster presentation  

    researchmap

  • Identification of Novel MHC Class II-Restricted Male-Specific mHAg Encoded bySMCY (JARID1D) International conference

    The American Society of Hematology 

     More details

    Event date: 2009.11

    Language:English   Presentation type:Poster presentation  

    researchmap

  • Identification of novel minor H antigens targeted by CTL in Phase 1 adoptive immunotherapy

    Nobuharu Fujii,Yoshiki Akatsuka, Seishi Ogawa, Stanley R. Riddell, Edus H. Warren

    日本血液学会 

     More details

    Event date: 2009.10

    Language:Japanese   Presentation type:Symposium, workshop panel (public)  

    researchmap

  • Analysis of the β T Cell Receptor Repertoire in Advanced Myelodysplastic Syndrome International conference

    The American Society of Hematology 

     More details

    Event date: 2008.11

    Language:English   Presentation type:Poster presentation  

    researchmap

  • Generation of CD8+ Cytotoxic T Cell Clones Recognizing BMI1-Derived Peptides International conference

    The American Society of Hematology 

     More details

    Event date: 2008.11

    Language:English   Presentation type:Poster presentation  

    researchmap

▼display all

Research Projects

  • 空間マルチオミックスを用いた慢性肺GVHDとの比較による慢性移植肺機能不全の病態解明

    Grant number:23K08295  2023.04 - 2026.03

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    松原 慧, 橋本 好平, 豊岡 伸一, 遠西 大輔, 杉本 誠一郎, 田中 真, 岡崎 幹生, 三好 健太郎, 藤井 伸治

      More details

    Grant amount:\4550000 ( Direct expense: \3500000 、 Indirect expense:\1050000 )

    researchmap

  • 同種造血細胞移植後閉塞性細気管支炎におけるマクロファージ標的治療の開発

    Grant number:23K07627  2023.04 - 2026.03

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    藤井 伸治, 遠西 大輔, 豊岡 伸一, 杉本 誠一郎, 藤原 英晃, 清家 圭介

      More details

    Grant amount:\4550000 ( Direct expense: \3500000 、 Indirect expense:\1050000 )

    researchmap

  • Characterization of localized macrophages in bronchiolitis obliterans after allo-HSCT

    Grant number:17K09616  2017.04 - 2020.03

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

    Fujii Nobuharu

      More details

    Grant amount:\4290000 ( Direct expense: \3300000 、 Indirect expense:\990000 )

    Bronchiolitis obliterans syndrome (BOS) remain one of the most devastating complications in hematopoietic cell transplantation (HCT). We studied infiltrated macrophages in gender mismatched HCT recipients who received lung transplantation for BOS. We found that most of the infiltrated macrophages are derived from donor. As for phenotypes, the macrophages in early stage of BOS were positive for CD68 and iNOS and negative for CD163, CD206, and TGF-β suggesting M1 macrophages. On the other hand, neither CD68 and iNOS nor CD163, CD206, and TGF-β was negative in late stage.

    researchmap

  • 移植片対固形腫瘍効果に関与するマイナー組織適合性抗原に対する液性免疫の検討

    Grant number:16790537  2004 - 2005

    日本学術振興会  科学研究費助成事業  若手研究(B)

    藤井 伸治

      More details

    Grant amount:\2700000 ( Direct expense: \2700000 )

    移植片対腫瘍効果(graft-versus-tumor : GVT effect)におけるマイナー組織適合性抗原(mHa)に対する液性免疫反応の関与を探索している。最近になりY染色体由来のmHaであるDBYに対する抗体反応がドナーリンパ球輸注後に増強すること、この液性免疫反応の有無と移植後再発が強く関連していることも報告されており、まず既知のmHa(HA-1,HA-2,HA-3,HA-8,HB-1,DBY,UTY,BCL2A1)に対する抗体反応の有無のスクリーニングを開始した。
    方法としてはSEREX2(Cancer Immunity3:5,2003)を用いることとした。まず、健常人より分離した単核球細胞をEBVで不死化しLCLを作成した。その細胞からRNAを抽出しcDNAを作成した。既知のそれぞれのmHaの全コード領域を増幅する特異的なプライマーを設計し、前述のcDNAをテンプレートとしてPCRによって増幅した。得られたPCR産物を用いてGatewayクローニングシステム(invitrogen)を用いて、目的とするmHaの由来蛋白を酵母細胞表面に発現させた。
    昨年の段階で、移植後の液性免疫反応が報告されているDBYと、既知のmHaの中で最もよく調べられているHA-1についてはこれらの作業がほぼ終了した。この1年では、他のmHaに関して酵母細胞表面への発現に成功した。今後、岡山大学において施行された固形腫瘍に対する同種移植後の保存血清、ならびに作成したmHaの由来蛋白を発現した酵母細胞を用いて、フローサイトメトリーでmHaに対する液性免疫反応を検討する段階である。また、慢性移植片対宿主病(chronic GVHDにおける液性免疫反応も同時に確認すべく、検体の収集を行っている。

    researchmap

  • Minor Histocompatibility Antigen in solid tumor cells

      More details

    Grant type:Competitive

    researchmap

  • 移植片対腫瘍効果におけるマイナー組織適合性抗原の役割

      More details

    Grant type:Competitive

    researchmap

▼display all

 

Class subject in charge

  • General Laboratory Medicine (2023academic year) special  - その他

  • General Laboratory Medicine (2022academic year) special  - その他

  • General Laboratory Medicine (2021academic year) special  - その他

  • General Laboratory Medicine (2020academic year) special  - その他